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Figure 1 Subtype diversity of HIV-1 infections prevalent world-wide 3
(Spira et al, 2003)
Figure 2 HIV prevalence in Sub-Saharan Africa (UNAIDS, 2002) 5
Figure 3 HIV-1 protease structure showing the position of resistance 17
associated mutations
Figure 4 Mutations associated with resistance to the currently available 20
PIs (Shafer, 2003; http://hivdb.stanford.edu/)
Figure 5 HIV-1 RT structure. The active site (positions 110, 185 and 25
186) is shown in red sticks in the p66 subunit
Figure 6 Mutations associated with resistance to the currently available 27
NRTIs (Shafer et al, 2003; http://hivdb.stanford.edu/) . ddC is
not currently used and is therefore not shown in the figure.
Figure 7 Mutations associated with resistance to the currently available 31
NNRTIs (Shafer et al, 2003; http://hivdb.stanford.edu/)
Figure 8 Development of drug resistance during incomplete viral 36
suppression (Quinones-Mateu and Arts, 2002)
Figure 9 Representative pol tree showing the relationships between 66
retrospective and contemporary sequences from South Africa,
Botswana, and other countries affected by the subtype C
epidemic. The sequences are coded by the country of origin and
year of isolation. The following sequences were included in the
analysis: 49 previously described isolates from Botswana
(accession numbers AF 110960, AF 110963, AF 110967,
AF110970, AF110972, AF110973, AF110978, and AF443074
to AF443115), 9 sequences from India (accession numbers
AF286232, AF286223, AF286231, AB023804, AF067159,
AF067155, AF067154, AF067157, and AF067158), 4
sequences from Tanzania (accession numbers AF286234,
AF286235, AF361874, and AF361875), 2 sequences from
Zambia (AF286224 and AF286225), 2 sequences from Brazil
(U52853 and AF2862228), 1 sequence from Ethiopia
(U46016), 1 sequence from Israel (AF286233), and 69
sequences from South Africa, including 5 previously described
sequences (AF286227, AY043173, AY043174, AY043175, and
AY043176), 3 sequences from another study (71), and 61
sequences newly generated from this study (14 retrospective
and 47 contemporary strains).
Figure 10 Phylogenetic relationship of C2V5 envelope sequences from 67
KwaZulu-Natal, Botswana, Zambia, and Tanzania
ix
Correlation of signature patterns with structure and function for
protease and reverse transcriptase. conKZN, KwaZulu-Natal
consensus; conA, conB, conC, and conD, consensus sequences
for subtypes A, B, C, and D, respectively; APV, SQV, RTV,
NFV, INV, drug binding sites for amprenavir, saquinavir,
ritonavir, nelfinavir, and indinavir, respectively; functn, RT,
reverse transcriptase; CTL, cytotoxic T-lymphocyte epitope; F,
drug-binding site; k, protein kinase C phosphorylation site; c,
casein kinase phosphorylation site; m, myristoylation site; aaaa,
amidation site; t, tyrosine kinase phosphorylation site; g, cyclic
AMP- and cyclic GMP-dependent protein kinase site; T,
thiocarboxanilide UC-781; N, nevirapine; Q, quinoxaline HBY
097; E, efivirenz; a, accessory mutation; P, primary mutation;
caret, extended 13 strand; S, bend; star, hydrogen-bonded turn; h,
helix; p, purifying selection pressure; d, Darwinian (positive)
selection pressure
Correlation of signature patterns with structure and function of
V3 loop. KNZenv, KwaZulu-Natal consensus; conA, conB,
conC, and conD, consensus sequences for subtypes A, B, C,
and D, respectively; k, protein kinase C phosphorylation site; c,
casein kinase phosphorylation site; n, N-linked glycosylation
site; caret, extended 13-strand; h, helix; 4, CD4+ binding site; d,
Darwinian (positive) selection pressure.
Schematic of the Gag and Gag-Pol processing sites showing the
12 individual protease cleavage sites: 5 cleavage sites in Gag
(p 17/p24, p24/p2, p2/NC, p7/pl, and pl Ip6gag), 6 cleavage
sites in Gag-Pol (NC/TFP, TFP/p6pol, p6pol/PR, PR/RT,
RT/p66, and p66/IN), and a single site in Nal
Phylogenetic relationships of the South African Tygerberg
virology (TV) cleavage site sequences relative to other subtypes
in the group M data set. This representative maximum-
likelihood tree is based on concatenation and analysis of the 12
protease site nucleotide sequences as a single segment of
360bp. An indication of the degree of sequence dissimilarity is
given by the distance from the central node. The percentage of
bootstrap trees out of 1,000 replications supporting a particular
phylogenetic group is shown alongside the node considered.
Amino acid polymorphisms at Gag, Gag-Pol, and Nef cleavage
sites. The letters refer to the amino acid substitutions; the
numbers in parentheses refer to the number of times the
substitution was observed. Each cleavage site sequence consists
of the 5 amino acids upstream and the 5 amino acids
downstream of the scissile bond, indicated by a shill. The
labeling of amino acids is according to the convention of P1 to
P5 going from the scissile bond toward the amino terminus and
P1' to P5' going toward the carboxy terminus. Positively
selected amino acids are marked with asterisks. Dots represent















Changes in HIV-1 subtype distribution and prevalence in CT 99
and KZN from 1992 to 2001. The HIV-1 prevalence is
represented by the background colour ranging from white (<1%
prevalence) to burgundy (>30% prevalence). Subtype
distribution is shown in the pie-charts. Prevalence rates were
obtained from the national HIV-1 seroprevalence surveys.
Longitudinal analysis showing the changes in resistance patterns, 113
viral load and CD4+ counts in five patients who developed drug
resistance during the first 8 to 15 months of therapy. These patien
were: START 4 (a), START11 (b), and MSFCK (c), MSFED (d)
and MSFSD (e).
Stacked bar graph showing the frequency of RT polymorphisms 114
before (blue) and after (pink) treatment. Values along the x-axis a
in increments of 20%. For example, the V35T polymorphism
occurred in 100% of the isolates before (blue) treatment, as well
100% of the isolates after (pink) treatment, while the V601
polymorphism occurred in 80% of the isolates before, as well as
after treatment. M184V was the most frequent primary resistance
mutation occurring after treatment. The K21I, K32N, K49R, V90
I135M, E203K, K281R, K311Q mutations were detected after
treatment, although at very low frequencies. The frequency of the
V35T mutation increased from 40% to 60% after treatment.
Changes at other positions (RT123 and RT277) resulted in a
decrease in frequency of mutations at these positions.
Subtype C specific Maximum-likelihood tree of all available 117
START and MSF sequences (including the generate Most
Recent Common Ancestor [anc]) and reference subtype C
strains from Botswana (BW), Brazil (BR), Ethiopia (ET), India
(IN), South Africa (ZA and TV), Tanzania (TZ) and Zimbabwe
(ZM). The tree was rooted with HXB2.
The predicted tertiary structures for START11. Sidechains are 119
coloured as followes: RT 65 (blue); 106 (bright green); 181
(red); 190 (orange); 274 (yellow); 275 (pink); 278 (purple); 281
(burgundy); 292 (dark green); 334 (turquoise). The Lysine at
RT65 occurs in the "fingers" domain of RT and usually comes
into contact with the template-primer complex during normal
RT activity. The change to an Arginine at month 2 causes a
marked change in the orientation of the side chain. The changes
that occur at the positively selected sites are more complex and
are located mainly in the "thumb" domain of the RT. At months
1 and 2, it appears that the side chain at RT281 curls upward,
with a corresponding downward movement of RT275. The
normal orientation is resumed from month 3. The V to I
mutation at RT274 from month 2 onwards does not appear to
have a dramatic impact on the RT structure
Figure 16
Figure 17
Figure 19b. The predicted tertiary structures for START4. Sidechains are 120
coloured as followes: RT 21 (dusky pink); 74 (sky blue); 101
(teal); 106 (bright green); 181 (red); 190 (orange); 184 (dark
xi
blue); 202 (blue); 203 (green); 207 (brown); 232 (turquoise);
219 (black); 311 (burnt orange). Mutations at RT202, 203 and
207 were positively selected. Although very closely situated to
each other, RT203 is more external then the other two residues.
Other positively selected residues, RT 311 and RT21 are also
situated on the surface of the RT enzyme. Mutations at these
locations probably serve to stabilize the enzyme.
Figure 19c
Figure 19d
The predicted tertiary structures for MSFCK. Sidechains are
coloured as followes: RT 102 (dark green); 103 (pink); 113
(light blue); 123 (bright blue); 135 (grey); 184 (dark blue); 190
(orange); 196 (bright pink); 215 (cream). Changes in
conformation for condons 196, 135 and 123 all occur from
MSFCK M6 onwards. Codon 102 lies in the palm domain of
HIV-1 RT and is very close to the NNRTI binding sites, and its
change in conformation is noted at the same time as the
acquisition of the K103N mutation in MSFCK_M14.
The predicted tertiary structures for MSFED. Sidechains are
coloured as followes: RT 67 (dusky pink); 101 (teal); 123
(bright blue); 184 (dark blue); 190 (orange); 116 (grey-green);
151 (pink); 334 (lime). Perhaps most important is the close




which causes multi NRTI resistance. Codon 67 s situated near
the opening of the binding groove and is in a good position to
interact with template primer complex.
121
122
Figure 19e The predicted tertiary structures for MSFSD. The only change 123
in MSFSD occur at codons 103 (pink), 135 (grey-green) and
184 (dark blue). Codon 135 appears to change from an Ito M in
association with the M184V mutation and reverts back to the
wild type in conjunction with the reversion to wildtype at codon
184.
Figure 20 Comparison of the predicted secondary structures for the 5 126
patients. Beta sheets are represented by an "E" and helixes are
represented by an "H". The time points are given after the
sample name and an underscore (eg START11_M1 represents
the structure for the month one sample. K65R and D67N appear
to cause lengthening of the helix in START11 and MSFED
respectively. The V901 mutation in MSFCK_M7 appears to
have the same effect. L74V does not appear to change the
secondary structure in that region. The secondary structure at
RT101-200 appeared to be conserved, with only slight
variability at RT189, but this could be an artifact of the
software. The length of the helix at RT 290-300 appeared to be
very variable, but the pattern was not consistent, nor was it
directly related to a mutation in that region. A predicted sheet
was conserved at RT315-316 in MSFED and MSFSD, but was
variable in the other isolates. Resistance mutations generally
did not occur in sheets or helices, except the following
mutations: K65R (sheet), L74V (helix), V106M (sheet), Y181C
and M184V (sheet).
xii
Figure 21 Neighbour-joining tree of sequences derived from the matched 135
mother-infant pairs. Maternal sequences obtained at baselines
and 6 weeks post delivery are denoted by the prefixes "b" and
"m" respectively. The child's sequence obtained at 6 weeks of
age, is labelled with the prefix "c". The time from delivery (in
weeks) is noted after the "p". Bootstrap re-sampling values of
>90% are represented by an (*). As expected, sequences from
matched mother-infant pairs were more closely related to each
other, than from sequences obtained from unrelated mothers
and infants
Figure 22 Maximum-likelihood tree of mother and infant pairs, with a 136
consensus subtype C sequence as the outgroup. Mothers'
sequences are denoted by a square and infants' sequences are
denoted by a circle. Resistant isolates are coloured in red and
non-resistant isolates are coloured in blue. No clustering of
resistant isolates was visible from the tree topology.
Figure 23 Comparison of functional sites in selected mothers' baseline 137
samples (a); non-resistant mothers (b) vs resistant mothers (c);
and non-resistant infants (d) vs resistant infants (e). The K103N
mutation resulted in the loss of a cAMP, cGMP dependant
protein kinase phosphorylation site at codons 102 to 105 in RT.
This was replaced with a myristoylation site at codons 99 to104
and a glycosylation site at codons 103 to 106. All resistant
infants lacked a tyrosine kinase phosphorylation site at codons
174 to 181, near the RT active site.
Figure 24 KAR01' s plasma viral load was still at detectable levels at 30 143
days after starting treatment, and only went to below detection
(<40 cpm) at 3 months. In contrast, the PBMC viral load
gradually increased to just below 1000cpm at 6 months. The
plasma viral load for KAR05 decreased more rapidly and was
already <40 cpm at 30 days. Unfortunately, the PBMC viral
load quickly increased after starting treatment and was still
above 1000cpm at 6 months. For KARI 1, the plasma viral load
decreased after starting treatment, but never went to below
detectable levels up to three months after starting treatment.
The PBMC viral load displayed an initial increase, followed by
a decrease to <40cpm at 30 days. By three months, the PBMC
viral load had increased marginally to 62 cpm. In KAR09,
neither the plasma nor PBMC viral load went to below 40 cpm
by three months.
Figure 25 Neighbour-joining tree of the resistant isolates and subtype 145
reference strains. Bootstrap values >90% are represented by a
"*". KAR09 isolates clearly clustered with the subtype B
reference strains, while KAR01, KAR05 and KARI 1 fell
within the subtype C cluster. As expected, sequences from each
isolate clustered together.
Figure 26 Comparison of RT sequences in the plasma and PBMCs for all 146
xiii
patients. Resistance mutations are shaded in yellow.
Figure 27 (a)
Figure 27 (b)
An HXB2 rooted neighbour-joining tree using sequences from
all the KAR09 (subtype B) available time points (represented
by purple squares and circles). There was no clustering of
PBMCs or plasma sequences, with very little genetic diversity
between the sequences obtained for this patient.
Neighbour-joining tree using sequences from all the time points
available for KAR01 (blue), KAR05 (red) and KAR11 (green)
(subtype C isolates). The tree was rooted with a subtype C
consensus sequence. Coloured squares represent plasma
sequences and coloured circles represent PBMC sequences
148
148
Figure 28 Bootscan result for MC77. The analysis was performed with a 154
sliding window of 250 by and a step of 50 bp. The breakpoints
were estimated to be just before the end of PR and
aproximately150 by in RT.
Figure 29 Bootscan result for MC 179. The analysis was performed with a 154
sliding window of 400bp and a step of 50 bp.
Figure 30 a) Frequency of resistance to the NRTIs, NNRTIs and PIs in the 157
resistant isolates.
Figure 30 b) Frequency of multi- NRTI and NNRTI resistance in the 157
isolates. From both figures, a high rate of NNRTI resistance is
evident
Figure 31 Levels of cross-resistance to the RT inhibitors. Most resistant 157
isolates showed a high level of resistance to all the NNRTI with
intermediate to high-level resistance also seen in the NRTIs,
albeit to a lesser extent.
Figure 32 Comparison of polymorphisms in the RT between treated 159
patients with and without resistance mutations. Polymorphisms
occurred at equal frequencies in resistant and non-resistant
isolates at RT positions 35, 173, 200, 207, 245, 293, while the
R211K mutation was found more frequently in resistant
isolates. Mutations at codons 135, 138 and 324 were found in
>40% and only in resistant isolates.
Figure 33 Template of the plate layout for determining the virus TCID50. 168
Figure 34 Template of the Excel spreadsheet for the calculation of the 168
virus TCID50.
Figure 35 Template of the plate layout for determining the virus drug 170
susceptibility. The drugs were serially diluted in duplicate, with
2 drugs per plate. Each plate contained the reference strain
pNL4-3.
Figure 36 Calculation of fold change. The fold change was calculated by 170
dividing the patient strain IC50 by the reference strain IC50.
xiv
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Abstract
As South Africa begins its National HIV-1 treatment program, it is urgent that we collect
data that will help define the phylogenetic relationships, transmissibility and drug
responsiveness of C viruses. In this thesis, data is presented on the genetic diversity of
locally circulating drug naive subtype C strains, as an indication of their natural
susceptibility to antiretroviral drugs, prior to the national roll-out of antiretroviral therapy.
At the time this thesis was initiated, antiretroviral therapy was only available in South
Africa in a few clinical trials and in the private sector, and it was therefore difficult to
obtain large numbers of samples from treatment-experienced patients. Nevertheless,
valuable information on the prevalence and patterns of resistance mutations in subtype C
infected patients was obtained from small studies on patients receiving HAART,
concomitant HAART and TB treatment, HAART and treatment for Kaposi Sarcoma, and
single dose nevirapine for the prevention of mother-to-child transmission of HIV-1
infection.
The results show that the general antiretroviral drug naive population do not harbour any
major resistance-associated mutations to the currently available protease and reverse
transcriptase inhibitors, with no differences in genetic variation between the different
ethnic groups infected with subtype C. Phenotyping of some of these isolates showed that
they were susceptible to the available protease and reverse transcriptase inhibitors, and
hyper-susceptible to the protease inhibitor, Lopinavir. Phylogenetic analysis of recent and
retrospective subtype C isolates showed that there are multiple lineages of subtype C
viruses circulating in South Africa, indicative of multiple introductions of subtype C
across its many borders. Polymorphisms in the protease, reverse transcriptase and C2-V5
region of envelope in these drug naive samples lead to significant variation in the number,
type and location of potential phosphorylation sites. There was also variation in the
cleavage sites controlling the initiation and rate of Gag and Gag-Pol processing (p2/NC)
and the activation of protease (TFP/p6gag) suggesting that there may be important
differences in the way that B and C viruses regulate polyprocessing and virion assembly.
Similar to studies on subtype B, 10 to 18% of the patients on HAART developed drug
resistance. However, those on concomitant HAART and TB treatment developed
resistance as early as one month after starting treatment. Generally, the resistance
mutations that were seen were consistent with those seen in treatment experienced subtype
B isolates. Of note was the high level of resistance to the entire class of NNRTIs. This
could be reflective of the predominant use of NNRTI-based regimens, as well as the low
genetic barrier in this class of drugs. The NNRTI mutations included the V106M mutation
that is considered a signature mutation of EFV experienced subtype C isolates. Resistance
was high (40%) in mothers and infants 6 weeks after each received a single dose of NVP.
K103N was most common mutation in the mothers, while Y181C was most common in
the infants. Of note were the changes in functional properties caused by these mutations,
by the introduction or alteration of putative myristoylation and phosphorylation sites in the
RT.
Taken together, these data suggests that the pattern of resistance in African patients will be
similar to that observed for the treatment of subtype B infection. However, patients should
be closely monitored for viral rebound very early on in treatment. Also, given the high rate
of resistance in mothers and infants after single dose NVP, the search for safer regimens to
prevent MTCT should be intensified. Although the mechanisms are unknown, our results
indicate that several of the phosphorylation-related substitutions in the pol and env genes
of KZN and other C viruses are highly conserved and positively selected. It will be
important to determine whether these sites play an important role in the replicative
capacity and proteolytic processing of C viruses, and in viral entry. These data provide
important benefits for public health policy and planning and for future patient treatment
management.
Chapter 1
Review of the Literature
1.1 HIV-1 Discovery and Classification
The acquired immunodeficiency syndrome (AIDS) was first recognized in 1981 among
homosexual men in the United States of America. It was only in 1983 that the organism
later termed the human immunodeficiency virus (HIV) by the International Committee of
Viral Taxonomy, was isolated by Barre-Sinoussi et al (1983). Soon after the discovery of
HIV, the significant genetic variability of the virus evoked intense interest. An increase in
the number of isolates from around the world, coupled with the vaccine initiative in the
early 1990s, led to the discovery of equidistant clades (or subtypes), which have since
been classified as subtypes A, A2, B, C, D, F 1 , F2, G, H, J, and K in addition to
circulating recombinant forms (CRFs) (Novitsky et al, 2001; Janssens et al 1997; Myers et
al, 1997; Louwagie et al, 1995). These subtypes form part of Group M (Major) viruses and
are responsible for the majority of HIV-1 infections in the world. Other HIV-1 sequences
can be classified either as 0 (Outlier), and N (Non-M and Non-O) groups (Gurtler et al,
1994; Myers et al, 1997; Robertson et al, 2000; Simon et al, 1998). It is thought that HIV
entered the human population in at least seven different simian zoonosis events in West
Central Africa (Hahn, 2000). HIV-1 shares the closest phylogenetic relationship with the
SIVcpz strain found in a West Africa chimpanzee subspecies called Pan troglodytes
troglodytes (Rambaut et al, 2004). The countries in West Central Africa (Gabone,
Cameroon and Equatorial Guinea) had little contact with the outside world until after
World War II when economic changes brought more travellers to Africa. This was
probably when the disease started its slow spread around the world with the earliest
evidence of HIV-1 infection found in the Congo in 1959 (Zhu et al, 1998).
1.2 Global Subtype Distribution
HIV-1 subtype B is the most prevalent subtype in North, Central and South America along
with subtype F, B/F recombinants, and to a lesser extent -but ever increasing -, subtype C
(Figure 1) (Spira et al, 2003). In Europe, subtype B is found in the west, while Central
Europe is dominated by subtype G and A/G recombinants (Korber et al, 2000; Esu-
Williams et al, 1997; Janssens et al, 1997). In Eastern Europe, subtype A featured early in
the epidemic (1995/1996), while subtype B spread among the injecting drug users (IDUs).
Both have now re-combined into a new CRF (A/B), which is spreading eastwards in that
region (UNAIDS, 2002). The Middle East, India, China and Nepal are dominated by
subtype C, while A/E recombinants appear in China, Thailand and the Philippines. Africa
as a whole has all known HIV-1 subtypes.
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Central Africa has the largest variety of subtypes (A, D, G, F, H, A/G, A/E), which is
indicative of a long-standing epidemic. In eastern Africa, subtypes A and D predominate,
although subtype C is also spreading upward from the south and could impact on the
incidence in the east in the future (Spira et al, 2003). West Africa is dominated by subtype
A, G and more recently, A/G recombinants (over 30% of new infections), with sporadic
occurrences of subtype D. Western Africa has a less severe epidemic, with a relatively
modest presence in Senegal, Mauritania and Cape Verde. North Africa has very little HIV-
1 infection, mostly subtype B, with prevalences below 1% in Morocco, Algeria, Libya and
Egypt. Southern Africa is dominated by subtype C (Janssens et al, 1997), with sporadic
cases of subtype A, B and D.
1.3 The Spread of Subtype C
Since subtype C began its devastating spread across southern Africa in the late 1980s,
major outbreaks have now occurred in every country in this region. It is also responsible
for the rapidly expanding epidemic in India, and is increasing in frequency in China and
Brazil. In fact, of the 5 million new HIV-1 infections in 2002, subtype C accounted for
>56% of these infections (Esparza et al, 2000). This is also influenced by the fact that
most new infections are from heterosexual contact, which is the main route of
transmission of HIV-1 subtype C.
1.3.1 Africa
Earlier in the epidemic (late 1970s), HIV was not as well established in southern Africa as
it was in central and eastern Africa, with the rate of spread being most rapid in east Africa
(Hawlan, 2000). This began to change in the 1980s, when subtype C began its spread
across southern Africa, starting in Tanzania, Zambia and Zimbabwe (Figure 2). In
Tanzania, the first cases of HIV-1 were reported in 1983 (Mhalu, 1989). Early studies
reported subtypes A and D as the predominant subtypes in this country (Holm-Hansen et
al, 1996), while later reports have found equal proportions of A, C and D (Vidal et al,
2000). Since then there has been a dramatic increase in the HIV prevalence, with a
concomitant increase in the prevalence of subtype C (12.7% in 2000 to 20% in 2003),
particularly in the regions that border near Malawi and Zambia (Kapiga et al, 2002;
Hoelscher et al, 2001; Renjifo et al, 1998). The interaction between Tanzania, Zambia and
Malawi has played a role in the spread of subtype C in this region, with >93% of
infections in Zambia due to subtype C (Handema et al, 2001; Morison et al, 2001; Trask et
al, 2002). The earliest sequenced isolate of subtype C in the public database originates
from Malawi. Malawi is one of the
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Figure 2. HIV prevalence in Sub-Saharan Africa (UNAIDS, 2002)
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few regions that have population-based data derived from two detailed surveys carried out
in northern Malawi in 1981 to 1984 and in 1986 to 1989 as part of a study on leprosy and
other mycobacterial infections (Ponninghaus et al, 1993 and 1987). McCormack et al
(2002) were able to subtype these samples. Their findings show that in 1982 to 1984,
subtypes A, D and C were all present. Overall, subtype C accounted for 55% of the early
samples (6/11). The next wave of sampling (1986 to 1989) showed an increase in the
number of subtype C isolates, which corresponded to 90% of the cases, with non-C
subtypes being more common in the north, bordering on Tanzania. They also found four
recombinants: two AC, one AD and one DC. It is thought that the construction of a main
road during the 1980s between Malawi and Tanzania could have influenced the spread of
subtypes between the two countries (McCormack et al, 2002).
By the early to mid 1990s, the rapid expansion of the HIV-1 epidemic caused by subtype
C had reached Botswana. HIV prevalence among antenatal clinic attendees tested in the
major urban areas of Botswana (Gaborone, Francistown, and Selebi-Phikwe) increased
from 6% in 1990 to 39% in 1997 (range of 34 to 43%) (Hensle, 1998). Outside of the
major urban areas, median HIV prevalence increased from no evidence of infection in
1985 to 34% in 1997. To date, all isolates from Botswana have been identified as subtype
C (Rodenburg et al, 2001).
Along with Botswana, South Africa, Zimbabwe, Namibia, Swaziland, Mozambique and
Lesotho have also borne the brunt of the subtype C epidemic (Essex 1999; Bredell et al,
1998; Janssens et al, 1997). Prevalences have increased in Namibia from 7% in 1994 to
31% in 2000. Information on HIV prevalence among antenatal clinic attendees has shown
a dramatic increase from 3.9% in 1992 to 34.2% in 2000 for Swaziland, and from 5.1% in
1991 to 42.2% in 2000 for Lesotho (UNAIDS, 2000). Similarly, prevalences in
Mozambique have increased from less than 1% in 1988 to 13.2 % in 2000. In South
Africa, only 166 cases of AIDS had been reported between 1982 and 1988 (Sher et al,
1989). However, by 1997 there was already a dramatic increase in HIV prevalence
although at unequal rates throughout the country. The highest prevalence was found in
KwaZulu Natal (northeast region) with a prevalence of 26.92%. In contrast, the prevalence
rates in the Western Cape were much lower with a prevalence of only 6.29%. Of the
isolates circulating in South Africa, 91% were subtype C (Van Harmelen, 1999). More
recent reports from South Africa have shown the prevalence rates to be as high as 36.2%
in KwaZulu Natal, while still a moderate 8.7% in the Western Cape (Rollins et al, 2002).
There has also been an increase in the number of non-C subtypes detected in South Africa
(subtypes A, D, G and A/G), mostly in individuals from other countries, however, some of
these were found in combination with C. This could also be indicative of local
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recombination (Bredell et al, 2002). Subtype C is the predominant subtype in KZN, with
only one C/D recombinant reported (Gordon et al, 2003).
In addition to its spread across the southern parts of Africa, subtype C is also prevalent in
Ethiopia, East Africa. Subtype C has been the predominant strain in the Ethiopian
epidemic from the beginning, with 98% of samples isolated harbouring subtype C viruses
(Abebe et al, 2001; Sherefa et al, 1994). The first case of HIV-1 infection in Ethiopia was
registered in 1984 in the capital city Addis Ababa (Tsega et al, 1988; Zewdie et al, 1988).
Prevalences began to increase from 11-13% in 1991, to 18% in 1996 (Fontanet et al, 1998;
National AIDS program 1994). However, this figure is starting to decline as the
prevalence rates of 15.1% in 2001 show. There are few studies describing the
epidemiology of AIDS in Burundi, also in the east of Africa. Subtype C is also the
dominant subtype in this region with a prevalence of 89% (Koch et al, in 2001). In Kenya,
HIV-1 infection was first reported in the mid-1980s in a group of Nairobi sex workers
(Kreiss, 1986; Obel 1984). Kenya also experienced a dramatic increase in HIV-1
prevalence during the 1990s, from 8.3% among women attending antenatal clinics in
1994, to 11% in 1997. Although subtype A is the major circulating subtype in Kenya,
subtype C is also present in a significant minority (6.9% among breast-feeding women)
(Neilson et al, 1999; Yang et al, 2004).
In Uganda, the first HIV/AIDS case was identified in 1982 (UNAIDS, 2001). Uganda
originally had one of the highest prevalences of HIV-1 infection in the world. In rural
regions of southwestern Uganda, overall seroprevalence rates had been reported to be
8.2% (1989) and 13% (1991) and were even higher in urban areas: 28.1% (1989) 40.4%
(1991). However, Uganda was the first African country to have substantially decreased the
effects of the HIV pandemic, with prevalences decreasing to 11.25% in 2000 (UNAIDS,
2001). Several studies have shown subtype A and D to be in similar proportion in Uganda
and comprise the major components of the epidemic in that region (Hu et al, 1999;
Brennan et al, 1997; Rayfield et al, 1998). Subtype C is still playing only a minor role in
the epidemic in Uganda, accounting for only 3-8% of the isolates (Downing et al, 2000;
Brennan et al, 1997). D/C recombinants have recently been isolated from Uganda (Wilbe
et al, 2003).
1.3.2 Southeast Asia
The HIV-1 epidemic first appeared in Southeast Asia in the late 1980s. In India, the
epidemic appeared to begin in 1986, when six female sex workers were found positive for
HIV antibodies in Tamil Nadu, in south India. (Seth and Sharma, 1991). Since then the
epidemic has spread rapidly through every region of the country (Srikanth et al, 1997).
Early studies in India identified subtype C as the major circulating subtype among female
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sex workers and blood donors, along with the sporadic presence of subtypes A and ThaiB
among the IDUs of Manipur in the northeastern part of India (Chakrabarti et al, 2000;
Maitra et al, 1999; Gadkari et al, 1998; Jameel et al, 1995; Tsuscie et al, 1995; Baskar et
al, 1994; Grez et al, 1994). The ThaiB strain may have been introduced independently into
this region through drug-trafficking links with southeast Asian countries such as Myanmar
and Thailand (Maitra et al, 1999; Sarkar et al, 1993). It is not known exactly when subtype
C was introduced into this population of IDUs, however, there was a definite increase in
prevalence relative to the ThaiB strain (from 46% to 68%) (Mandal et al, 2002). Subtype
C probably arrived in China from India, via the over-land heroin trafficking routes (Beyrer
et al, 2000; Yu et al, 1998; Neild et al, 1997). Beyer and colleagues (2000) suggested that
subtypes B, and later C spread among the IDUs from Burma (which produces 60% of the
world's heroin) to China across its eastern border. Phylogenetic analysis by Rodenburg et
al (2001) have supported the suggestion that subtype C viruses now circulating in China
may have been introduced from India, showing that viruses from China were more closely
related to certain viruses from India (Rodenburg et al, 2001). There is now evidence that B
and C have recombined and are spreading northwards in China (UNAIDS 2002; Yu et al,
1998; Neild et al, 1997; Beyrer et al, 2000)
1.3.3 Brazil
Brazil is the largest country in South America and is one of the most affected by the HIV-
1 epidemic. The HIV-1 subtype distribution is complex when compared to other South
American countries. Subtype B is the main circulating subtype, but other subtypes such as
F, B, C and now B/C and B/F recombinants are also currently circulating (Bongertz et al,
2000; Caride et al, 2000; Couto-Fernandez et al, 1999; Brindeiro et al, 1999; Gao et al,
1998; Sabino et al, 1994; Csillag et al, 1994). Subtype C was already present in the
southern regions of Brazil from as early as 1992, although the initial incidence was small
(3%) (Bongertz et al, 2000; Brindeiro et al, 1999; Gao et al, 1998; Csillag et al, 14). More
recent studies have shown a dramatic increase from the previous figures, with a prevalence
of 30% for subtype C in the south and southeast regions, although the increase was less as
one moved further north (Soares et al, 2003a; Soares et al, 2003b). The high incidence of
subtype C in this region coupled with the equally high incidence of subtype B, facilitated a
number of recombination events demonstrated by the presence of B/C and C/B
recombinants Soares et al, 2003b).
1.4 Differences Between Subtypes B and C
At the molecular level, there are some characteristic differences between subtype B and C.
These were first noted by Johansson et al, (1995), who compared the LTR sequences from
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the available Ethiopian HIV-1 strains with Swedish HIV-1 subtype B strains and earlier
published data. In all the Ethiopian HIV-1 subtype C strains, the first five nucleotides,
(G/A)CAGA, were different in the Swedish subtype B strains. The most striking
difference in the LTR region was the presence of putative third NF-KB site in the
Ethiopian strains located upstream of the usual sites. At the same time, the core enhancer
sequence GGGACTTTCC at site I was modified by a deletion of the A nucleotide and a
change of the first T to a G (Johansson et al, 1995). The presence of an extra NF-KB site
could be related to an increased fitness in subtype C since subtype C LTR sequences have
a higher transcriptional activation relative to subtype, B and an increased response to the
cytokine tumour necrosis factor alpha (Montano et al, 1997; Jeeninga et al, 2000; Montano
et al, 2000). However, Rodenburg et al, (2001) found that the putative third NF-KB site
frequently contained deletions or mutations that changed its consensus sequence, or were
not found in some sequences, suggesting that this site may not be functional after all.
Another difference seen between the two subtypes is the presence of acidic amino acids at
positions 11 and 25 in the V3 env sequence of subtype C viruses, which is a feature of
viruses that use the CCR5 co-receptor for cell entry (Ping et al, 1999). CXCR4 co-receptor
utilization and a syncytium-inducing phenotype are rare among subtype C isolates
(Bjorndal et al, 1999; Cecilia, 2000; Tscherning et al, 1998). A switch from CCR5 to
CXCR4 co-receptor tropism and NSI to SI phenotype has been associated with
progression to AIDS in individuals infected with subtype B viruses. This has not been the
case with most subtype C strains, which remain CCR5 tropic and NSI in primary
lymphocyte cultures (Abebe et al, 1999; Bjorndal et al, 1999; Morris et al, 2001). Studies
on animal models have suggested that there are different pathogenic sequelae for infection
with CCR5 or CXCR4 utilizing strains (Berkowitz et al, 1998 and 1999; Harouse et al,
1999). This is strong evidence to suggest that the mechanism of pathogenesis and
transmission is different in subtypes C and B. However, there have also been reports from
South Africa and Zimbabwe on co-utilization of CCR5 and CXCR4 in subtype C isolates
(Cilliers et al, 2003; Janse van Rensburg et al, 2002; Johnston et al, 2003). Janse van
Rensburg et al, (2002) reported a change in the phenotypic characteristics of recently
isolated subtype C strains, as compared to their previous study using older subtype C
samples, and suggest that this is a result of a maturing of the subtype C epidemic in South
Africa. Meanwhile, Johnston et al, (2003) suggest that antiretroviral treatment could create
an environment facilitating the emergence of CXCR4 tropism in subtype C viruses. In
their study of 28 patients from Zimbabwe, viruses from 50% of those on treatment induced
syncytium formation when cultured with MT2 cells and the majority of those viruses were
capable of using both CCR5 and CXCR4 as co-receptors for viral entry.
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It has also been suggested that subtype C viruses grow more readily in Langerhans cells
than subtype B (Soto-Ramirez et al, 1996). These cells line the cervix, vagina and foreskin
of the penis and could possibly facilitate the spread of the virus through vaginal
intercourse. This is discussed further in section 1.5. Other differences between the two
subtypes include a truncated rev protein (Gao et al, 1998; Rodenburg et al, 2001) and a
five-amino acid insertion in the vpu transmembrane in subtype C (Gao et al, 1998;
Novitsky et al, 1999).
1.5 Transmission of Subtype C
HIV is transmitted through blood, genital secretions and breast-milk. It remains uncertain
whether the existence of different subtypes has important implications for the transmission
of HIV.
1.5.1 Horizontal Transmission
Many studies have found subtype B to predominate in HIV-1 infections acquired
homosexually and by IDUs. Non-B infections are mostly seen in heterosexually acquired
HIV-1 infections, and are usually among individuals with an epidemiological link with
Africa or Asia (Herring et al, 2003; Liitsola et al, 2000; Op de Coul et al, 2001; Reinis et
al, 2001; Lukashov et al, 1995). In fact, heterosexual transmission is responsible for the
majority of new infections in southern Africa and India, a region where subtype C
predominates (Mandal et al, 2000; Tien et al, 1999). As already mentioned, subtype C may
replicate in Langerhans cells, which are found in genital mucosal epithelium and are
thought to be the cells through which vaginal infection occurs. Langerhans cells are
antigen-presenting cells found in the epidermis, and in oral and genital mucosal
epithelium. They are, however, absent from rectal mucosa (Lalvani and Shastri, 1996).
Therefore, one could argue that subtype C appears to be better adapted to penile-vaginal
transmission, while subtype B may be more efficiently transmitted through blood (Mastro
et al, 1997). Reports of subtype C transmission in China and India show that subtype C is
transmitted to a lesser extent via intravenous drug use (Saraswathy et al, 2000). The spread
of subtype C in these regions may also be influenced by heterosexual transmission from
the IDUs to their partners.
1.5.2 Mother-to-child Transmission (MTCT)
In KZN, South Africa, MTCT accounts for 34% of HIV infections (Rollins et al, 2002).
Transmission of HIV-1 from mother to infant may occur in utero, intra-partum, or
postpartum through breast-feeding. Factors associated with perinatal transmission include
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1.6 Prevention of Mother-to-Child Transmission (pMTCT)
Preventative strategies include routine antenatal voluntary counselling and testing (VCT),
various combinations of a shortened period (3-6 months) of exclusive breast-feeding,
perinatal administration of ARVs, and provision of safe and affordable replacement feeds.
1.6.1 Use of Nevirapine (NVP) in pMTCT
Although long course anti-retrovirals (ARVs) and caesarian section substantially reduces
vertical transmission, they are not practically achievable in most developing countries. The
low cost of Nevirapine (NVP) (US$2) and simplicity of administration offers a great
advantage for its use in MTCT prevention treatments, particularly for low-income
countries (Saloojee, 2001). NVP has been widely used in adults as one of a combination of
drugs to treat established HIV infection, but is also effective when given alone as a single
dose to the mother at the beginning of labour and one dose administered to the baby within
72 hours of birth. NVP given to HIV-positive pregnant women rapidly crosses the
placenta into the fetus with its effects lasting through the first week of life. The
pharmacokinetics of NVP are characterised by rapid absorption and distribution, followed
by prolonged elimination. The primary route of NVP elimination is through metabolism
by the cytochrome P450 enzyme system. NVP elimination accelerates during long term
administration because of autoinduction of the enzymes involved in its elimination
pathway. A regimen of a single 200mg oral dose administered to the mother during labour,
and a single 2 mg/kg dose administered to the newborn at 48 to 72 hours after birth
maintains serum NVP concentrations above 100 lig/L (10 times the in vitro 50% inhibitory
concentration against wild-type HIV-1) throughout the first week of life (Mirochinick et
al, 2000). Clinical trials have confirmed the efficacy of NVP in preventing mother-to-child
transmission (MTCT) of HIV. The HIVNET 012 trial in Uganda showed that NVP was
able to reduce MTCT, with only 8.1% of infants exposed to NVP acquiring HIV at birth
(Guay et al, 1999). Almost all the babies in the trial were breast fed, resulting in ongoing
exposure to HIV. However, at 14 weeks, the rate of HIV infection was only 13%, while at
12 months the transmission rate was 15.7%, confirming that the reduction in the risk of
transmission associated with NVP prophylaxis persists for at least the first year of life,
despite the ongoing risk posed by breast-feeding (Guay et al, 1999). The Petra study
conducted in Tanzania, Uganda and South Africa using various short-course regimens,
found that Zidovudine (AZT) plus Lamivudine (3TC) given at birth and for 7 days
postpartum to both mother and babes was effective in reducing transmission (Petra Study
Team, 2002). In the South African Intrapartum NVP Trial (SAINT), 1307 mother-infant
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pairs were randomised to either NVP during labour and post-delivery, or multiple doses of
AZT/3TC during labour and for one week after delivery to mother and baby. In both
treatment arms, about 40% of infants were breast-fed. Eight weeks after birth there was no
significant difference observed between the rate of HIV infection or death across the two
treatment arms, with a rate of 12.3% in the simpler NVP arm, and 9.3% in the more
involved and expensive dual therapy arm (Moodley et al, 2003).
1.6.2 Resistance after Single Dose NVP
Evidence of drug resistance among women given NVP monotherapy during labour has
raised concerns about this intervention. Single mutations in HIV-1 RT that can cause high
level NVP resistance are likely to exist in most HIV-1 infected patients at low levels prior
to ARV drug exposure (Richman et al, 1994). This favours the emergence of NVP
resistance following NVP exposure (Eshleman et al, 2002). The emergence of NVP
resistance after only a single dose is also a consequence of the long half-life of NVP upon
initial dosing, before the induction of hepatic enzymes that speed up its metabolism
(Katzenstein, 2000). Therefore, women receiving NVP for pMTCT experience a lengthy
exposure (up to 2 weeks) of active but diminishing concentrations of NVP, creating
selective pressure similar to those associated with NVP monotherapy (Havlir et al, 1996;
Richman et al, 1994; Wei et al, 1995). The NVP-resistant viruses usually fade from
detection in women and infants over time as wildtype viruses repopulate the viral
quasispecies and become the predominant strain (Eshleman et al, 2001b). Therefore, it is
likely that, in most cases, the re-introduction of NVP at delivery during a second
pregnancy should result in the suppression of HIV replication, since most of the viral
variants would be sensitive. If resistance mutations were to re-emerge, it would likely
occur after delivery, and with the addition of two new ARVs, one would expect that HIV
replication could be maximally suppressed and transmission prevented. However, there is
growing evidence that the K103N mutation can persist as a minor population of the viral
quasispecies for many years, which can very quickly re-emerge with the reintroduction of
drug selection pressure (Little et al, 2004; Mellors et al, 2004; Palmer et al, 2004). Mellors
et al, (2004) have shown that low-frequency NNRTI—resistant variants contribute to the
failure of EFV-based regimens.
Recent reports suggest that risk of NVP resistance may depend on viral subtype (Eshleman
et al, 2001a and 2004a). Eshleman and colleagues (2004a) have shown that the emergence
of NVP resistance was higher in subtype D versus subtype A, and suggested that the rate
of NVP resistance would vary from region to region, depending on which subtypes were
prevalent. In the studies in Uganda on the emergence of resistance after single dose NVP,
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resistance was found in 19% of women at 8 weeks post dose, with the K103N mutation
most common. The Y181C mutation occurred most commonly in the infants. Further
analysis of cloned variants showed that the Y181C mutation was detected as early as 7
days after a single dose of NVP, but faded in most women by 6-8 weeks, while the K103N
mutation was more likely detected at 6-8 weeks than 7 days (Eshleman et al, 2004b).
Eshleman and colleagues (2004b) suggested that the more rapid emergence and fading of
Y181C versus K103N mutations was linked to differences in the NVP susceptibility and
fitness of HIV-1 with these mutations.
A recent study conducted in Zimbabwe described a higher rate of NVP resistance in
subtype C infected women, with 75% of the women showing resistance at 2 weeks and
34% at 8 weeks after NVP prophylaxis (Kantor et al, 2003b). This has led to concerns
about the efficacy of NVP in South Africa and other resource-poor settings where subtype
C predominates. Even more unsettling is the report of HIV shedding of resistant virus in
the breast-milk after NVP prophylaxis, where 65% of the breast-milk samples tested
showed NVP mutations (Lee et al, 2003).
1.7 Increased Fitness of Subtype C
Viral fitness is defined as the in vivo capacity of the naturally occurring viral population to
expand in a specified ecosystem, such as human individuals, in which target cells may be
scarce, and immune responses, competing viruses, and pharmacological agents are
typically present. Within a given viral quasispecies, each clone has a fitness representative
of its viral properties (e.g. activity and stability) undergoing selection in that particular
environment. During viral replication within a defined environment, different genomes
encode viruses that replicate at high rates and mutate, but generally remain under the same
selective pressure (Domingo et al, 1999). Therefore, positive (Darwinian) selection
implies that one or more members of the quasispecies are better suited to a given
environment, while negative selection eliminates unfit variants (Domingo et al, 1999;
Domingo and Holland, 1997).
In vivo assays provide the best estimate of viral fitness, using either sequencing (De Ronde
et al, 2001; Devereux et al, 2001; Goudsmit et al, 1997; Goudsmit et al, 1996; Lukashov et
al, 2001), differential hybridization (Eastman et al, 1998; Eastman et al, 1995) or primer-
guided nucleotide incorporation assays (Frost et al, 2000). However, most in vivo fitness
studies have been performed on blood samples (Eastman et al, 1998; Goudsmit et al, 1997;
Goudsmit et al, 1996), and do not take into account the fitness of that strain in other body
compartments. Host-host comparisons are also difficult due to the differences in host
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genetics and immune response. Therefore, in vivo fitness studies are limited to the
emergence of specific quasispecies or drug resistant mutants, and cannot determine the
impact of specific substitutions on replicative capacity (Quinones-Mateu and Arts, 2002).
Multiple methods have been employed to measure HIV-1 replication capacity in vitro
(Clavel et al, 2000; Nijhuis et al, 2001). Viral fitness is best defined in this context by
replicative capacity during growth competition experiments (Quinones-Mateu and Arts,
2002; Holland et al, 1991). However, many studies have equated viral fitness with the
catalytic activity of HIV-1 enzymes (Back et al, 1996; Nijhuis et al, 1999); virus turnover
on HIV-1 infected individuals (Devereux et al, 2001; Goudsmit et al, 1997; Goudsmit et
al, 1996); virus production in monoinfected cultures (Croteau et al, 1997; Doyon et al,
1996; Martinez-Picado et al, 1999; Sharma et al, 1997); using virus particle ratios (Bleiber
et al, 2001), and an HIV-induced event in a single-cycle infection assay (Bjorndal et al,
1997; Maeda et al, 1998; Zennou et al, 1998). The replicative capacity of HIV-1 strains
can provide information on their potential impact on viral load, drug resistance, and
disease progression (Quinones-Mateu and Arts, 2002). For example, the "fittest" isolate
that survives in growth competition assays may also lead to increased virulence within the
host. However, many of these methods have shortcomings. For example, the methods of
measuring viral fitness in vitro is by its replication capacity over a single cell replication
cycle, which may not be a true representation of in vivo fitness as it is replicating under
ideal circumstances including an abundance of target cells, and the absence of inhibitors
and competitors (Mammano et al, 1998).
Differences with regard to replication capacity or fitness may exist among various HIV
subtypes (Spira et al, 2003). Some studies have found that higher rates of viraemia
coupled with lowest CD4 counts have led to a more rapid disease progression in subtype C
infected individuals (Hu et al, 1999; Nielson et al, 1999; Kanki et al, 1999; Spira et al,
2003). Recent outgrowth of subtype C in southern Africa, India, and China has fuelled
speculation that subtype C isolates may be more fit in vivo. However, Ball et al (2003)
have shown subtype C HIV-1 isolates to be significantly less fit than subtype B isolates in
vitro. Increased fitness of subtype B over subtype C was also observed in primary CD4+ T
cells and macrophages from different human donors, but not in skin-derived human
Langerhans cells. Detailed analysis of the retroviral life cycle during several B and C virus
competitions indicated that the efficiency of host cell entry may have a significant impact
on relative fitness. Furthermore, phylogenetic analyses of fitness differences suggested
that, for a recombined subtype B/C HIV-1 isolate, higher fitness mapped to the subtype B
env gene rather than the subtype C gag and pol genes. These results suggest that subtype B
and C HIV-1 may be transmitted with equal efficiency (Langerhans cell data), but that
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subtype C isolates may be less fit following initial infection (T-cell and macrophage data)
and may lead to slower disease progression (Ball et al, 2003).
Velazquez-Campoy et al (2001) reported that proteases from the C and A subtypes exhibit
higher biochemical fitness in the presence of widely prescribed protease inhibitors.
Naturally occurring amino acid polymorphisms found in proteases from the C and A
subtypes lower the binding affinities of existing clinical inhibitors up to a factor of 7.5,
which by themselves are not enough to cause drug resistance, but instead significantly
amplifies the effects of the drug-resistant mutation. By including the enzyme kinetic
properties in the analysis, the biochemical fitness of the C and A subtype drug-resistant
mutants can be up to 1000-fold higher than that of the wild-type B subtype protease in the
presence of the studied inhibitors. They concluded that this might have important
consequences on the long-term viability of current HIV-1 protease inhibitors (Velazques-
Campoy, 2002).
1.8 HIV-1 Antiretroviral Therapy
There are currently four classes of approved ARVs available. The HIV-1 reverse
transcriptase (RT) and protease (PR) enzymes are the molecular targets for 3 classes of
ARV drugs: the protease inhibitors (PIs), nucleoside/nucleotide reverse transcriptase
inhibitors (NRTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The
fourth class of ARVs is the recently approved fusion inhibitor, T20.
1.8.1 HIV-1 Protease
HIV-1 protease is an aspartic protease composed of two identical, non-covalently
connected subunits, ninety-nine amino acids in length (Figure 3) (Loeb et al, 1989). The
subunits form a substrate-binding cleft that is covered with a mobile flap. The
hydrophobic substrate-binding cleft recognizes, and cleaves, the viral Gag, GagPol
polyprotein and Nef precursors to yield the structural proteins and enzymes of the virus
(Baldwin et al, 1995, Chen et al, 1995; Gulnik et al, 1995; Mahalingam et al, 2001; Olsen
et al, 1999).
1.8.1.1 Protease Cleavage
The structural and enzymatic proteins that comprise the virus core are initially translated
as part of the Gag and GagPol polyprotein precursors. Protease cleaves at 12 sites: 5 in
Gag (p17/p24, p24/p2, p2/NC, p7/p1 and p1/p6m); 6 sites in GagPol (NC/TFP, TFP/p6/" 1,
pEr i/PR, PR/RT, RT/p66 and p66/IN and a single site in Nef.
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Figure 3. HIV-1 protease structure showing the position of resistance associated mutations.
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Accurate and ordered processing of these precursors is an essential step in the production
of infectious viral particles (Kaplan et al, 1994; Mervis et al, 1988). For the GagPol
cleavage process, the first site to be cleaved is the p2/NC site to give 2 products, one with
the MA, CA and p2 and the other with NC, TFP, p6P°/, PR, RTp51, RTp66 and IN. This is
followed by cleavage at TFP/p6P °/ to once again give two products, this time with NC and
TFP and the other product with the remaining sites. Finally, the remaining products are
cleaved to give their individual proteins. A similar process occurs for the Gag cleavages.
Firstly, the precursor is cleaved at p2/NC to give two products consisting of the MA, CA
and p2, and the second product consisting of the NC, p1 and p6g ag proteins. This is
followed by cleavage at the MA/CA site and simultaneous cleavage at pl/ p6g ag.
Finally, the remaining sites CA/p2 and NC/pl are cleaved (Cote et al, 2001; Pettit et al,
2003; De Oliveira et al, 2003). The timing of the initiation of these cleavages is regulated
such that the cleavage products remain in the virus particle, even though processing
appears to initiate while the polyprotein precursors are still cell associated (Kaplan et al,
1994; Karacostas et al, 1993).
Sequences at the protease cleavage sites have been studied to determine protease-substrate
interactions and regulation of Gag processing, particularly the amino acids immediately
upstream of the scissile bond (P1) and the amino acid immediately downstream of the
scissile bond (P1'). The initial cleavages are carried out by the precursor-associated
immature protease, including the cleavages that release the mature protease itself. The
mature protease is responsible for the later cleavages. Thus, during virus assembly, the
active dimeric enzyme originates as the result of the dimerization of two GagPol
precursors. Once the protease domain is liberated from the precursors by cleavage at its N
and C termini, a free and mature dimer, consisting of two protease monomers, is produced
(Tessmer et al, 1998). Pettit et al (2002) showed that the rate of cleavage by the viral
protease could be improved with the introduction of specific alternative amino acids at the
P1 position. Substitutions at certain sites in Gag (MA/CA, CA/p2, NC/p1) mediated
enhanced rates of cleavage, while for the other two sites (p2/NC, pl/p6); the wild-type
amino acid conferred optimal cleavage (Pettit et al, 2002). The size of the amino acid at
P1' also affected the rate of cleavage. PI resistant isolates with replication impaired Gag or
GagPol processing can partially compensate by acquiring amino acid substitutions at gag
cleavage sites (Prado et al, 2002; Mammano et al, 1998; Zennou et al, 1998). This is
supported by changes seen in the protease cleavage sites within Gag (p2/ NC, NC/pl and
NC/TFP) after PI therapy in PI resistant individuals (Cote et al, 2001).
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1.8.1.2 Protease inhibitors
There are seven FDA-approved protease inhibitors (PIs): Amprenavir (APV), Indinavir
(IDV), Lopinavir (LPV - manufactured in combination with Ritonavir as Kaletra),
Nelfinavir (NFV), Ritonavir (RTV), Saquinavir (SQV) and Atazanavir (ATZ). The
function of the PIs is to prevent Gag-Pol polyproteins from successfully entering the active
site and being cleaved. This consequently prevents the assembly of new, fully functional
HIV virions.
1.8.1.3 Resistance to Protease Inhibitors
Most PR resistance mutations prevent inhibitor binding by altering the structure of the
substrate cleft (Baldwin et al, 1995; Chen et al, 1995; Gulnik et al, 1995; Mahalingam et
al, 2001; Olsen et al, 1999). Primary resistance mutations line the substrate cleft and occur
at the following codon positions: D3ON, V32I, G48V, 150V, V82A/F/T/S, I84V and
L90M. The protease flaps (residues 33-62) extend over the substrate-binding cleft and are
flexible to allow entry and exit of the polypeptide substrates and products (Shao et al,
1997, Scott et al, 2000). The tips of the flap, residues 46-54, are mobile and are also the
site of many drug resistance mutations. As these mutations are outside of the substrate-
binding region, they do not provide measurable resistance on their own. Instead, these
mutations (at codons 46, 47, 53, and 54) either compensate for the decreased kinetics of
enzymes with active site mutations or cause resistance by altering enzyme catalysis, dimer
stability, inhibitor binding kinetics, or active site re-shaping through long-range structural
perturbations (Erickson et al, 1999). Mutations associated with resistance to the currently
available PIs are shown in Figure 4. Many PIs are now co-administered with a sub-
therapeutic dose of Ritonovir (a P450 enzyme inhibitor) to inhibit the body's drug
clearance mechanism, thereby increasing the plasma levels of the PI (Hurst et al, 2000).
Since PIs are competitive inhibitors, the increased PI concentrations relative to the normal
substrate are partly responsible for the enhanced ARV activity of these boosted PI
regimens. Boosted PI levels can overcome small reductions in susceptibility conferred by
early PI mutations, thus prolonging viral suppression (Condra et al, 2000; Kempf et al,
2001). Therefore viral rebound requires the acquisition of a greater number of mutations
that produce even greater reductions in susceptibility.
1.8.1.3.1 L24I
This mutation has been reported in patients receiving lDV and has not been shown to
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D3ON only occurs in patients receiving NFV. It does not confer in vitro or clinical cross-
resistance to the other PIs on its own (Patick et al, 1996; Markowitz et al, 1998; Winters et
al, 1998a; Zolopa et al, 1999). However, cross-resistance to IDV, RTV, and SQV has been
observed in isolates that have D3ON along with mutations at protease codon positions 88
and 90 (Parkin et al, 2001).
1.8.1.3.3 V32I
The V32I mutation occurs in patients receiving IDV, RTV or APV. By itself, it appears to
cause minimal resistance to any one PI. It causes high-level resistance when present with
other PI resistance mutations M46I, I47V, V82A and I84V (Parkin et al, 2003a).
1.8.1.3.4 M46I/L
The M46L mutation has been reported in patients treated with IDV, RTV, APV and NFV
and contributes resistance to each of the PIs except SQV (Condra et al, 2000; Molla et al,
1996; Schapiro et al, 1996; Patick et al, 1998).
1.8.1.3.5 I47V
Mutations at codon 47 have been reported in patients receiving IDV, RTV, APV, and
often occur in conjunction with the V32I mutation (Markland et al, 2000; Parkin et al,
2003a).
1.8.1.3.6 G48V
This mutation occurs primarily in patients receiving SQV and rarely in patients receiving
IDV (Jacobsen et al, 1995; Patick et al, 1996; Hertogs et al 1998; Winters et al, 1998a). Its
affect on APV and LPV is not known. It often occurs with mutations at codon positions 54
and 82 and isolates with all three mutations are phenotypically resistant to each of the PIs
(Shafer et al, 1998; Palmer et al, 1999).
1.8.1.3.7 I5OV/L
The 150V mutation has been reported in patients receiving APV as their first PI (Maguire
et al 2002). It causes reduced APV susceptibility, and has been shown to cause cross-
resistance to RTV and LPV in vitro (Partaledis et al, 1995; Tisdale et al, 1995; Colonno et
al, 2000; Molla et al, 2001; Parkin et al, 2001; Prado et al, 2002). 150L occurs in patients
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receiving ATZ as their first PI (Colonno et al, 2002). In addition to causing reduced ATZ
susceptibility, it causes hypersusceptibility to each of the remaining PIs (Colonno et al,
2002).
1.8.1.3.8 F53L
This mutation has been in more than 10% of patients treated with multiple PIs and has
been associated with phenotypic resistance to LPV (Kantor et al, 2002a; Kempf et al,
2001).
1.8.1.3.9 I54V/T/L/M
Mutations at this position have been reported in patients treated with 1DV, RTV, APV,
SQV, and LPV and contribute resistance to each of the available PIs (Condra et al, 2000;
Molla et al, 1996; Schapiro et al, 1996; Patick et al, 1998).
1.8.1.3.10 G73C/S/T
These mutations have been reported in patients receiving IDV, SQV or occasionally NFV
monotherapy, but usually are found in patients failing multiple PIs (Shafer et al, 1999; Wu
et al, 2003). It usually occurs in conjunction with the L9OM mutation (Kantor et al,
2002a).
1.8.1.3.11 V82A/T/F/S
V82A/T/F/S occurs in HIV-1 isolates from patients receiving lDV or RTV (Condra et al,
1996; Molla et al, 1996). V82A is the most common mutation at this position, while V82S
is the least common. Alone, these mutations confer decreased susceptibility to lDV, RTV
and LPV however, when present with other PI mutations they contribute phenotypic and
clinical resistance to each of the PIs (Shafer et al, 1998; Sham et al, 1998; Winters et al,
1998a; Falloon et al, 2000; Kempf et al, 2001). V82I occurs more frequently in untreated
individuals with non-B isolates (1% of subtype B versus 5-10% of non-B subtypes), and
confers minimal or no resistance to the available PIs (Gonzales et al, 2001; Brown et al,
2001; Descamps et al, 1998; King et al, 1995).
1.8.1.3.12 I84V/A/C
Mutations at this codon position have been reported in patients receiving only one PI
(either 1DV, RTV, SQV or APV) and cause cross-resistance to each of the PIs (Condra et
al, 1996; Molla et al, 1996; Craig et al, 1998; Hertogs et al, 2000; Sevin et al, 2000). I84V
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tends to develop in isolates that already have the L9OM mutation (Kantor et al, 2002a).
I84A and 184C occur rarely, but are also associated with resistance to multiple PIs when
present with other PI mutations (Mo et al, 2003).
1.8.1.3.13 N88D/S
Mutations at position 88 have been reported in patients receiving NFV or occasionally
IDV. Alone, these mutations cause low-level NFV resistance. When they occur in
conjunction with D30N or M46I, they cause high-level resistance to NFV (Colonno et al,
2000; Petropoulos et al, 2000; Ziermann et al, 2000). N88S causes hypersensitivity to
APV but the clinical significance of this is not known (Ziermann et al, 2000).
1.8.1.3.14 L9OM
The L9OM mutation has been reported in patients treated with SQV, NFV, IDV and RTV.
And causes cross-resistance to each of the available PIs (Lawrence et al, 1999; Zolopa et
al, 1999; Falloon et al, 2000; Hertogs et al, 2000; Para et al 2000; Dronda et al, 2001;
Kempf et al, 2001). The mechanism by which L9OM causes PI resistance is not known.
1.8.1.3.15 Polymorphisms in PR and Resistance
Amino acid variants at codons 10, 20, 36, 63, 71, 77, and 93 also make frequent
contributions to drug resistance when present with other protease mutations (Figure 4)
(Condra et al, 1995; Rose et al, 1996; Martinez-Picado et al, 1999; Nijhuis et al, 1999;
Mammano et al, 2000). Codon 63 is the most polymorphic of these sites. Mutations at
these positions increase in heavily treated patients (Wu et al, 2003; Hertogs et al, 2000;
Yahi et al, 1999). In some HIV-1 subtypes, mutations at codons 20, 36 and 93 occur at
higher rates than they do in subtype B isolates (Cornelissen et al, 1997; Shafer et al, 1999;
Pieniazek et al, 2000; Gonzales et al, 2001). It has been suggested that individuals
harbouring isolates containing multiple accessory mutations may be at a greater risk of
virologic failure during PI therapy (Perez-Alvarez et al, 2001; Perno et al, 2001).
However, most studies to date have not supported this hypothesis (Frater et al, 2001;
Perez-Alvarez et al, 2001; Perno et al, 2001; Servais et al, 2001; Kuritzkes et al, 2000;
Bossi et al, 1999; Harrigan et al, 1999). In addition, mutations at position 17, 22, 23, 45,
58, 66, 74, 75, 76, 83 and 85 in PR have recently been associated with treatment, but the
phenotypic and clinical impact of these mutations are not yet known (Parkin et al, 2003a;
Wang and Larder et al, 2003; Wu et al, 2003).
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1.8.2 HIV-1 Reverse Transcriptase (RT)
The RT enzyme is both an RNA-dependent DNA polymerase and DNA-dependent DNA
polymerase. RT is a heterodimer consisting of p66 and p51 subunits (Figure 5). The p66
subunit consists of 560 amino acids containing a polymerase domain (the DNA-binding
groove and the enzyme's active site), an RNase H subdomain and connection subdomain
(Larder and Stammers, 1999; Sarafianos et al, 1999a). The shape of the polymerase
domain of the p66 subunit can be likened to a human hand with subdomains referred to as
fingers, palm, and thumb. Most RT inhibitor resistance mutations are in the 5' polymerase
coding regions, particularly in the "fingers" and "palm" subdomains (Shafer et al, 2003).
The p51 consists of the first 440 amino acids of the p66 subunit, but displays no enzymatic
activity and functions as a scaffold for the enzymatically active p66 subunit.
1.8.2.1 Nucleoside/nucleotide RT Inhibitors (NRTIs)
There are currently seven nucleoside analogues, and one nucleotide analogue approved by
the FDA, including Zidovudine (AZT), Didanosine (ddI), Zalcitibine (ddC), Stavudine
(d4T), Lamivudine (3TC), Abacavir (ABC) and Emtricitibine (FTC) (Figure 6). Tenofovir
disoproxil fumarate (TDF) is the only FDA-approved nucleotide analogue. The NRTIs are
prodrugs that must first be phosphorylated by host cellular enzymes before they can be
used by the RT enzyme. Nucleosides must be tri-phosphorylated and nucleotides must be
di-phosphorylated. The phosphorylated NRTIs compete with natural deoxynucleoside
triphosphates (dNTPs) for incorporation into the newly synthesized DNA chains where
they cause chain termination and block further extension of the proviral DNA during RT
(Shafer et al, 2003).
1.8.2.2 NRTI Resistance
NRTI resistance can occur by two biochemical mechanisms. In the first, certain mutations
allow the RT enzyme to discriminate against NRTIs during synthesis and prevent their
addition to the growing DNA chain (Larder and Stammers, 1999; Sarafianos et al, 1999a;
Huang et al, 1998). The second mechanism is mediated by nucleotide excision mutations
(NEMs) that increase the rate of ATP-dependent hydrolytic removal of the chain-
terminating NRTI and enable continued DNA synthesis (Shafer et al, 2003; Anion et al,
2000; Meyer et al, 1999; Anion et al, 1998). This mechanism of resistance has also been











eN 184 215 *1"1114 ,70 	:74 ,,Ø,;441.0
69 65 188
:
Vt:1,4!,*,. 219 89 	c













233 460 ♦ /41' 103
•
41 89238 e'tici. iovx (p 3 .
70 210






 INIC 74*' f. -
'" A,* • .'411;
t  ,,. /115
108
,..4"   • -1 '.219 441* :  -1 '
2884
' - *",-
• , - f,.. o , 1156
106 '.,..: * .,
49 103•4° 	46184 i'' .
-,*.,„ , Ar * 	411,.. 161
1100488 f181,0 "It
236 t 444
,, -4,179 •n •#,. 139








Figure 5. HIV-1 RT structure. The active site (positions 110, 185 and 186) is shown in red sticks in the
p66 subunit
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1.8.2.2.1 Nucleotide Excision Mutations (NEMs)
The nucleotide excision mutations mediate the ATP-dependent hydrolytic removal of a
dideoxy nucleotide monophosphate (ddNMP) from a terminated cDNA chain (Meyer et al,
2000; Anion et al, 1998). They were originally identified for their role in causing AZT
resistance, but several studies have since shown that the NEMs are associated with clinical
resistance to AZT, d4T, ABC, and to a lesser extent, to ddl, ddC and TDF (Miller et al,
2001; Miller and Larder, 2001; Wainberg et al, 2001) (Figure 6). The interaction of the
incoming dNTP with a ddNMP-terminated primer results in the formation of a stable
"dead-end" catalytic complex between RT, primer, template, and dNTP (Sarafianos et al,
2003; Miller et al, 2001; Lennerstrand et al, 2001; Boyer et al, 2001; Tong et al, 1997).
The formation of such a dead-end complex interferes with the ability of NEMs to facilitate
the resumption of virus DNA chain elongation. The bulky azido group of AZT may
interfere with the formation of such a dead-end catalytic complex by sterically preventing
the addition of the next dNTP (Boyer et al, 2001; Lennerstrand et al, 2001).
Various combinations of mutations at codons 41, 67, 70, 210, 215, and 219 have been
implicated in the removal of the ddNMP (Meyer et al, 2000; Anion et al, 1998; Huang et
al, 1998; Harrigan et al, 1996; Kellam et al, 1992; Larder et al, 1989). Biochemical studies
suggest that D67N and K7OR are the mutations most responsible for rescue of chain-
terminated primers (Meyer et al, 1999; Anion et al, 1998). Some studies suggest that the
T215Y/F mutations lead to increased RT processivity (Caliendo' et al, 1996, Anion et al,
1998). Mutations at positions 41 and 210 usually occur with mutations at position 215 and
appear to stabilize the interaction of 215Y/F with the dNTP binding pocket (Yahi et al,
2000; Huang et al 1998; Harrigan et al, 1996; Hooker et al, 1996). Mutations at positions
67 and 219 may occur with mutations at position 70 or with mutations at position 215,
suggesting alternate pathways for the development of resistance to the NRTIs (Shafer,
2003). In summary, the favoured pathway for the development of resistance is:
M41L/T215Y---÷M41L+T215Y—M41L+K210W+T215Y—>M41L+D67N+K210W+T215Y
with D67N/K7OR—+K219Q/E/N-A167N+K7OR/K7OR+1(219Q—T215Y+1(219Q as the
alternate pathway.
The NEMs interfere with the clinical response to AZT, d4T, ddI and ABC (Molina et al,
2003; Kozal et al, 1993). A combination of three or more NEMs with M184V results in
complete loss of ABC activity (Lanier et al, 2004; Lanier et al, 1999). M184V also
appears to reverse the effect of the NEMs on resistance to d4T and TDF (Naeger et al,
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Figure 6. Mutations associated with resistance to the currently available NRTIs (Shafer, 2003;
http://hivdb.stanford.edu/) . ddC is not currently used and is therefore not shown in the figure.
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suggest that TDF usually retains antiviral activity even in patients with extensive previous
NRTI therapy (Miller et al 2001; Schooley et al, 2001).
1.8.2.2.2 K65R
K65R is seen mainly in patients receiving triple NRTI regimens lacking AZT (Gallant et
al, 2003; Roge et al, 2003). It confers intermediate levels of resistance to ddl, ABC, ddC,
3TC, FTC and TDF, and low-level resistance to d4T (Parkin et al, 2003b; Miller et al,
2000; Petropoulos et al, 2000; Wainberg et al, 1999; Tisdale et al, 1997; Gu et al, 1994,
Zhang et al, 1994). However, it also causes hypersensitivty to AZT (Rhee et al, 2003).
Position 65 interacts with the y-phosphate of the bound dNTP and improves discrimination
between the dNTPs and most NRTIs (Lanier et al, 2003; Parkin et al, 2003). The K65R
mutation has been shown to increase RT replication fidelity and processivity in vitro, but
has also been associated with a decrease in replicative capacity (Miller et al, 2003; Shah et
al, 2000; Anon et al, 1996). K65R generally occurs in association with other mutations
(such as M184V and Q151M) that discriminate between the NRTIs and the natural dNTP
substrates (Gonzales et al, 2003).
1.8.2.2.3 T69D/N/SA Ins
Mutations at position 69 include T69D/N/S/A, as well as single and double amino acid
insertions. T69D has been reported in patients treated with either of the available NRTIs
(Shafer, 2003; Fitzgibbon et al, 1992). In site-directed mutagenesis studies, other
mutations at this position including T69N, T69S, and T69A have been shown to confer
resistance to AZT, ddl, ddC, and d4T (Winters et al, 2001). The 691ns occurs in
approximately 2% of heavily treated patients and when alone, causes low level resistance
to each of the NRTIs. When it occurs together with T215Y/F and other AZT-resistance
mutations it causes high-level resistance to each of the NRTIs, including a 20-fold
resistance to TDF which is the highest reported level of resistance to this drug (Masquelier
et al, 2001; Larder et al, 1999; Winters et al, 1998b; de Jong et al, 1999). It has been
suggested that this mutation may act in a similar manner to the NEMs by causing ATP-
mediated primer unblocking (Lennerstrand et al, 2001).
1.8.2.2.4 L74V/I
L74V is usually seen in patients treated with ddI or ABC monotherapy and causes
intermediate resistance to ddI and ddC and low-level resistance to ABC (Harrigan et al,
2000; Miller et al, 2000; Tisdale et al, 1997; Winters et al, 1997; Kozal et al, 1994; Shafer
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et al, 1994; St. Clair et al, 1991). It also causes hypersensitivity to AZT and TDF (Parkin
et al, 2003b; Shafer, 2003; Miller et al, 2001; St. Clair et al, 1991). L74V plays a role in
the repositioning of the template/primer complex (Sturmer et al, 2003). This mutation has
also been shown to be the cause of decreased RT processivity and decreased replication in
cell culture (Sharma et al, 1999). Recent evidence suggests that L74V causes a reduction
in the efficiency of the excision reaction associated with RT (Frankel et al, 2004). L741
causes intermediate resistance to ddI (Kantor et al, 2002a).
1.8.2.2.5 V75T/I/M/A
The V75T mutation is rarely found in vivo. It develops in isolates cultured in the presence
of increasing concentrations of d4T and causes intermediate resistance to d4T, ddI and
ddC (Lacey et al, 1994). Mutations at this position cause drug resistance through
nucleotide discrimination as well as through a non-ATP-mediated mechanism of primer
unblocking (Lennerstrand et al 2001; Selmi et al, 2003). V75I generally occurs in isolates
that also have the multinucleoside resistance mutation, Q151M. The V75M/A mutations
contribute to d4T resistance (Rhee et al, 2003; Bloor et al, 1998).
1.8.2.2.6 M184V/I
M184V sterically hinders inhibitor binding by changing the geometry of the dNTP binding
pocket by direct interaction of the altered residue with the incoming dNTP, thus leading to
a decrease in 3TC incorporation (Sarafianos et al, 1999b; Drosopoulos et al, 1998).
Several in vitro studies have shown that RT enzymes with M184V displayed increased
fidelity and decreased processivity (Drosopoulos et al, 1998; Sharma et al, 1999; Oude et
al, 1997; Wainberg et al, 1996; Boyer et al, 1995; Back et al, 1997). M184V is usually the
first mutation to develop in isolates from patients receiving incompletely suppressive 3TC-
containing regimens (Staszewski et al, 2001; Descamps et al, 2000; Havlir et al, 2000;
Maguire et al, 2000). It is also selected during therapy with ABC, ddC, ddI and FTC
(Quinn et al, 2003; Harrigan et al, 2000; Miller et al, 2000; Winters et al, 1997; Gu et al,
1992). M184V, in combination with the NEMS or in combination with mutations at
positions 65, 74, or 115 in RT, leads to both in vitro and in vivo ABC resistance (Harrigan
et al, 2000; Katlama et al, 2000; Lanier et al, 1999; Palmer et al, 1999). The M184V
mutation also reverses T215Y-mediated AZT resistance by its ability to impair the rescue
of chain-terminated DNA synthesis (Gotte et al, 2000; Shafer et al, 1998; Larder et al,
1995; Boucher et al, 1993; Tisdale et al, 1993). However, this can be overcome by the
presence of four or more AZT resistance mutations (Whitcomb et al, 2003; Shafer et al,
1998; Tisdale et al, 1993). Re-sensitisation does not appear to apply to AZT resistance
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caused by Q151M (Shafer et al, 1996). M1841 also causes high-level resistance to 3TC. It
usually develops before M184V in patients receiving 3TC because HIV-1 RT is more
prone to G to A mutations than to A to G mutations (i.e. ATG to GTA) (Keulen et al,
1997; Ji et al, 1994). However, the enzymatic efficiency of M1841 is less than that of
M184V and nearly all patients with mutations at this position eventually also develop
M184V (Frost et al, 2000).
1.8.2.2.7 Q151M
Q151 is in the B2 strand in the fingers domain of p66 subunit of HIV-RT and are in direct
contact with the incoming dNTP. Its role is to participate in the positioning of the
incoming dNTP in the HIV-RT active site (Courcambeck et al, 2002). Alone, the Q151M
mutation causes intermediate levels of resistance to AZT, ddl, ddC, d4T and ABC (Van
Laethem et al, 2000; Iversen et al, 1996; Shafer et al, 1996; Shirasaka et al, 1995). It
causes high-level resistance to each of these NRTIs and low-level resistance to 3TC and
TDF when present with mutations at positions 62, 75, 77, and 116 (Miller et al, 2000;
Palmer et al, 1999). This mutation was found to develop in up to 50% of patients who had
received dual therapy with ddI and AZT/d4T (Cowley et al, 2001; Shafer et al, 1994).
Q151M confers ability of RT to discriminate between an analogue and its natural
counterpart and has no effect on repair of analogue termination (Deval et al, 2002).
MultiNRTI resistance via the Q151M pathway is more common in non-B subtypes
(Kantor et al, 2003a).
1.8.2.3 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
There are currently three FDA-approved NNRTIs, namely, NVP, delavirdine (DLV), and
efavirenz (EFV) (Figure 7). The NNRTIs bind to a hydrophobic pocket close to the RT
active site (Hsiou et al, 2001). They inhibit HIV-1 replication allosterically by displacing
the catalytic aspartate residues relative to the polymerase binding site (Esnouf et al, 1995;
Spence et al, 1995; Kohlstaedt et al, 1992).
1.8.2.4 NNRTI resistance
Resistance usually emerges rapidly when NNRTIs are administered as monotherapy or in
the presence of incomplete virus suppression, with a single mutation in the NNRTI-
binding pocket resulting in high-level resistance to one or more NNRTIs (Figure 7). Many
researchers suggest that this rapid appearance of resistance may be caused by the selection
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Jackson et al, 2000; Havlir et al, 1996; Wei et al, 1995). NNRTI resistance mutations may
compromise virus replication by changes in the conformation of the dNTP binding pocket
and changes in RNaseH activity (Van Laethem et al, 2000; Archer et al, 2000; Kleim et al,
1994).
1.8.2.4.1 K103N/S/R/Q/T
K103N occurs more commonly than any other mutation in patients receiving NNRTIs and
causes high-level resistance to each of the available NNRTIs (Bacheler et al, 2000;
Demeter et al, 2000; Hanna et al, 2000; Conway et al, 2001; Deeks et al, 2001; Torti et al,
2001; Petropoulos et a; 2000; Huang et al, 1999; Young et al, 1995). Alone, the K103N
mutation causes resistance to each of the available NNRTIs (Casado et al, 2000; Demeter
et al, 2000; Joly et al, 2000). K103S appears to have the same effect as the K103N
mutation (Harrigan et al, 2003). K103R does not appear to cause NNRTI resistance on its
own, but can cause cross-resistance to all of the NNRTIs when present with V179D
(Petropoulos et al, 2003). The K103Q/T mutations do not appear to cause NNRTI
resistance.
Position 103 is located in the vicinity of an entrance to the binding pocket. The structure of
the RT enzyme is only minimally changed by the K103N mutation. Unliganded, it forms a
network of hydrogen bonds that are not present in the wildtype enzyme which could
stabilize the closed pocket form of the enzyme and interfere with the ability of inhibitors
to bind to the enzyme (Hsiou et al, 2001).
1.8.2.4.2 V106A/M/I
V106A causes high-level resistance to NVP, intermediate levels of resistance to DLV, and
low-level resistance to EFV (Bacheler et al, 2001; Petropoulos et a; 2000; Balzarini et al,
1998, Fujiwara et al, 1998; Young et al, 1995; Byrnes et al, 1993; Emini et al, 1993;
Larder et al, 1993). V106M is a putative subtype C specific mutation occurring in EFV
treated patients and causes high-level resistance to each of the NNRTIs but does not arise
under pressure by NVP or DLV (Brenner et al, 2003). Subtype C tends to get the V106M
rather than the V106A because of the GTG to ATG mutation at amino acid position 106.
Subtype B usually has a GTA to GCA mutation. When on EFV treatment, the V106M
mutation is followed by mutations at codons 181 and 188 (Brenner et al, 2003). V1061 is a
treatment-associated polymorphism that has a minimal effect on susceptibility to the
currently available NNRTIs (Shafer, 2003).
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1.8.2.4.3 A98G/S
A98G causes low-level resistance to each of the NNRTIs (Petropoulos et al, 2000; Young
et al, 1995; Byrnes et al, 1994). A98S is a polymorphism that does not appear to be
associated with resistance (Shafer, 2003).
1.8.2.4.4 L100I
L100I causes intermediate resistance to EFV and DLV and low-level resistance to NVP
(Petropoulos et al, 2000; Fujiwara et al, 1998; Winslow et al, 1996; Young et al, 1995;
Byrnes et al, 1994; Byrnes et al, 1993). L100I usually occurs with K103N in patients
receiving EFV (Bacheler et al, 2000).
1.8.2.4.5 K101E/R/Q/P
K101E causes low-level resistance to each of the NNRTIs (Petropoulos et al, 2000; Young
et al, 1995; Byrnes et al, 1994). K101R/Q do not appear to be associated with drug
resistance. Although K101P occurs frequently in heavily treated patients, its phenotypic
impact has not yet been reported (Shafer, 2003).
1.8.2.4.6 V1081
V1081 causes low-level resistance to each of the NNRTI (Petropoulos et al, 2000; Young
et al, 1995; Byrnes et al, 1994).
1.8.2.4.7 V179D/I
V179D causes low-level resistance to each of the NNRTIs (Winslow et al, 1996; Young et
al, 1995; Byrnes et al, 1994; Byrnes et al, 1993). V 1791 is a common polymorphism that is
not associated with drug resistance (Shafer, 2003).
1.8.2.4.8 Y181C/I
Y181C/I occurs commonly in patients treated with NVP and causes high-level resistance
to NVP and DLV and low-level resistance to EFV (Petropoulos et al, 2000; Fujiwara et al,
1998; Young et al, 1995; Byrnes et al, 1994; Byrnes et al, 1993).
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1.8.2.4.9 Y188C/L/H
Mutations at this position occur in patients treated with NVP and EFV and cause high-
level resistance to NVP and EFV and intermediate resistance to DLV (Petropoulos et al,
2000; Fujiwara et al, 1998; Young et al, 1995; Byrnes et al, 1994; Byrnes et al, 1993).
1.8.2.4.10 G190A/S/E/C/Q/V/T
The most common mutations at this position, G190A and S, cause high-level resistance to
NVP and intermediate (G190A) or high (G190S) levels of resistance to EFV (Petropoulos
et al, 2000; Fujiwara et al, 1998). The other mutations at this position are also markedly
less susceptible to NVP and EFV (Huang et al, 2003). Most G190 mutations cause
hypersusceptibility to DLV, except G190E, which causes low-level resistance to DLV
(Huang et al, 2003). Certain 190 substitutions (C, Q, V, T, and E have been shown to have
markedly reduced fitness in vitro (Huang et al, 2003; Kleim et al, 1994). This was
correlated with reduced virion-associated RT activity and incomplete PR processing of the
viral p55 (gag) polyprotein (Huang et al, 2003).
1.9 Inhibitors of HIV-1 Fusion and Entry
Since the development of resistance to any ARV treatment regimen is unavoidable, there
is a constant need for the development of new classes of drugs. T-20 (by Trimeris and
Roche) is the first agent in the new class drug called fusion inhibitors that target the entry
stage of the virus life cycle. The HIV-1 env glycoprotein consists of a surface glycoprotein
(gp120) and a transmembrane glycoprotein (gp41). During HIV-1 infection, the virus's
gp120 binds to both a CD4 and chemokine receptor on the target cells, followed by a
conformational change in gp41 that promotes the fusion of the viral and cellular
membranes (Eckert et al, 1999). For successful fusion to occur, the heptapeptide repeat
domains (HR-1 and HR-2) of gp41 must form a hairpin structure (Chan et al, 1998). T-20
is a 36-amino-acid peptide that corresponds to a part of the HR-2 region (residues 127-
162) and binds to HR1 near the fusion domain, preventing interactions with the HR-2
region and keeping the virus and cell membranes from fusing (Kilby et al, 1998). It has
been shown to be effective for patients with viruses resistant to RT and PR inhibitors when
given by means of intravenous infusion or twice-daily subcutaneous injection (Lalezari et
al, 2003; Kilby et al, 1998). It has also been shown to be effective subtype C isolates in
vitro (Cilliers et al, 2004).
In a study of treatment-experienced patients in which T-20 was added to an optimised
ARV regimen, 32% of subjects achieved either a greater than 1.0 log i n copies/ml reduction
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in plasma HIV-1 RNA levels from baseline or a viral load less than 400 copies/ml.
Thirteen percent of subjects achieved a viral load less than 50 copies/nil (Lalezari et al,
2003). In another study, a regimen of APV/RTV/ABC/EFV, with or without T-20 (at 1 of
3 doses), was evaluated in PI-experienced NNRTI-naive patients. Again, T-20 recipients
were more likely to achieve a plasma HIV-1 RNA level less than 400 copies/ml, with the
greatest reduction in viral load observed in those subjects receiving a T-20 dose of 100 mg
twice daily (Lalezari et al, 2003). However, resistance was observed to evolve in studies of
T-20 monotherapy and should therefore be used as part of a regimen consisting of several
active agents (Sista et al, 2002). Resistance is associated with changes in the HR1 region,
particularly in the GIV motif (Wei et al, 2002; Kilby et al, 2002; Hanna et al, 2002). This
motif is highly conserved among HIV-1 isolates (Hanna et al, 2002; Xu et al 2002).
1.10 HIV-1 and the Mechanisms of Drug Resistance
During uncontrolled HIV infection, the high HIV replication rate and RT-induced
mutation rate generates every possible mutation in the HIV genome each day (Richman et
al, 1994). This results in a large pool of genetically related but distinct HIV strains called
quasispecies, each of which has the potential to develop into the dominant strain. During
treatment with ARVs, the likelihood that resistant mutants will emerge is not only a
function of the fidelity of the viral RT enzyme and rate of virus replication, but is also
determined by the ability of the viral target site to mutate. For example, AZT selects for
mutations in the RT more readily in vitro and in vivo than d4T, probably because of the
relatively large 3'-azido group on AZT, making it even more different to the physiological
thymidine than d4T. Therefore, the RT molecule can more readily mutate to interact
differently with this unphysiologic sugar moiety on AZT, thus selecting for mutations
more easily than against d4T. Similarly, 3TC has a distinctive sugar moiety that probably
accounts for the rapidly emergence of resistance to this drug (Gao et al, 1993; Schinazi et
al, 1993; Tisdale et al, 1993).
Figure 8 demonstrates the development of drug resistance during incomplete viral
suppression. With increasing drug exposure, the selective pressure on the replicating virus
population increases to promote the more rapid emergence of drug-resistant mutants. As
long as significant levels of virus replication are sustained, the likelihood of such mutants
increases. As antiviral activity increases still more, the amount of virus diminishes to the
point where the likelihood of resistance emerging begins to diminish.
This likelihood becomes nil when replication is completely inhibited (Richman, 1994).
However, with continuing viral replication in the absence of completely suppressive
antiviral drug activity, the cumulative acquisition of multiple mutations can occur over
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Figure 8. Development of drug resistance during incomplete viral suppression (Quinones-Mateu and
Arts, 2002)
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time (Condra et al, 1995; Larder et al, 1989). The selective pressure of drug treatment
permits the outgrowth of these pre-existing mutants (Coffin et al, 1995). After the failure
of a particular regimen, it is difficult to dissect out the component of the drug regimen that
is attributable to the acquisition of drug resistance. This is possibly due to the fact that
patients who are more likely to develop drug resistance are more likely to have
confounding factors that will predispose to a poor prognosis (Richman, 1994). Also,
patients may contain mixtures of certain viruses with different susceptibilities, and these
populations may be represented differently in different organs of the patient under
treatment. Therefore the key to ensure antiviral efficacy is total viral suppression with a
potent combination ARV regimen. This is because resistant mutants do not emerge if a
regimen can prevent the outgrowth of pre-existing mutants and block ongoing replication
that permits the emergence of new mutants. A second approach is to switch to an alternate
therapy against which the population has no cross-resistance. However, when a patient
changes to a new regimen, the rate of viral replication and selection of mutations is
influenced by the extent to which the mutations selected by the previous regimen also
confer resistance to the new drugs. If the virus has some degree of cross-resistance,
mutation-generating replication events continue to occur at a rate determined by the
overall effectiveness of the new regimen, resulting in the more rapid development of
resistance.
It therefore seems that the development of drug resistance is an inevitability, and therapies
must be designed to optimise treatment in the face of resistant populations. One approach
to sustain antiretroviral drug activity is to generate plasma drug levels that exceed the
susceptibility of drug-resistant viruses (Havlir et al, 1996). Another approach is to use
multiple drugs targeted to the same viral protein (convergent therapy), whereby mutations
induced by drug 1 may sensitise the virus to drug 2, or may prevent the emergence of
viable mutants to drug 2 (Chow et al, 1993).
1.11 Rate of Selection of Resistance
Besides the effect of the potency of the drug regimen and the adherence to the regimen,
the inherent replication rate of a resistant virus also influences the rate of its emergence
(Richman, 1994). Some resistance mutations do not appear to substantially affect the viral
replication rate and will appear as the dominant quasispecies much faster, while those that
compromise viral replication may take longer to emerge, or may acquire additional
compensatory mutations that help to restore the viral replication rate. Also, some
mutations occur as single nucleotide changes (eg, NNRTIs) and will appear faster than
those that require two base changes (eg, T215Y, T69D).
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1.12 Disappearance of Resistance Mutations
The same factors that influence the development of a resistant population also affect the
"disappearance" of mutations from the dominant species (Quinones-Mateu and Arts. 2002;
Richman, 1994). An example of when this occurs is during treatment interruption, where
there is no longer any drug selection pressure and the most efficiently replicating strain
(which could be the wild-type strain) becomes the dominant quasispecies. This "reversion
to wild-type" can occur within a few weeks of therapy cessation. Although the drug
resistance mutations would no longer be detectable by conventional genotypic assays,
these strains still persist in the minority species. The minor populations can re-emerge
rapidly if selective pressure is reapplied. Similarly, resistance mutations may be "lost"
when a different drug regimen is used against a drug-resistant variant without any cross-
resistance to the new regimen. Quasispecies that carry previously selected mutations that
are no longer advantageous and may be associated with a reduced rate of replication, will
tend to be out competed by virus strains that are able to replicate more efficiently without
these mutations, and may disappear from genotypic reports (Shafer, 2003; Quinones-
Mateu and Arts. 2002).
1.13 Hypersusceptibility
This is defined as an increased susceptibility to a particular drug, i.e. virus replication is
inhibited by lower amounts of drug than those required to inhibit a reference wild-type
strain. It has been shown that a number of NRTI-resistance mutations cause
hypersensitivity to the NNRTIs (Whitcomb et al, 2002). Patients with NNRTI
hypersusceptibility have better outcomes on NNRTIs than do non-hypersusceptible
patients (Shulman et al, 2001; Haubrich et al, 2002; Hammer et al, 2002; Katzenstein et al,
2003).
1.14 Drug Resistance in Non-B Subtypes
With a growing demand for treatment and access to antiretroviral therapy in resource-
limited settings, the susceptibility and resistance patterns of non-subtype B viruses,
particularly subtype C, to antiretroviral drugs is an important question. Initial reports
suggest that non-B subtypes respond equally as well as subtype B to therapy (Turner et al,
2004; Laurent et al, 2002; Shafer et al, 1997). A study of 72 drug naive subtype C isolates
from South Africa found no naturally occurring primary RT or protease drug resistance
mutations (Gordon et al, 2003). Another study from Zimbabwe found that subtype C
38
viruses were as susceptible as subtype B to commonly used nucleoside and non-nucleoside
RT inhibitors (Shafer et al, 1997). Turner et al (2004) found that although polymorphisms
in non-B subtypes reflect different patterns of codon usage, this may only rarely affect the
patterns of drug resistance-associated mutations. On the other hand, a study by Dumans et
al (2004) found that a polymorphism at position 210 in subtype F resulted in a lower
prevalence of the L210W mutation in subtype F patients from Brazil. In addition, some
studies have reported differences in the response of non-B isolates to therapy (Gonzalez et
al, 2004; Grossman et al, 2002a; Navratne et al, 2002; Loemba et al, 2002; Loveday et al,
2002). Loveday et al (2002) found a significantly inferior virologic response in subtype C
versus subtype B infected patients at 24 and 48 weeks of follow-up.
In the PR region, the D3ON appears at very low rates in NFV treated non-B isolates
(Gonzalez et al, 2004; Grossman et al, 2004; Navratne et al, 2002), while common in
subtype B isolates treated with NFV. Gonzalez et al (2004) found that the D3ON mutation
drastically reduced subtype C fitness in vitro, which could account for the lack of
prevalence of this mutation in subtype C treated isolates. Non-B isolates failing NFV
treatment more commonly developed the L9OM mutation (Gonzalez et al, 2004; Grossman
et al, 2002a; Navratne et al, 2002). The N88S mutation was more common in CRF'01_AE
strains in Japan, with D3ON and N88D not seen at all. N88S is also frequently associated
with L9OM in subtype G isolates (Camancho et al, 2004). The rate of some protease
resistance mutations was higher in subtype B sequences (positions 10, 30 and 90), while
others were higher in subtype C sequences (positions 36, 41, 89 and 93) (Auerbuck et al,
2002). Similarly, Qari et al (2004) found distinct patterns of resistance with PI treatment in
subtype F and A/G isolates. They also found that L1 0V and V771 amplified PI resistance
in their subtype F and A/G isolates. Within the RT, subtype C viruses were found to
develop the key nucleoside excision mutations (NEMS) at positions 41, 67, 70, 210, 215,
and 219, but to a lesser extent than subtype B viruses (Bollyky et al, 2002; Grossman et al,
2002b). Pillay et al (2002a) from South Africa, found that a high percentage (6/12) of
subtype C positive infants treated with ddI plus d4T developed resistance, including the
multi-drug resistant Q151M mutation. Novel mutations present at higher rates in treated
persons infected with subtype C include mutations at RT positions 20, 36, 48 53, 123, 174
and 214 (Bollyky et al, 2002; Kantor et al, 2002b). Spira et al (2003) also report a cluster
of silent mutations in subtype C isolates at amino acid positions RT 65, 138 and 161
linked to NRTIs resistance in vitro.
Differences also occur for the NNRTI class of drugs. The most notable difference is the
V106M resistance mutation seen in subtype C patients treated with EFV, which does not
arise under pressure by NVP or DLV (Brenner et al 2003). The V106M mutation is said to
confer high-level multi non-nucleoside RT inhibitors (NNRTI) resistance. This mutation
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occurs because the sequence for valine in subtype C isolates is GTG, while it is GTA in
subtype B. The change from V to M (ATG) is therefore easier in subtype C isolates as it
only requires a single nucleotide substitution, while the V to M mutation in subtype B
isolates would require two substitution events. The V106A (GTA to GCA) mutation
occurs more commonly in subtype B isolates, and causes NVP resistance without any
cross-resistance to the other NNRTIs. Eshleman et al (2004b) found that subtype
influences the selection and fading of the NVP resistance mutations K103N and Y181C.
In a study on the pattern of NNRTI resistance in non-B subtypes, Cane et al (2004) found
that the G190A mutation occurred more frequently in subtype A and C isolates than
subtype B. The impact of other signature sequences in subtype C and other non-B
subtypes on response to ARV therapy needs to be further investigated (Kantor et al,
2003a; Loemba et al, 2002; Grossman et al, 2001).
1.15 Transmission of ARV Drug Resistance
The transmission of HIV-1 viruses that are resistant to ARVs has serious implications both
for the treatment of individuals and for public health. Individuals infected with a resistant
strain of HIV often have fewer drugs from which to choose as many of the drugs are cross-
resistant and this lowers the chances of that individual benefiting from long-term therapy.
This may also have grave implications for perinatal transmission prevention programs, as
drug resistant virus circulating in these areas may cause these programs to fail. Poor
adherence because of stigma, side effects and cost, is one of the main causes of the
development of drug resistance (Little, 2001). There is a growing concern that drug-
resistant strains will spread as more people take ARVs without full viral suppression. On
the other hand, some researchers feel that while the spread of drug-resistant virus is a
threat, it is unlikely to have an impact at epidemic levels since people with resistant HIV
strains also have wild-type strains in their pool of viruses, which are possibly more
transmissible than resistant strains (Boden et al, 1999; Loveday et al, 1999). There is
emerging evidence that resistant virus is less infectious, with a recent study suggesting that
resistant virus has only a 25% capacity to infect others compared to wild-type virus (Leigh
Brown et al, 2003). However, another study has found that in individuals who were
infected with resistant viruses, all the resistant mutations detected in the index case
persisted in the infected patients, even after they had disappeared from the index case after
treatment interruption (Ravaux et al, 2003). Another study has shown that transmission-
acquired resistance does not appear to influence the rate of disease progression, as it does
in individuals that develop resistance (Pillay et al, 2002b).
40
There is currently an upward trend in the transmission of drug resistance, probably as a
result of the increased use of ARV therapy. Studies from the 1990s found less than 10% of
new infections involved drug-resistant virus, but more recent studies in Europe and the US
have shown a dramatic increase of up to 27% (Wensig et al, 2003; Little et al, 2002; UK
Collaborative Group 2001). However, a Swiss study found that the transmission of drug-
resistant viruses peaked in 1997, contradicting the notion of a rise in transmission of drug-
resistant virus (Yerly et al, 2001). They suggested that better control of viremia over time
and greater attention to the need for adherence might have reduced the risk of transmission
of resistant virus (Yerly et al, 2001).
Little surveillance data exists on the prevalence of drug resistant HIV in resource-limited
settings. The only country in which resistance has been systematically studied in a
treatment naive population is Brazil. A study by Dumans et al (2002) conducted on sample
collected in 1998, after the introduction of free access to HAART in Brazil in 1996, found
that there were no primary resistance mutations in either the PR or RT region. A national
survey conducted on samples collected in 2001 found a slight increase, with around 2%
showing genotypic resistance to each of the three drug classes and 8% showing resistance
to at least one drug (Brindeiro et al, 2003). A smaller pilot survey among 71 treatment
naïve patients in Rio de Janeiro found only one case of drug resistance, associated with
3TC (Dias Tavares et al, 2003). To increase the data in these regions, the WHO and the
International AIDS Society have established a joint surveillance project to track
prevalence of genotypic resistance in treatment naïve individuals after the introduction of
HAART.
1.16 Resistance Testing
HIV drug resistance testing is an invaluable asset in HIV treatment management
(Kuritzkes, 2004; Katzenstein, 2003). It is designed to identify gene mutations or viral
growth characteristics that suggest reduced drug susceptibility. Current methods of HIV
resistance testing include in vitro genotypic assays and phenotyping (drug-susceptibility
assays) that detect mutations known to confer drug resistance. The HIV genotype refers to
the actual DNA sequence of the virus, while the phenotype reflects the physical traits
expressed by the genotype. There are limitations to both genotypic and phenotypic assays:
they are both unable to detect minor drug resistant populations and there is limited
knowledge about the clinical significance of certain combinations of mutations and of
certain levels of phenotypic drug resistance. (Hirsch et al, 2003; Vandamme et al, 2001;
Shafer et al, 2000).
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Genotypic assays are more commonly used in clinical settings because of their wider
availability, lower cost and quicker turnaround. Generally they utilize a two-step
procedure of PCR to amplify a specific region of the HIV genome (RT and PR) and a
specific mutation detection methodology that distinguishes each type of genotyping assay.
The three most prevalent mutation detection methods are DNA sequencing, gene chip
arrays and the line probe assay (Wilson, 2003). DNA sequencing has been the gold
standard genotyping technology and has the advantage of identifying potentially every
drug resistance associated mutation (Richman, 2000). There are variety of sequencing
assays available: the HIV-1 GenotypR PLUS (Specialty Laboratories); TRUGENE HIV-1
genotyping test (Visible Genetics); VircoGEN II (Virco), Viroseq HIV genotyping system
(Applied Biosystems); GeneSeq (ViroLogic), HIV-1 Mutation Analysis (Focus
Technologies), HIV ViroTYPE (Rheumatology Diagnostoc Laboratory); GenoSure
(LabCorp and Virco); and HIV-1 Genotype (Quest Diagnostics) (Tobin and Frenkel, 2002;
Wilson, 2003). The value of genotyping depends on an understanding of the relationships
between identified mutations and specific drug susceptibility, as well as viral fitness
(Wilson, 2003).
There are a number of on-line databases to assist in genotype interpretation: the Los
Alamos HIV Sequence Database (http://hiv-web.lanl.gov); the Stanford HIV RT and
Protease Sequence Database (http://hivdb.stanford.edu/hiv); the HIVResistanceWEB
(http://www.hivresistanceweb.com); and The International AIDS Society-USA
(http://www.iasusa.org).
Phenotypic tests measure virus drug susceptibility, resulting from known or unknown
resistance-related mutations and their interactions. Various biological methods have been
developed to assess the drug susceptibility of HIV-1 (Brun-Vezinet et al, 1992; Japour et
al, 1993; Larder et al, 1990). In most cases these assays require the cocultivation of patient
peripheral blood mononuclear cells (PBMCs) with donor PBMCs to obtain a viral stock.
Kellam et al, (1994) and later Maschera et al, (1995) developed an innovative method for
generating viruses for drug susceptibility testing, called the recombinant virus assay
(RVA). RVA involves the production of viable virus in vitro by homologous
recombination of RT-PCR products from plasma virus with an infectious PR or RT
deleted cloned HIV-1 provirus. The resulting recombinant viruses derive all their
biological properties from the subtype B molecular clone, except for RT and PR, which
are encoded by the genes from the patient isolates. Boucher et al (1996) improved on this
method, using the cell-killing assay described by Pauwels et al (1988), instead of the
limiting HeLa CD4+ plaque reduction assay to assess the drug susceptibility of the
viruses. The cell-killing assay measures the capacity of a virus to induce lysis of target
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Table 1. Recommendations from expert panels for resistance testing.
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cells. Drug susceptibility results are reported as the amount of drug required to inhibit viral
replication by 50% (IC50) or 90% (IC90). The result is reported as the fold-change in viral
susceptibility compared with a wild-type reference strain. HIV strains deemed "resistant"
to a particular drug might still be inhibited by that drug, although higher concentrations of
drug are required. Whether that concentration of drug is pharmacologically achievable in
vivo determines the efficacy of that drug against those less susceptible strains.
The widespread use of resistance testing has led to the development of formal guidelines
by expert panels (Table 1). The International AIDS Society-USA Consensus Panel on
Resistance Testing, the Panel on Clinical Practices for Treatment of HIV infection of the
US Department of Health and Human Services (DHHS) and the EuroGuidelines Group for
HIV Resistance have all published recommendations for the appropriate use of drug
resistance testing (US Department of Health and Human Services, 2003; Hirsch et al,
2003; The EuroGuidelines Group for HIV Resistance, 2001). All three panels recommend
that information obtained through resistance testing be used in conjunction with a patient's
treatment history, viral load and immunologic status, as well as medication tolerance and
compliance. All panels also recommend drug resistance testing in first and multiple drug
treatment failures, as well as prior to starting therapy in patients with acute or established
infection (Shafer, 2003).
1.17 Objectives
The objectives of this thesis are:
To define the spectrum of naturally occurring resistance-associated polymorphisms and
mutations in RT and protease of subtype C viruses;
To determine how these polymorphisms and mutations impact on the structure-function
relationships of the RT and protease;
To determine how these genetic substitutions impact on response to antiretroviral therapy,
focusing on drug regimens that are affordable, safe and effective for use in Africa.
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Chapter 2
Sequence Analysis Methods and Bioinformatics Tools
2.1 Sequence Analysis Methods
Bioinformatics is a rapidly developing branch of biology that uses techniques and
concepts from informatics, statistics, mathematics, chemistry, biochemistry, physics and
linguistics. Bioinformatics tools can be used to assemble sequences into a contiguous
consensus sequence (contig), perform sequence alignments, perform phylogenetic
analyses, translate DNA sequences into protein sequences, as well as predict protein
structure and function. This thesis involves extensive analysis of HIV-1 env, RT and pol
sequences using a broad usage of different bioinformatics tools.
To rule out contamination between samples before beginning any sequence analysis, each
new sequence was compared to other sequences amplified at the same time, as well as to
other sequences previously amplified in our laboratory. Newly-acquired sequences were
analysed by constructing a phylogenetic tree, and analysing the tree for extreme inter-
patient clustering or extreme intra-patient divergence. Sequences were also compared to
published sequences by performing a BLAST search (Altschul et al, 1997) at the Los
Alamos website (http://hiv-web.lanl.gov/content/hiv-db) . Blast is a program that finds
sequences with very high similarity to the query sequence, which could indicate
contamination. Sequences datasets were aligned with CLUSTALW (Thompson et al,
1994), a program for multiple sequence alignment, and manually edited based on the
codon alignment (aligning the nucleotide sequence using the amino acid code). This was
done using the GDE (Genetic Data Environment) v 2.2 (Smith et al, 1994) -based Linux
interface (De Oliveira et al, 2002) which is discussed in more detail below. Phylogenetic
trees were initially generated with the F84 model of substitution and the neighbour-joining
method (version 4.0b2a/4.0b10) of PAUP* (Phylogenetic Analysis Using Parsimony)
(Swofford, 1999) (Sinauer Associates, Sunderland, Mass.). For subtype analysis, new
sequences were compared to subtype reference strains available at the Los Alamos
subtype database (http://hiv.lanl.gov/content/hivdb/SUBTYPE  REF/align.html). For these
analyses, the phylogenetic trees were rooted with a homologous region of HIV-1 group 0
(OCM MP5180). To investigate whether the sequences were recombinant forms of HIV-
1, recombination analyses were performed with Simplot (Lole et al, 1999), a method that
uses a sliding-window approach to calculate bootstrap plots for constructing neighbor-
joining trees with the DNADIST, NEIGHBOR, or CONSENSE programs of the PHYLIP
package (Felsenstein, 1989). To further examine inter- and intra-patient relationships,
subtype C specific trees were constructed with selected reference sequences obtained from
the GeneBank and Los Alamos public databases. To ensure that the best model of
evolution was used for these analyses, the respective datasets were tested using Model
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Test v 3.0 (Posada and Crandall, 1998). This program runs within PAUP*. The best model
was then pasted into the sequence file for that particular dataset (in nexus format) and used
for subsequent analysis.
To investigate sites under positive selection, the codeml option in the PAML
(Phylogenetic Analysis by Maximum Likelihood) (Rambaut, 2000) software package was
used to calculate the ratio of nonsynonymous to synonymous amino acid substitutions
(dn/ds) or co. This value is a measure of natural selection pressure at the protein level and
provides a powerful tool for understanding the mechanisms of DNA sequence evolution.
An individual amino acid was considered to be positively selected if the dnlds ratio was
significantly greater than 1.0.
Ancestral sequences were reconstructed using the baseml application in the PAML
package. This method involved the use of maximum-likelihood methods and a nucleotide
substitution model to identify nucleotide substitutions along each branch of the tree (Yang,
2000; Yang et al, 2000). Genetic diversity was measured for individual datasets using a
Kimura 2-parameter (K2P) model implemented in the MEGA (Molecular Evolutionary
Genetics Analysis) program version 2.0 (Kumar et al, 2001) (Arizona State University,
Tempe). Nucleotide sequences were also translated and analysed for the presence of
signature patterns using VESPA (Viral Epidemiology Signature Pattern Analysis) (Korber
and Myers, 1992). Biologically important sites were predicted using PROSITE, a database
of protein families and domains, which was run in GENEDOC, a windows-based multiple
sequence alignment editor. The different software packages and their applications are
briefly discussed below.
2.1.1 Likelihood Ratio Test (Anisimova et al, 2001)
All models in the Likelihood Ratio Test (LRT) are nested i.e. all models are a special case
of the General Time Reversible (GTR) model. For example, the K2P model is a special
case of the more complex HKY85 model because HKY85 assumes that base frequencies
can vary, while the K2P model assumes equal base frequencies (see Table 2). Therefore,
the K2P model uses less parameters and is a simpler model. Simpler models are quicker to
run and have less error associated with model parameters. However, more complex
models account take additional variables into account (Table 3) and, thus are more likely
to lead to the true tree.
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Table 2. The most commonly used evolutionary models are described. The models increase in
complexity from the Jukes-Cantor (simplest) to General Time Reversible (most complex) model.
Model Substitution rate/base frequency Number of free parameters
Jukes- Cantor (JC) One rate of substitution
Equal base frequencies
No free parameters
F81 One rate of substitution
Unequal base frequencies
Three free parameters for base
frequencies
Kimura's Two Parameter (K2P) Two types of substitution (tratio)
Equal base frequencies
One free parameter for tratio
HKY85 Two types of substitution (tratio)
Unequal base frequencies
One free parameter for tratio
Three free parameters for base
frequencies
General Time Reversible (GTR) Six types of substitution
Unequal base frequencies
Five free parameters for substitution
rate matrix (rmatrix)
Three free parameters for base
frequencies
Table 3
The addition of among-site variation to the above models increases their complexity as follows: 
A proportion of sites invariant (I) One additional free parameter for pinvar
Gamma distribution (G) One additional free parameter for gamma rate parameter
Both combined (G+I) Two additional parameters
The LRT can test whether the more complex model of evolution is significantly better
than a similar, but simpler model. The most commonly used models of evolution are listed
in Table 2. The LRT uses the following formula:
LRT = 2([-lnLnull] — [-lnLalternative])
Where L is the maximum likelihood of the tree topology under the hypothesis and data.
The degrees of freedom (equal to the difference in the number of free parameters) is used
to calculate the Chi Square Critical Value, which determines whether the null hypothesis
is significantly better than the alternative model. For example, to test if the more complex
GTR model (8 free parameters) is better suited to the data than the simpler HKY85 model
(4 free paramters), the —1nL of that topology and data for each model is calculated. Eg:
GTR —1nL=1784.84185; HKY85 —1nL=1787.08478. Because HKY85 is a special case of
the GTR model, it is the null hypothesis. Therefore:
LRT = 2(1787.08478 — 1784.82185) = 4.52586
Degrees of Freedom = 8-4 = 4
Chi Square Critical Value = 9.488
Since the LRT value is less than 9.488, the null hypothesis for two types of substitution is
not significantly different to 6 types of substitution, and the simpler model can be used in
the analysis.
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2.1.2 Model Test (Posada et al, 1998)
Modeltest 3.0 evaluates 56 models of evolution/variations within the framework of a
nested hierarchical analysis. Briefly, the data file is opened in PAUP* and the control file
(modelblock3) is executed. This file contains a set of PAUP* commands that calculates a
neighbour-joining tree, evaluates the tree under the entire suite of models, and saves the
likelihood scores to a separate file. The models evaluated in this step include the simplest
(JC) to the most complex, or parameter-rich (GTR) model, with the sequential addition of
a proportion of invariant sites and gamma-distributed rates. The output (model.scores) is
then run through modeltest. This program runs a series of log-likelihood tests on nested
model comparisons using the LRT described above. Modeltest also makes another
comparison of the models, with the Akaike Information Criterion (AIC), which allows for
comparison of different models without the nested requirement. The AIC rewards models
for good fit but penalizes extra parameters. Each model gets an AIC score. Smaller
values of AIC indicate better models and the one with the best AIC score is selected.
AIC = -2 lnL + 2n where n = # of independently adjusted parameters in model
2.1.3 PAUP* (Swofford, 1999)
PAUP* is used to infer and interpret phylogenetic trees. It provides full support for tree
searching under DNA maximum-likelihood and distance-based optimality criteria (in
addition to parsimony). A wide range of DNA substitution models are available, including
the GTR model and its submodels (Jukes-Cantor, Kimura 2P, HKY85, F84 used in
DNAML and fastDNAml, Tamura-Nei). PAUP* also allows the investigator to choose the
structure of any model for likelihood, with the option of either having the program
estimate the parameters during the analysis (increased computational time), or letting the
investigator set the parameters to values obtained otherwise (for example, from
Modeltest).
2.1.4 SimPlot (Lole et al, 1999)
SimPlot identifies recombinant genomes. Although SimPlot reads most sequence file
formats, for our purposes, all files were saved in fasta format. To run the program, the
query sequence (the suspected mosaic) was aligned with a set of reference
sequences. Note that SimPlot can analyse no more than 26 groups of sequences (or
individual sequences. The program generates a graph consisting of a set of lines (or
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optionally strings of points) that reflect the similarity (or distance) of each Reference
sequence (or Group) to the query sequence. In order to generate this plot a sliding window
is passed across the alignment in small steps (the window size and step size are
selectable). For the analyses, a sliding window of 400 by and a step-size of 50 by was used
. The BootScanning option in the SimPlot software package was used to identify the
breakpoints in the recombinants (Salminen et al, 1995). To perform BootScanning, the
PHYL1P software suite (Felsenstein) is needed, which is available for download from
ftp ://evoluti on. genetic s .washington. edu/pub/phylip. In this application, a minimum
number of three reference strains are compared with the query sequence. Again, a window
size of 400 by and a step-size of 50 by was used to calculate bootstrap plots for the
construction of neighbour-joining trees with DNADIST, NEIGHBOR or CONSENSE
programs of the PHYL1P package.
2.1.5 PAML (Rambaut, 2000; Yang et al, 2000)
PAML is a package of programs for phylogenetic analyses of DNA or protein sequences
using maximum likelihood (ML). It is maintained and distributed for academic use free of
charge by Ziheng Yang. It has many capabilities including, estimating the branch lengths
in a phylogenetic tree and assessing parameters of evolution including the
transition/transversion rate ratio, the shape parameter of the gamma distribution for
variable evolutionary rates among sites, and rate parameters for different genes. It can also
be used for testing hypotheses concerning sequence evolution, such as rate constancy and
independence among nucleotide or amino acid sites, rate constancy among lineages (the
molecular clock), and homogeneity of evolutionary process in multiple genes. Finally, it
can also be used for calculating substitution rates at each site and reconstructing ancestral
nucleotide or amino acid sequences, as well as phylogenetic tree reconstruction by
maximum likelihood and Bayesian methods.
In this thesis, two different applications of the PAML software package were used —
codeml program to identify sites under positive selection, and the baseml program for
ancestral reconstruction and estimation of the mutation rate.
2.1.5.1 Baseml
Baseml can perform ML analysis of nucleotide sequences: estimation of tree topology,
branch lengths, and substitution parameters under a variety of nucleotide substitution
models (JC69, K80, F81, F84, HKY85, TN93, REV); constant or gamma rates for sites;
molecular clock (rate constancy among lineages) or no clock, among-gene and within-
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gene variation of substitution rates; models for combined analyses of multiple sequence
data sets; calculation of substitution rates at sites; reconstruction of ancestral nucleotides.
The default control file for baseml is baseml.ctl. An example and the description of each
of the parameters is shown in the appendix.
2.1.5.1.1 Estimation of Mutation Rate
The option clock=3 in the baseml.ctl file implements Andrew Rambaut's TipDate models
(Rambaut 2000). For this application, the dates are specified at the end of the sequence
names. To run this analysis, a ML tree was constructed in PAUP* using the appropriate
model of evolution. The same dataset was exported in PHYLIP v3.2 format. The file was
then edited (in a text editor) to remove the "YF" found at the beginning of the file. The
name of the sequence file and tree file were entered into the baseml.ctl control file. After
running the analysis, the mutation rate was obtained from the output "rst" file.
2.1.5.1.2 Reconstruction of Ancestral Sequences
Nucleotides of extinct ancestors can be reconstructed based on contemporary sequence
data. This was originally done using Parsimony methods based on the criterion that the
number of changes along the tree at each site is minimized. Algorithms based on this
criterion were developed by Fitch (1971) and Hartigan (1973). Baseml uses a likelihood
approach to determine the branch lengths and the substitution pattern for ancestral
reconstruction and assigns a nucleotide to an interior node at a site according to its
posterior probabilities (Yang et al, 1995). To run the reconstruction, a ML tree was
constructed in PAUP* using the appropriate model of evolution for that dataset. The same
dataset was exported in PHYLIP v3.2 format. The file was then edited (in a text editor) to
remove the "YF" found at the beginning of the file. The name of the sequence file and tree
file were entered into the ancestor.ctl control file. After running the analysis, the results
were collected in the "rst" file. The tree file was extracted from the "rst" file and viewed in
TREETOOL. The respective ancestral nodes were identified for each patient. The "rst"
file also contained the reconstructed nucleotide sequences for each ancestral node. These
were saved in fasta format and translated into the amino acid sequences in GDE. Patient
sequences were then compared to the generated ancestral sequences.
2.1.5.2 Codeml
Codeml performs ML analysis of protein-coding DNA sequences using codon substitution
models (Goldman and Yang 1994). The program allows for the calculation of the codon-
usage table; estimation of synonymous and nonsynonymous substitution rates; likelihood
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ratio test analysis of positive selection or relaxed selective constraints along lineages based
on the do/ rate ratios; identification of amino acid sites or evolutionary lineages
potentially under positive selection; reconstruction of ancestral codon sequences. The
format of the sequence files and the requirement of a ML tree from the same dataset was
the same as for baseml. The variables in the program files were also used in the same way
as the baseml.ctl file, except that the option for codon sequences was used. The number of
substitution sites (nssites) were varied according to the model for the dN/dS ratio (w)
(Nielsen and Yang, 1998; Yang et al, 2000). Nssites = m corresponds to model Mm in
Yang et al (2000). Three models were used: neutral (1), selection (2) and discrete (3). The
posterior probabilities for site classes as well as the expected w values for sites were listed
in the "rst" file, used to pinpoint sites under positive selection.
2.1.6 VESPA (Korber and Meyer, 1992)
The VESPA program detects signature patterns (distinctive amino acid or nucleotide
residues) in a set of query sequences relative to a set of reference sequences. VESPA
calculates the frequency of each amino acid (or nucleotide) at each position (column) in an
alignment for the query and the reference set, and selects the positions for which the most
common character in the query set differs from that in the background set. For this
application, nucleotide sequences were translated into amino acid sequences and exported
in NEXUS, non-interleaved format, using GDE2.2. The NEXUS file was then opened in a
text editor and all other information besides the sequence names and amino acid sequences
were removed. VESPA was run using a "query set" and a consensus subtype A, B, C or D
sequence as the "background" set. The output file was opened in a text editor to extract the
results.
2.1.7 PROSITE (Hulo et al, 2004)
PROSITE is a curated database of protein families and domains hosted by the Swiss
Institute of Bioinformatics. It is based on the observation that most proteins can be
grouped, on the basis of similarities in their sequences, into families that share functional
attributes. By analyzing the constant and variable properties of such groups of similar
sequences, it is possible to derive a signature for a protein family or domain, which
distinguishes its members from all other unrelated proteins. These protein signatures,
which are detailed in the PROSITE database and listed in Table 4, were used to assign
sequences to a specific family of proteins and consequently, function.
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Table 4. Protein signature sequences
Function Signature Sequence
N-glycosylation site N-{P}STHPI
cAMP- and cGMP-dependent protein kinase phosphorylation site [RK](2)-x-[ST]
Protein kinase C phosphorylation site [ST]-x-[RK]
Casein kinase II phosphorylation site [ST]-x(2)-[DE]
Tyrosine kinase phosphorylation site [RK]-x(2,3)-[DE]-x(2,3)-Y
N-myristoylation site G- IEDRKIIPFYWI-x(2)-[STAGCM- IP I
Amidation site x-G-[RK]-[RK]
2.1.8 SWISS-MODEL (Schwede et al, 2003)
Swiss-Model (http://www.expasy.org/swissmod/SWISS-MODEL.html)  is a site for 3D
homology modelling of protein structure. The Swiss-Model process is detailed as follows:
The software program BLASTP2 finds all similarities of the target sequence with
sequences of known structure from the ExNRL-3D database. The program SIM then
selects all templates with sequence identities above 25% and projected model size larger
than 20 residues. Input files are then generated for ProModll, which generates all the
models found in ExPDB. Gromos96 performs energy minimisation of all models. Models
can be visualised with Deep View Swiss-pdbViewer, an interface allowing the analysis of
several proteins at the same time (Guex and Peitsch, 1997).
2.1.9 PhD (Rost et al, 1994)
Secondary structure was predicted using the PhD software program via the Predict protein
server (http://www.embl-heidelberg.de/predictprotein/  predictprotein.html). PhD uses a
standard feed-forward neural network. The first network predicts the secondary structure
of the central residue in a 13-residue window. Afterwards the predicted secondary
structure is fed into the second network which also predicts the secondary structure using
the output from the first net as its input. Finally several different networks are created,
using slightly different parameters for the training and a jury network is trained using the
output from the two earlier layers. After the predictions, if a helix is greater than three
residues long, it is kept as a helix, and if it is three or less, it is changed into a loop.
Prediction of secondary structures is a step towards the prediction of the three-dimensional
structure of a protein by providing a rough estimate of structural features, and with at least
one known homologue available, the PhD method has an expected overall accuracy of
71.4% for proteins (Rost et al, 1994).
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2.1.10 HIV-1 Genetic Data Environment (GDE)-Based LINUX Interface (De Oliveira
et al, 2002)
This was another tool developed in our laboratory (De Oliveira et al, 2002), which was
available for the analysis of the sequence data. GDE is a "front-end" sequence analysis
program originally developed for Sun UNIX TM systems with an OpenView X Window
manager (Smith et al, 1994). GDE was subsequently adapted to Seqlab, a graphical user
interface (GUI) that incorporates most of the software distributed in the GCG toolset
(Womble, 2000). LINUX, a re-implementation of UNIXTM, is one of the most frequently-
used operating systems. The combined GDE-LINUX approach, GDE-L, reduces the
complexity and repetitive nature of input/output formatting and facilitates the development
of user-defined local databases that are population-, pathogen- and/or disease-specific.
New software is integrated into GDE-L by editing a unique menu file that controls the
menu appearance (.GDEmenus). This same menu file is then used to send the parameter
and input files to applications such as BLAST, CLUSTALW, PAUP* and READSEQ. All
formats supported by the READSEQ sequence conversion software are readily accepted in
GDE-L. Newly-created .GDEmenus files are then copied to a home directory. Accessory
PERL scripts permit the automatic integration of sequence and BLAST-formatted datasets
without editing the menu control file. All of the sequence-specific databases, phylogenetic
datasets and programs needed to perform these analysis have been integrated into a single
HIV-1 GDE-Linux interface. This interface was used for sequence location, (numbering
according to the HXB2 reference strain), contamination detection, multiple alignment




Molecular Characteristics of Human Immunodeficiency Virus
Type 1 Subtype C Viruses from KwaZulu-Natal, South Africa:
Implications for Vaccine and Antiretroviral Control Strategies
3.1 Introduction
One of the most dramatic changes in the global AIDS pandemic has been the rapid
emergence and devastating spread of human immunodeficiency virus type 1 (HIV-1)
subtype C (De Oliveira et al, 2001; Kuiken et al, 1999; Rollins et al, 2002; Sharp et al,
1994; UNAIDS/W.H.O. Working Group on Global HIV/AIDS and STD surveillance,
2000). As a result of this rapid escalation, HIV-1 C viruses now account for more than
56% of all global infections (Esparza et al, 2000). First identified in retrospective
specimens from Ethiopia and South Africa (Johansson et al, 1995; Salminen et al, 1996;
Zacharova et al, 1997), subtype C began a devastating spread across southern Africa in the
late 1980s (De Oliveira et al, 2001). Major outbreaks have now occurred in every country
of southern Africa, with some regions reporting adult prevalence rates as high as 40%
( Department of Health/Directorate Health Systems Research; Rollins et al, 2002; Van
Harmelen et al, 1999). Recent studies suggest that subtype C is spreading northward into
the Congo, Tanzania, Burundi, and Kenya, where it is becoming increasingly predominant
relative to other subtypes (Janessens and Nkengasong, 1997; Koch et al, 2001; Rodenburg
et al, 2001). C viruses also dominate the rapidly expanding epidemic in India
(Shankarappa et al 2001) and are increasing in frequency in China (Gao et al, 1998;
Rodenburg et al, 2001; Yu et al, 1998) and Brazil (Brindeiro et al, 1999; Soares et al,
2003). C/D recombinants have been identified in several countries, including Tanzania,
Kenya, and India (Hoelscher et al, 2001; Koulinska et al, 2001; Renjifo et al 1998), and
C/B recombinants have been detected in China (Yang et al, 2002). The reasons for the
increase in HIV-1 C are not known but may be related to host, viral, or socioeconomic
factors. At the viral level, it has been suggested that an extra NF-KB binding site in the
long terminal repeat may enhance gene expression, altering the transmissibility and
pathogenesis of C viruses (Tatt et al, 2001). Others have suggested that C viruses may be
more stable and that their protease genes may have increased catalytic activity relative to
other subtypes (Velazquez-Campoy et al, 2001). Additional features of subtype C include
a five-amino-acid insertion in the transmembrane domain of Vpu (McCormick-Davis et al,
2000), a prematurely truncated second exon of rev (Gao et al, 1998; Rodenburg et al,
2001; zur Megede et al, 2002), and an increase in amino acid variation at protease
cleavage sites (de Oliveira et al, 2003). Recent advances in sequencing and bioinformatics
(De Oliveira et al, 2003; Posada and Crandall, 1998; Pybus et al, 2001; Yang et al, 2000)
make it easier to analyze full-length HIV-1 sequences and correlate the genetic
information with the immunological and biological properties of the virus. These
advances, combined with the development of promising vaccine candidates and
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simplified, more affordable drug regimens, are paving the way for enhanced prevention
and treatment efforts in southern Africa. As with HIV-1 B, it is expected that safe and
efficacious treatment of C infections will not only reduce the morbidity and premature
death associated with HIV-1 and AIDS (Garcia et al, 2002; Inter-Agency Task Team on
Mother-to-Child Transmission of HIV; Kazatchkine et al 2000; Palella et al, 1998) but
will also play a role in reducing transmission (Jackson et al, 2001). Since we are on the
brink of implementing intervention strategies in a region of the world where subtype C
infections predominate, it is urgent that we collect information that will help define the
phylogenetic relationships, transmissibility, and drug responsiveness of C viruses. In this
study, we analyzed the C2V5 and pol subgenomic regions of 72 contemporary viruses
from KwaZulu-Natal and compared the results with those for 18 retrospective C isolates
from South Africa.
3.2 Methods
3.2.1 Specimen Collection and Processing
A total of 72 treatment-naive HIV-1-infected children (n=16) and adults (n=56)
representing different ethnicities, genders, age groups, and stages of disease were selected
for study. Samples were obtained in Durban and surrounding areas, including Ulundi and
the Hlabisa region of northern Kwazulu-Natal and Tongaat and Phoenix in the coastal
region north of Durban. Participants were recruited from among symptomatic and
asymptomatic adult patients, tuberculosis patients, women and children attending district
health clinics, and children being treated for pneumonia. After obtaining informed
consent, blood samples were collected in EDTA anticoagulant tubes (most adult patients)
or as dried blood spots (most pediatric patients). Plasma was isolated within 6 h of
collection; dried blood spots were stored with desiccant at -20°C until analyzed.
3.2.2 Viral Load and CD4+ T-cell counts
RNA was extracted from plasma and dried blood spots with a guanidinium-silica method
(Nuclisens isolation kit; Organon Teknika) and an automated extractor (Organon-
Teknika). Virus levels were measured with the Nuclisens HIV-1 QT kit, an assay with a
quantitative range of 40 to >500,000 copies of HIV-1 RNA/ml of plasma. When applied to
50 of dried blood, the lower limit of detection is 1,600 HIV-1 RNA copies/ml of blood.
Specificity of the method has been previously assessed and shown to be greater than
57
98.9% (Cassol et al, 1997). CD4+ cell counts in venous blood were determined according
to a standard FACSCount method.
3.2.3 Sequencing of the Envelope C2V5 Region
Sequencing of env was performed directly on a 621-bp PCR product generated from the
C2V5 region (nucleotides 7026 to 7646, relative to HXB2) (Korber et al, 1998). RNA was
extracted from plasma with the ViroSeq method (Applied Biosystems). Plasma RNA and
Nuclisens-extracted dried blood spot RNA were reverse transcribed to cDNA with
Superscript II and random hexamer primers (Invitrogen Corp., San Diego, Calif.). The
RNA template and random primers (100 ng) were heated to 70°C for 10 min, chilled on
ice, and reverse transcribed at room temperature in a 20 [il reaction volume containing 1X
reaction buffer, 10 mM dithiothreitol, 0.5 mM each deoxynucleoside triphosphate, and 200
U of Superscript reverse transcriptase (Invitrogen) at 42°C for 50 mM, followed by 15 min
at 70°C. The C2V5 env region was amplified from the cDNA with MK605 (5'-AATG
TCAGCACAGTACAATGTACAC-3'; positions 6945 to 6969) and CD4R2 (5'-
TATAATTCACTTGTCCAATTGTCC-3'; positions 7652 to 7675) as outer primers
(Cassol et al, 1996) and (M13F)-ES7 (5'-tgtaaaacgacggccagtCTGTTAAATGGCAGTC
TAGC-3'; positions 7002 to 7021) and (M13R)-ES8 (5'-caggaaacagctatgaccCA
CTTCTCCAATTGTCCCTCA-3'; positions 7648 to 7668) as inner primers. The first and
second PCR steps were carried out in final volumes of 25 ill and 50 1.11, respectively,
containing 1X PCR buffer, 2.0 mM MgC12, 0.2 mM each deoxynucleoside triphosphate,
2.5 pmol of each primer, and 1.25 U of Amplitaq Gold. The PCR conditions were 95°C
for 13 min, followed by six cycles at 95°C for 30 s, 65°C for 45 s, and 72°C for 60 s, with
a decrease of 1°C per cycle. This was followed by 29 cycles at 95°C for 30 s, 60°C for 45
s, and 72°C for 60 s, with an increase of 5 s for each extension cycle, and a final extension
of 72°C for 10 min. Amplified DNA was visually quantified by agarose gel
electrophoresis, purified on a Microcon (Amicon) spin column, and sequenced on an
automated 3100 genetic analyzer (Applied Biosystems Inc., Foster City, Calif.) with M13
sequencing primers and a Big-Dye terminator cycle sequencing kit.
3.2.4 Sequencing of Reverse Transcriptase and Protease
Sequencing of pol (nucleotides 2253 to 3485, relative to HXB2) (Korber et al, 1998) was
performed with the ViroSeq HIV-1 genotyping system (Applied Biosystems). Plasma and
dried blood spot RNAs were reverse transcribed with Moloney murine leukemia virus
reverse transcriptase. A 1.8-kb fragment containing the protease (amino acids 1 to 99) and
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reverse transcriptase (amino acids 1 to 312) regions was then amplified in a 40-cycle PCR
with Amplitaq Gold DNA polymerase and AmpErase dUTP/uracil-N-glycosidase to
minimize the risk of cross-contamination. PCR products were visually quantified by
agarose gel electrophoresis. Following purification, the products were sequenced with six
of the seven kit primers (primer D was not used) and Big-Dye terminator reagents and run
on a 3100 genetic analyzer as described above. Sequences were assembled, translated, and
analyzed for the presence of amino acid polymorphisms. A report was generated for each
sequence, with mixtures of wild-type and mutant bases being classified as mutant.
3.2.5 Genetic Subtyping and Phylogenetic Analysis
To rule out contamination between samples, each new sequence was compared to other
sequences amplified at the same time, as well as to other sequences previously amplified
in our laboratory and published sequences in the Los Alamos BLAST search database
(Altschul et al, 1997). The sequences were aligned with CLUSTAL W (Thompson et al,
1994) and manually edited with the codon alignment of the Genetic Data Environment
(GDE 2.2) program (Smith et al, 1994). New sequences were then compared to subtype
reference strains in the Los Alamos subtype database (http://hiv-web.lanl.gov/content/hiv-
db/SUBTYPE REF /align.html). Following degapping with the degapped option in
PAUP*, phylogenetic trees were generated on a Linux computer with the F84 model of
substitution and the neighbor-joining method (version 4.0b2a) of PAUP* (Swofford,
1999). Trees were rooted with a homologous region of HIV-1 group 0 (0CM_MP5180).
To examine intrasubtype relationships, each KwaZulu-Natal sequence was analyzed
against a subset of published C sequences from Zimbabwe, South Africa, Brazil,
Tanzania, Zambia, Ethiopia, Israel, and eastern India. Appropriate evolutionary models
were selected with the Akaike identification system (Akaike, 1997), implemented in
MODELTEST 3.0 (Posada and Crandall, 1998). With this method, a pairwise distance
matrix was calculated and used to construct neighbor-joining maximum likelihood trees.
Parameters of the reverse transcriptase/protease model, TVM + I + G, were: fA = 0.3986,
fc = 0.1653, fG = 0.2033, and fT = 0.2328; R matrix values, RA_,c = 2.7534, RA_,G =
10.1383, RA—>T = 0.9138, RC—,G = 1.3684, RC—,T = 13.5383, and RG--,T = 1.0000; proportion
of invariable sites = 0.4263; and heterogeneous variable site distribution (gamma) with
alpha shape = 0.8233. Parameters of the env model, GTR + I + G, were: fA = 0.3801, fc =
0.1838, fG = 0.2890, fT = 0.1472; R matrix values, RA—C = 3.3002, RA--.G = 8.3576, RA--q
= 3.7717, RC—>G = 1.9646, RC—q . = 23.3707, RG--q = 1.0000; proportion of invariable sites
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= 0.1534; and heterogeneous variable site distribution (y) with alpha shape (a) = 0.7332.
Trees were viewed with Treetool and Treeview.
3.2.6 Genetic Diversity and Intersubtype Recombination Analysis
Mean genetic distances were measured with the Kimura-2 parameter model implemented
in MEGA (Kumar et al, 2001). To investigate whether the sequences were recombinant
forms of subtype C, recombination analyses were performed with the recombination
identification program (Siepel et al, 1995), Bootscanning (Salminen et al, 1995),
recombination detection program (Robertson et al, 1995), and Simplot (Lole et al, 1999), a
method that uses a sliding-window approach to calculate bootstrap plots for constructing
neighbor-joining trees with the DNADIST, NEIGHBOR, or CONSENSE programs of the
PHYLIP package (Felsenstein, 1998).
3.2.7 Nucleotide and Amino Acid Sequence Analysis
Nucleic acid sequences were also analyzed with SNAP (http://hiv-web.lanl.gov ) (Korber
and Myers, 1992) and Codeml, a program from the PAML software package (Rambaut,
2000). Various software programs were then used to calculate the ratio of synonymous to
nonsynonymous amino acid substitutions as a measure of natural selection pressure at the
protein level. Programs included SNAP and MEGA (Kumar et al, 2001), which calculate a
synonymous-to-nonsynonymous (dsl dn) substitution ratio, and Codeml, which calculates a
w (dnI ds) value. High rates of synonymous mutation are indicative of conservation and a
strict requirement for biological function, while high rates of nonsynonymous substitution
are indicative of adaptive change, presumably in response to host selection pressure. To
identify amino acid patterns that are characteristic of Kwazulu-Natal viruses, nucleotide
sequences were translated and aligned and the consensus Kwa7u1u-Natal sequence was
analyzed by viral epidemiology signature pattern analysis (Korber and Myers, 1992).
Consensus sequences were screened for the presence of biologically important sites with
Prosite, a database of protein families and domains.
3.2.8 Identification of Resistance Mutations and Correlation with Phenotype
The Stanford HIV-SEQ and B-test programs were used to identify and assess the impact of
resistance-associated mutations and polymorphisms on phenotypic resistance. Each
reverse transcriptase and protease sequence was compared to that of a subtype B reference
strain, HXB2, in the Stanford HIV reverse transcriptase and protease sequence database
(http://hivdb.Stanford.Edu/hiv/) . Mutations associated with reduced sensitivity to
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antiretroviral drugs were assigned a drug penalty score based on genotypic-phenotypic
correlative data.
3.2.9 Nucleotide Sequence Accession Numbers
GenBank accession numbers for sequences obtained in this study including information on
the year of specimen collection and risk category are provided in Table 5.
3.3 Results
3.3.1 Study Population
Demographic and laboratory results for the 72 Kwazulu-Natal patients are summarized in
Table 6. Six specimens came from three sets of epidemiologically linked sex partners.
After recording the genotype, the male partner of each couple was excluded from further
analysis. Many adult patients had HIV-1-related symptoms; 10 had tuberculosis. Two
children were asymptomatic; the remaining 14 children had a variety of symptoms,
ranging from pneumonia to weight loss, hepatomegaly, splenomegaly, and diarrhea. All of
the children were black. To investigate genetic change over time, 18 retrospective samples
(8 from Kwazulu-Natal and 10 from Cape Town) were sequenced and included in the
analysis.
3.3.2 Genetic Divergence, Subtyping, and Phylogenetic Tree Analysis
As shown in Table 7, the average intersequence divergence among KwaZulu-Natal
sequences was significantly higher than among subtype C sequences from Brazil and
India, but comparable to values observed for Botswana and other countries in southern
Africa. There was no measurable difference in diversity between Indian and black or
between adult and pediatric subgroups. Eleven env samples carried insertions and
deletions and could not be sequenced directly from the PCR product. Overall, KwaZulu-
Natal env sequences differed from the reference sequences of subtypes A, B, and D by
30.4%, 29.3%, and 32.2%, respectively. Pol sequences differed from subtype A, B, and D
reference strains by 11.6%, 11.08%, and 11.01%, respectively. Maximum-likelihood and
neighbor-joining distance methods were used to determine subtype. As expected, 60 of 61
(98.4%) matched env-pol sequence pairs and all of the retrospective sequences grouped as
subtype C. These phylogenetic relationships were supported by bootstrap values of >95%.
One sample, ZA021p01, had different env and pol subtypes, suggesting recombination
between these two regions. Further analysis by recombination identification program,
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Table 5. GenBank accession numbers and year of sampling'
pa/ sequence name Gcnebank accession no. Yr of sampling Transmission
° any sequence name` Genebank accession no.
ZA004p01 AY136957 2001 P NA
ZA005p01 AY136958 2001 A ZA005c01 AY137011
ZA006p0I AY136959 2001 P NA
ZA007p01 AY136960 2001 A ZA007c0 I AY137012
ZA008p01 AY136961 2001 A NA
ZA009p01 AY136962 2001 A ZA009e01 AY137013
ZAOI0p0I AY136963 2001 A ZA010e01 AY137014
ZA011p01 AY136964 2001 A ZA011601 AY 137015
ZA012p0 I AYI36965 2001 A NA
ZA013p0 I AY136966 2001 A ZA013c01 AY 137016
ZA014p01 AY136967 2001 A ZA014e01 AY 137017
ZA015p0 I AY136968 2001 A NA
ZA016p0I AY136969 2001 A ZA016e01 AY137018
ZA017p01 AY136970 2001 A ZA017e01 AY137019
ZA018p01 AY136971 2001 A ZA018c01 AY137020
ZA019p0I AYI36972 2001 A ZA019e01 AY137021
ZA020p0 I AY136973 2001 A ZA020e01 AY137022
ZA021p0 I AY136974 2001 A ZA021e01 AY137023
ZA022p01 AY I 36975 2001 A ZA022c01 AY137024
ZA025p01 AY136978 2001 A NA
ZA024p0I AY136977 2001 A ZA024e01 AYI 37026
ZA023p01 AY136976 2001 A ZA023e01 AY137025
ZA026p0I AYI36979 2001 P NA
ZA027p01 AY136980 2001 P ZA027c01 AY137027
ZA028p01 AY136981 2001 A ZA028e01 AY137028
ZA029p0 I AY136982 2001 A NA
ZA030p0 I AY136983 2001 A ZA030e01 AY137029
ZA031p0 I AY136984 2001 A ZA031c01 AY137030
ZA032p0 I AY136985 2001 A ZA032e01 AY137031
ZA033p01 AYI 36986 2001 P ZA033e01 AY137032
ZA034p01 AYI 36987 2001 e ZAO34eOI AYI37033
ZA035p0 I AYI 36988 2001 P ZA035c01 to be submitted
ZA036p0 I AY136989 2001 P ZA036e0I AY137034
ZA037p01 AY136990 2001 P ZA037c01 AY137035
ZA038p0 I AY 136991 2001 P ZA038e01 AY137036
ZA039p01 AY136992 2001 P ZA039e01 AY137037
ZAO4OpOI AY136993 2001 P ZA040e01 AY137038
ZA041p0I AY136994 2001 P NA
ZA042p01 AY136995 2001 P ZA042c01 AY137039
ZA043p0 I AY136996 2001 P ZA043e01 AY137040
ZA044p01 AY136997 2001 P ZA044e0I AY137041
ZA045p01 AY136998 2001 A ZA045e0I AY137042
ZA046p01 AY136999 2001 A NA
ZA047p0 I AY196498 2001 A ZA047e0I AY137043
ZA048p0I AY196499 2001 A ZA048c01 AY137044
ZA049p01 AY196500 2001 A ZA049e0 I AY137045
ZA050p01 AY196501 2001 A ZA050e01 AY137046
ZA051p01 AY196502 2001 A ZA051e01 AY137047
ZA052p01 AY196503 2001 A ZAO52eOI AY137048
ZA053p01 AY196504 2001 A ZA053e01 AY137049
ZA054p01 AY196505 2001 A ZA054e01 AY137050
ZA055p01 AY196506 2001 A ZA055c01 AY137051
ZA057p0 I AY196507 2001 A ZA057e0I AY137053
ZA058p0I AY196508 2001 A ZA058e01 AY137054
ZA059001 AY196509 2001 A ZA059e01 AY137055
ZA060p01 AY196510 2001 A ZA060e0 I AY137056
ZA061p0I AY19651 I 2001 A ZA061e01 AY137057
ZA062e01 AY196512 2001 A ZA062c01 AY 137058
ZA063p0 I AY137008 2001 A ZA063e01 AY137059
ZA064p0 I AY137006 2001 A ZA064e01 AY137060
ZA065p01 AY137007 2001 A ZA065e0 I AY137061
ZA066p01 AY137004 2001 A ZA066c01 AY137062
ZA068p01 AY 196513 2001 A ZA068e0I AY137064
ZA069p0I AY196514 2001 A ZA069601 AY137065
ZA071p02 AY137000 2001 A ZA071e01 AY137067
ZA073p01 AY196515 2001 A ZA073e0I AY137070
ZA074p01 AY196516 2001 A ZA074e0I AY13707I
Za075p01 AY196517 2001 A ZA075e0I AY137069
ZA077p02 AY137001 2001 A ZA077601 AY137073
ZA078p02 AYI37003 2001 A ZA07800e02 AY137072
ZA079p02 AY137002 2002 A ZA079GRe02 to be submitted
ZA080p0 I AY137005 2001 A NA
pol and env sequences from the same virus and individual are shown on the same line. All samples were
collected in Durban, South Africa, and surrounding regions.
h
' adult (heterosexual) transmission; P, pediatric (perinatal) transmission.
NA, not available.
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recombination detection program, Bootscanning, and Simplot confirmed that ZA021p01
was an intersubtype recombinant that typed as subtype C in env and as a C/D recombinant
in pol, with the breakpoint for recombination occurring approximately twothirds of the
way along the reverse transcriptase gene.
To investigate within-subtype clustering, trees were constructed with published C
sequences from eight different countries (Figures 9 and 10). Full-length reference
sequences were selected because these strains contained both the env and pol genes.
Unlike sequences from India, where seven out of nine (77.7%) samples grouped as a
single monophyletic group, KwaZulu-Natal sequences were widely dispersed across
multiple clusters, or sublineages. The topology of samples within these maximum-
likelihood and neighbor-joining trees was similar for both env and pol and for
retrospective specimens collected prior to 1992. As shown in Figure 9, many of the
retrospective sequences were localized internally, closer to the root of the sublineage. For
most trees, the bootstrap support for the delineated sublineages was higher than 70%.
Overall, 58 of the 69 (84.0%) KwaZulu-Natal sequences grouped within sublineages. The
number of samples within each sublineage ranged from 3 to 14 for env and from 4 to 12
for pol. One of the largest sublineages consisted of only KwaZulu-Natal sequences. The
remaining sublineages contained sequences from other countries in southern Africa
(primarily Botswana, but also Tanzania and Zambia), in addition to those from KwaZulu-
Natal. One Kwa- Zulu-Natal sample clustered with sequences from Brazil, Ethiopia,
Zambia, and Israel. Sequences from different patient groups were distributed across the
phylogenetic tree and showed no obvious evidence of geographic or subgroup clustering
based on ethnicity, age, or sex (Figure 10).
3.3.3 KwaZulu-Natal and Subtype-specific Signature Motifs
The Kwazulu-Natal protease consensus sequence was identical to the consensus sequence
of subtype C at 100% of 99 amino acids, but differed from the consensus of subtypes A,
B, and D at seven, eight, and six positions, respectively (Figure 11). Compared to the B
consensus, amino acid substitutions were identified at 32 different positions. The mean
number of substitutions was nine, with 65 (94.2%) isolates having eight or more
substitutions relative to subtype B. The reverse transcriptase consensus differed from the
subtype C consensus at only one position, codon V60I. Forty-three (62.3%) of the
KwaZulu-Natal sequences had an isoleucine at reverse transcriptase codon 60 rather than
the valine residue that is typical of B and C subtypes. This polymorphism was not present
in the consensus sequence of retrospective samples. Comparison of the KwaZulu-Natal
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Mean age ±SD (range) 38.4 yrs 15.72 mo
Sex, no. of subjects (%)
Male 19 (34) NA
a
Female 37 (66) NA
Ethnicity, no. of subjects/total (%)
Black 46/72 (64) 30/56 (54) 16/16 (100)
White 2/72 (3) 2/56 (4) 0/16 (0)
Coloured 2/72 (3) 2/56 (4) 0/16 (0)
Indian 22/72 (31) 22/56 (39) 0/16 (0)
CD4 cell count, no. of subjects/total (%)
200 cells/mm' 12/40 (30) NA
201 to 500 cells/mm3 17/40 (43) NA
^ 501 cells/mm' 11/40 (28) NA
Average CD4 cell count cells/mm3 366 NA
Plasma HIV RNA, no. of subjects/total (%)
400 copies/ml 0/50 (0) 0/36 (0) 0/14 (0)
401 to  104 copies/ml 7/50 (14) 7/36 (19) 0/14 (0)
>104 to  105 copies/ml 16/50 (31) 14/36 (39) 2/14 (14)
>10 5 copies/ml 27/50 (53) 15/36 (42) 12/14 (86)
Average Plasma HIV RNA (copies/ml) 248,260 113,020 383,500
HIV-1 subtype, no. of subjects/total (%)
Subtype C 60/61 (98) 48/49 (98) 12/12(100)
D/C recombinant 1/61 (2) 1/49(2) 0/12 (0)
aNA = not available
Table 7. DNA distances between subtype C sequences from different population groups.
Country and ethnic group
(no. of viruses)
Mean % distance (SE)






South Africa (73 )
Indian(from KZN) (19)






4.93 (0.27) 2.39 (0.24)
5.07 (0.34)
4.9 (0.3)
5.92 (0.30) 2.86 (0.24)
3.44 (0.29) 2.22 (2.28)
4.86 (0.47) 2.08 (0.43)
5.16 (0.6) 2.23 (0.5)
















consensus to that of subtype B revealed 19 different amino acid substitutions. Thirty-six
(52.2%) had 21 to 25 substitutions and another 33 (47.8%) had 14 to 20 substitutions
relative to HIV-1 B. The most frequent substitutions are shown in Table 8. The
characteristic GPGQ motif at the tip of the V3 loop was conserved in 98.4% of KwaZulu-
Natal samples (Figure 12). The RIGPGQTFYATG dodecapeptide (amino acids 13 to 24 of
V3), previously identified in 69.1% of V3 sequences from Calcutta, India (CIN), was
detected in only 28.6% of KwaZulu-Natal specimens. One of the most variable amino
acids was the C-terminal glycine (G). Overall, 34.9% of KwaZulu-Natal sequences had an
asparagine substitution at this position; 19% had a deletion mutation. Most (87.7%) of the
substitutions and deletions were present within the black subgroup. The deletion mutation,
present in 24.2% of Black and 5.3% of Indian sequences, caused a decrease in length of
the V3 loop from 35 to 34 amino acids. With the exception of a single D25K mutation, no
basic amino acid substitutions were detected at V3 loop positions 11, 24, or 25.
3.3.4 Amino Acid Substitutions Associated with Drug Resistance
The amino acid sequence of each Kwa Zulu-Natal sequence was compared to sequences in
the Stanford University HIV reverse transcriptase and protease sequence database in order
to identify polymorphisms and mutations previously associated with drug resistance in
HIV-1 B infections. No primary resistance mutations to protease inhibitors were detected
in any of the KwaZulu-Natal samples. However, a substantial number of accessory
(secondary) mutations were found at the following positions, in order of decreasing
frequency: I93L (97.1%), M36I (85.5%), M63P/S/UV/H (37.7%), K2OR (13.0%), V77I
(7.2%), and LlOI (1.4%). Similarly, no primary or accessory mutations to resistance
against nucleoside reverse transcriptase inhibitors were identified. However, three patients
were found to harbor resistance mutations to nonnucleoside reverse transcriptase
inhibitors: patient ZA024p01 had a K103N mutation, and her male partner, ZA023p01,
carried a G190A mutation in addition to K103N. A third patient, ZA010p01, had a single
A98G mutation. Table 9 summarizes the frequency and pattern of these mutations.
3.3.5 Amino Acid Substitution and Selection Pressure
KwaZulu-Natal sequences were then compared internally to assess the mutational
behavior of reverse transcriptase and protease in the absence of drug therapy. Analysis by
the likelihood ratio method of Yang (Yang, 2000) indicated that both genes were under
strong purifying (negative) selection pressure (dn/ds or w < 1), with >95% of sites having
wl = 0.019 and w2 = 0.395. In contrast, only 5 (5.1%) amino acids in protease (codons 12,
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Figure 9. Representative pol tree showing the relationships between retrospective and contemporary
sequences from South Africa, Botswana, and other countries affected by the subtype C epidemic. The
sequences are coded by the country of origin and year of isolation. The following sequences were included
in the analysis: 49 previously described isolates from Botswana (accession numbers AF110960, AF110963,
AF 110967, AF 110970, AF 110972, AF 110973, AF 110978, and AF443074 to AF443115), 9 sequences from
India (accession numbers AF286232, AF286223, AF286231, AB023804, AF067159, AF067155,
AF067154, AF067157, and AF067158), 4 sequences from Tanzania (accession numbers AF286234,
AF286235, AF361874, and AF361875), 2 sequences from Zambia (AF286224 and AF286225), 2 sequences
from Brazil (U52853 and AF2862228), 1 sequence from Ethiopia (U46016), 1 sequence from Israel
(AF286233), and 69 sequences from South Africa, including 5 previously described sequences (AF286227,
AY043173, AY043174, AY043175, and AY043176), 3 sequences from another study (Van Harmelen et al,
2001), and 61 sequences newly generated from this study (14 retrospective and 47 contemporary strains).
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Figure 10. Phylogenetic relationship of C2V5 envelope sequences from KwaZulu-Natal, Botswana, Zambia,
and Tanzania.
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19, 35, 37, and 63) and 15 (4.8%) amino acids in reverse transcriptase (codons 36, 39, 123,
135, 162, 166, 174, 196, 207, 211, 214, 245, 272, 277, and 286) were found to be under
strong positive Darwinian (d) selection (w = 2.055). As shown in Figure 11, these amino
acids were not randomly distributed but were located at discrete loci along the reverse
transcriptase and protease genes. Seven (35%) amino acids that were under positive
(diversifying) selection pressure (protease positions 12S and 191; reverse transcriptase
positions 36A, 39E, 123G, 211K, and 245Q) were present in both the KwaZulu-Natal and
subtype C consensus sequence but not in the consensus sequences of subtypes A, B, and
D, suggesting that these signature residues may offer a subtype-specific fitness advantage
to C viruses.
3.3.6 Impact of Substitution on Functional Motifs
Naturally occurring polymorphisms also resulted in significant variation in the number
and type of phosphorylation sites. Overall, 17 potential phosphorylation sites were
identified in the pol gene, 3 in the protease and 14 in the reverse transcriptase. Twelve of
the pol sites were conserved among KwaZulu-Natal patients and in the consensus
sequences for subtypes A, B, C, and D (Figure 11). These included the predicted protein
kinase C site at codons 12 to 14 near the N terminus of the protease and the two casein
kinase II phosphorylation motifs at the active site. Most KwaZulu-Natal sequences had an
S-X-K rather than a T-X-K motif at protease codons 12 to 14. Conserved phosphorylation
sites in reverse transcriptase included protein kinase C codons 68 to 70; tyrosine kinase
codon 49 to 56; cyclic AMP/cyclic GMP-dependent codons 65 to 67, 102 to 105, and 125
to 128; and CKII codons 3 to 6, 107 to 110, 191 to 194, 215 to 218, and 253 to 256. Two
KwaZulu-Natal patients lacked a cyclic AMP phosphorylation site at reverse transcriptase
codons 102 to 105 due to the presence of a K103N mutation. Some phosphorylation sites,
such as the CKII sites at reverse transcriptase positions 39 to 41 and 200 to 203, were
present in subtypes A, B, and D but absent from most of the Kwa Zulu-Natal and subtype
C sequences. Other differences included the absence of an internal myristoylation site
(Maurer-Stroh et al, 2002) at reverse transcriptase codons 196 to 201 in nine patients and
the presence of an amidation site at protease codons 67 to 70 in subtype A, subtype C, and
all but two of the Kwazulu-Natal sequences. With a single exception, all of the natural
reverse transcriptase mutations were embedded within cytotoxic T-lymphocyte, T-helper,
or overlapping cytotoxic T-lymphocyte/T-helper epitopes, as defined for B viruses. Of
particular interest, with respect to the env gene, was a cluster of substitutions located at or
in close proximity to the bottom of the V3 loop, a region known to play a major role in
viral tropism and coreceptor usage. This cluster included amino acid -1, immediately
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Table 8. Frequency of the most common amino acid substitutions in the pol gene compared to subtype B.






























Table 9. Amino acid substitutions at codons associated with drug resistance'
Patient no. Protease substitution(s) Reverse transcriptase substitution(s)
21 M36I
36, 29, 62 I93L
7, 8, 11, 13, 14, 15, 16, 19, 27, M36I, I93L
30, 31, 32, 33, 34, 37, 39, 40,
41, 42, 47, 51, 53, 54, 55, 57,
59, 61, 73, 78, 79, 80
20 V771, 193L
10 M36I, I93L A98G
35, 66, 74 L63P, I93L
49 K2OR, V77I, I93L
5, 9, 22, 38, 58, 68, 69 K2OR, M36I, 193L
12, 17, 18, 25, 26, 28, 45, 46, M36I, L63P/T/S/H, 193L
48, 50, 52, 63, 64, 65, 71, 75,
77
6 M36I, V77I, I93L
23 L63T, V771, 193L K103N*, G190A
24 L63T, V771, I93L K103N*
44 Ll OE M361, L63P, I93L
60 M36I, L63P, V77I, 193L
43 K2OR, M36I, L63V, I93L
iNN411-3,%Stiqasterlqtsuai)2PANOS-FgisAlearVcTiP girj,SRTNPR9?-niti leli6h Pfgge
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Protease 10 20 30 40 50 60 70 80 90 99
conKZN PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDOILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLEF
conA  - - - - - - - - - - - - TV-I---L  - - - - - - - - - - - - - - - - - D  - - - - - - - - - - - - - - - - - - - - - - - - - K  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - I  - - - - - - 
conB  - - - - - - - - - - - - - - - - - - M R  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - H  - - - - - - - - - - - - - - - - - - - - - - L---I  - - - - - - 
conC
conD  - - - - - - - - - - - - T--I---L H  - - - - - - - - - - - - - - - - - - - - - - L---I  - - - - - - 
APV  - - - - - - - - - - - - - - - - - - - - - - - - - - • • 4.. •  - - - - ••••  - - - - - - - - - • - - - - - 
SQV  - - - - - - - - - - - - - - - - - - - - - - - - - • • go •  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
RTV  - - - - - - - - - - - - - - - - - - - - - - - - - - - - • *Imo  - - - - - - - - - - - - - - - - - - - - - - •••  - - - - - - - - - • - • - - - 
NFV  - - - - - - - - - - - - - - - - - - - - - - - - - - - - • *04. - - - - - - •• - - - - - - - - - - - ••• - - - - - 
INV  - - - - - - - - - - - - - - - - - - - - - - - - - - - - • 4.11.  - - - - - - • - - - - - - - - - - - - - - - -
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Figure 11. Correlation of signature patterns with structure and function for protease and reverse
transcriptase. conKZN, KwaZulu-Natal consensus; conA, conB, conC, and conD, consensus sequences for
subtypes A, B, C, and D, respectively; APV, SQV, RTV, NFV, INV, drug binding sites for amprenavir,
saquinavir, ritonavir, nelfinavir, and indinavir, respectively; functn, RT, reverse transcriptase; CTL,
cytotoxic T-lymphocyte epitope; F, drug-binding site; k, protein kinase C phosphorylation site; c, casein
kinase phosphorylation site; m, myristoylation site; aaaa, amidation site; t, tyrosine kinase phosphorylation
site; g, cyclic AMP- and cyclic GMP-dependent protein kinase site; T, thiocarboxanilide UC-781; N,
nevirapine; Q, quinoxaline HBY 097; E, efivirenz; a, accessory mutation; P, primary mutation; caret,
extended _-strand; S, bend; star, hydrogen-bonded turn; h, helix; p, purifying selection pressure; d,
Darwinian (positive) selection pressure.
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Figure 12. Correlation of signature patterns with structure and function of V3 loop. KNZenv,
KwaZulu-Natal consensus; conA, conB, conC, and conD, consensus sequences for subtypes A, B, C, and D,
respectively; k, protein kinase C phosphorylation site; c, casein kinase phosphorylation site; n, N-linked
glycosylation site; caret, extended (3-strand; h, helix; 4, CD4+ binding site; d, Darwinian (positive) selection
pressure.
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upstream from the cysteine residue at the beginning of V3, and amino acid positions 11
and 13 within the V3 loop itself. In common with other C viruses, strains from 89.0% of
KwaZulu-Natal patients had amino acid substitutions that resulted in elimination of the N-
linked glycosylation site at position - 1 (amino acid 301 according to the numbering of
Korber at al, 1998). In 91.0% of patients, loss of glycosylation was associated with a
serine (S) substitution at position 11 and the presence of a positively charged arginine (R)
residue at V3 position 13. The resultant S-X-R motif gave rise to a second, alternative
protein kinase C site immediately adjacent to the phosphorylation site at amino acids 8 to
10. These findings suggest a potential linkage between deglycosylation and
phosphorylation in the V3 loop of C viruses. Most A variants also carried the extra protein
kinase C site at position 11 to 13 but lacked the N-linked glycan at position -1. Instead, a
more distal N-X-S glycosylation site (positions-7 to -5) was frequently absent in A
viruses. Another protein kinase C site, located downstream from the C terminus of V3 at
positions 45 to 47 (relative to V3), was missing in most KwaZulu-Natal viruses. This site
is highly conserved among subtype B viruses. In common with subtype B, KwaZulu-Natal
and other C viruses contained a highly conserved CKII site at amino acids 68 to 71.
3.4 Discussion
Despite the dramatic impact of HIV-1 and AIDS on the KwaZulu-Natal region of South
Africa, few studies have examined the genetic diversity and molecular phylogeny of
KwaZulu-Natal viruses. To date, only eight full-length South African sequences have been
published (Van Harmelen et al, 2001; zur Megede et al, 2002). The primary goals of this
study were to identify regions of high variability, characterize amino acids that are unique
to local strains, and identify sites that are highly conserved and thus likely to be important
for vaccine development and the assessment of antiretroviral therapy. Our results indicate
that C viruses in KwaZulu-Natal have a higher level of nucleotide diversity than
previously reported (Van Harmelen et al, 1999; Van Harmelen et al, 2001) and that the
epidemic, in its explosive phase, is characterized by multiple circulating sublineages in
both the Indian and black communities. The restricted distribution of subtype C viruses
from India compared to the multilineage pattern of Indian viruses from Africa indicates
that the two Indian epidemics have different origins and different evolutionary histories.
The presence of retrospective samples (collected prior to 1990) at internal (basal) branches
in three of the sublineages suggests that each lineage is derived from a different founder
variant and that these variants have been cocirculating in South Africa for at least 10
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years. Of significant note was the cosegregation and close relatedness of sequences from
Kwa-Zulu-Natal black and Indian inhabitants, not only to each other, but also to published
sequences from Botswana. This close relationship with sequences from Botswana was not
observed in a previous study (Novitsky et al, 2002), presumably because of the small
number of samples included from South Africa (n = 5). Taken together, our findings
confirm the existence of multiple HIV-1 C sublineages in southern Africa and demonstrate
that the spread of these different lineages has been substantial. The finding that C viruses
from KwaZulu-Natal are substantially more diverse than those in India and Brazil is
consistent with other studies and has been attributed to the longer duration of the AIDS
epidemic in Africa (Brindeiro et al 1999; Shankarappa et al, 2001). The overall
evolutionary rate of pol and env sequences, as measured by a dated-tip likelihood method
(Rambaut, 2000), was 35% and 68% higher than that of subtype B. Despite the high level
of diversity, KwaZulu-Natal viruses were remarkably well conserved at the amino acid
level, both within subtype C and among different individuals. This is due to the fact that a
large number of the nucleotide substitutions are silent (synonymous) mutations that cause
no change in the amino acid sequence. As a result, the consensus sequence for the
KwaZulu-Natal protease was identical to the consensus sequence for subtype C, while the
reverse transcriptase consensus sequences differed from the C consensus at a single amino
acid, codon 60. High rates of synonymous-to-nonsynonymous nucleotide change have also
been observed among subtype C isolates from Zimbabwe (Shafer et al, 1997) and Ethiopia
(Loemba et al, 2002). This inherent property of African subtype C viruses is a reflection of
the differential pressure exerted on the three positions of the amino acid code or the
KwaZulu-Natal reverse transcriptase gene, the mutation rate for the third position of the
codon was four times higher than that observed for the second position and 30 times
higher than for the first codon position (data not shown). The conservation of subtype C at
the amino acid level offers considerable promise for the development of a consensus- or
ancestor-based "supervaccine" (Novitsky et al, 2002). Recent primate studies suggest that
it may be possible to overcome diversity and achieve cross-protection against different
HIV-1 variants (Dunn et al, 1997; Shibata et al, 1997). However, it should be stressed that
the long-term impact of silent mutations on vaccine efficacy is not known. In the context
of antiretroviral therapy, one recent study found that, despite numerous naturally occurring
mutations in reverse transcriptase, C viruses from Zimbabwe were as susceptible as
subtype B viruses to commonly used nucleoside and nonnucleoside reverse transcriptase
inhibitors (Shafer et al, 1997). However, another recent study found that, although C
viruses in Ethiopia were susceptible to reverse transcriptase inhibitors, the presence of
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silent mutations led to a more rapid emergence of resistance (Loemba et al, 2002). These
data emphasize the need for carefully designed prospective trials to determine whether
existing polymorphisms influence the development of resistance in C-infected patients.
With the exception of two primary resistance mutations, K103N and G190A, which
occurred in a single husband-wife pair, none of the reverse transcriptase or protease
polymorphisms occurred at drug-binding sites or at active sites of the enzymes. Both
mutations are known to cause high-level resistance to nevirapine in persons infected with
subtype B (Raffi et al 2000). Although believed to be naturally occurring, the possibility
that these mutations represent treatment-induced changes cannot be excluded. As many as
15% of patients in the private sector in South Africa have received or are currently
receiving some form of antiretroviral therapy. Many protocols include nevirapine because
of its low cost and long half-life. Nevirapine is also being increasingly used for the
prevention of mother-to child HIV-1 transmission in KwaZulu-Natal and other regions of
Africa (Jackson et al, 2001).
All of the remaining pol polymorphisms occurred in regions involved in the three-
dimensional configuration of reverse transcriptase and protease. One such polymorphism,
which occurred in a single patient, was A98G in the reverse transcriptase. This mutation
was also detected in a treatment-naïve patient from Ethiopia (Loemba et al, 2002). In
persons infected with subtype B, A98G has been associated with low-level resistance to
nonnucleoside reverse transcriptase inhibitors. Other polymorphisms were localized within
the hinge region of protease, a region that induces conformational changes during drug
binding. A subset of these mutations, M36VR41K/H69/L89 M, has been linked to
increased catalytic activity in subtypes A and C (Velazquez-Campoy et al, 2001). Another
series of polymorphisms, at codons 12, 15, 19, and 93, occurred in >80% of Kwa7ulu-
Natal viruses and formed a KwaZulu-Natal/subtype C signature motif. The first three
amino acids of this motif are located near the N terminus of protease, in an extended J3-
strand; the fourth, 193L, is located in a hydrogen-bonded turn, immediately upstream of
the protease/reverse transcriptase cleavage site. The marked dominance of I93L among C
viruses, its close proximity to the protease/reverse transcriptase cleavage site, and its
linkage to the T12S/T15V/L19I signature warrant further investigation. Studies of HIV-1
B have reported that mutations in the protease and Gag-Pol cleavage sites contribute to
drug resistance, are specifically selected during therapy, and can lead to improved enzyme
kinetics (Cote et al, 2001; Doyon et al, 1996c These conserved codons were concentrated
within active sites and at drug-binding sites in reverse transcriptase and protease and at
nucleoside triphosphate binding sites in reverse transcriptase. The remaining 5% of amino
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acids were under strong positive selection pressure and were concentrated in regions
associated with maintaining the tertiary structure and facilitating conformational changes.
Some positively selected codons, such as protease 63 and reverse transcriptase 123 and
174, showed extensive interpatient and intersubtype variation. Other codons (such as
protease 12S and reverse transcriptase 39E, 245Q, 272P, and 277R) were highly conserved
among Kwa-Zulu-Natal and subtype C sequences and formed part of an HIV-1 C
signature sequence. The conservation of codons in the face of strong diversifying pressure
suggests that they may play an important role in the evolutionary, structural, and
phenotypic properties of C viruses. A few positively selected codons were conserved
across several subtypes, suggesting that they may contribute to the evolutionary history of
group M viruses. Although many factors contribute to the generation of new variants, one
of the most important is related to cytotoxic T lymphocytes and the role they play in
recognizing epitopes presented by major histocompatibility complex class I molecules.
With a single exception, all of the naturally occurring reverse transcriptase mutations were
embedded within cytotoxic T-lymphocyte, T-helper, or overlapping cytotoxic T-
lymphocyte/T-helper epitopes as previously defined for B viruses (Korber et al, 2000).
Several signature sequences in env also mapped to known subtype B cytotoxic T-
lymphocyte epitopes, including the heavily glycosylated regions at the bottom of V3 and
the associated protein kinase C phosphorylation site at V3 position 11. Information on
subtype C epitopes is just beginning to emerge and, when combined with novel methods
of analysis, may lead to new insights into the immune selection pressures occurring during
seroconversion and in response to therapy. By examining sites under positive selection
pressure, we may be able to identify targets of the host immune system and select
appropriate epitopes for inclusion in a subtype C vaccine. Although it is well known that
most C viruses lack a V3 glycosylation site and a basic amino acid residue at position 11,
the biological significance of these findings remains unclear. Disruption of V3
glycosylation has also been reported to occur in 52%, 34%, and 20% of subtype G, A, and
D viruses, respectively. Studies of subtype B have suggested that this N-linked glycan may
play a role in the interaction of gp120 with its coreceptors (Li et al, 2001) and in perinatal
transmission. Nakayama et al, (1998) found that absence of this V3 glycan caused a
marked reduction in CXCR4-dependent but not CCR5-dependent viral entry. Others have
suggested that the V3 glycan is not necessary for CXCR4 usage (Losman et al, 1991) and
that its absence leads to enhanced infectivity of CXCR4-expressing cells (Polzer et al,
2001). Li et al. (2001) found that multiple factors contribute to coreceptor usage and that
the effects exerted by the V3 glycan are both isolated and context dependent. Similarly,
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the absence of a basic amino acid at position 11 of V3 and at positions 24 and 25 has been
associated with a non-syncytium-inducing phenotype and CCR5 coreceptor-using
properties, while the presence of basic charge has been correlated with CXCR4 and
syncytium-inducing phenotypes (Hoffman et al, 1999; Hoffman et al, 2002; Hwang et al,
1991; Kato et al, 1999; Nakayama et al, 1998). As with deglycosylation, these correlations
have been imprecise. Our findings, showing a potential linkage between V3
deglycosylation and the presence of a serine phosphorylation site at position 11, suggest
that factors other than glycosylation and charge may have to be taken into account when
assessing the function of V3. Based on the knowledge that C viruses are almost
exclusively non-syncytium inducing and CCR5 using, it is tempting to speculate that
deglycosylation may allow better access to the CCR5 coreceptor, while phosphorylation
may alter the conformation of gp120, exposing retroviral sites that are needed for efficient
CCR5-mediated viral entry. Although highly speculative, this possibility warrants further
study given the critical importance of V3 for host cell recognition and viral entry.
Differences were also observed in the number and position of phosphorylation sites in
reverse transcriptase and protease. Phosphorylation is known to modulate the activity of
many proteins that interact with nucleic acids, including DNA and RNA polymerase. It is
also known that, in addition to reverse transcriptase and protease, several protein kinases
are incorporated into mature HIV-1 virions (Tozer et al, 1999), where they are available
not only to regulate the activity of reverse transcriptase and protease, but also to
participate in interactions with the host cell. Phosphorylation of threonine residue at
reverse transcriptase codon 215 has been shown to increase discrimination against
azidothymidine, leading to drug resistance (Lazaro et al, 2000), and phosphorylation of
protease substrates can lead to impaired proteolytic cleavage (Tozer et al, 1999). Our data
indicate that several phosphorylation sites in the pol gene of Kwazulu -Natal and subtype
C viruses are highly conserved and positively selected. It will be important to determine
whether these sites play a significant role in the replicative capacity and proteolytic
processing of C viruses.
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Chapter 4
Variability at Human Immunodeficiency Virus Type 1 Subtype
C Protease Cleavage Sites: an Indication of Viral Fitness?
4.1 Introduction
One of the most dramatic changes in the human immunodeficiency virus type 1 (HIV-1)-
AIDS epidemic has been the rapid emergence and devastating spread of subtype C viruses
(Kuiken et al, 2002; http://www.unaids.org/epidemicupdatedecOl/report /index  html).
HIV-1 C now accounts for >56% of all circulating viruses and is the most commonly
transmitted subtype worldwide (Esparza and Bhamarapravati, 2000). Subtype C
predominates in southern Africa (Gordon et al, 2003; Novitsky et al, 1999; Van Harmelen
et al, 1999) and India (Shankarappa et al, 2001) and is increasing in frequency in China
Gao et al, 1998, Rodenburg et al, 2001) and Brazil (Brindeiro et al, 1999; Gonzales et al,
2003; Soares et al, 2003). The disproportionate increase in C viruses relative to other HIV-
1 strains suggests that subtype C may be more easily transmitted or that it has a higher
level of "fitness" at the population level. One possible explanation is that founder effects
relating to the ongoing introduction of subtype C into new population groups with
different host factors, or different social and sexual practices, may be responsible for the
rapid spread. However, founder and host effects cannot account for the fact that C viruses
are overtaking preexisting virus subtypes in several different geographical regions,
including Yunnan Province in China and the southern region of Brazil (Brindeiro et al,
1999; Gao et al, 1998; Rodenburg et al, 2001; Soares et al, 2003). It is increasingly evident
that additional (non-host) viral factors are also contributing to the rapid spread of HIV-1
C. Viral studies indicate that subtype C has distinct genetic and phenotypic properties that
differentiate it from other HIV-1 subtypes. Various studies have postulated that an extra
NF-KB binding site in the long terminal repeat (Rodenburg et al, 2001), a prematurely
truncated Rev protein (Gao et al, 1998, Rodenburg et al, 2001), or a 5-amino-acid
insertion in Vpu (McCormick-Davis et al, 2000) may influence viral gene expression,
altering the transmissibility and pathogenesis of C viruses (Tatt et al, 2001). Factors
related to viral entry and pathogenesis, such as the CCR5 and non-syncytium-inducing
properties of C isolates (Ball et al, 2003; Peeters et al, 1999; Ping et al, 1999), may also
contribute to the increased spread of C viruses. One area of research that is receiving
consideration is the possibility that C viruses have a more active, catalytically efficient
protease (Velazquez-Campoy et al, 2001). The C protease is highly conserved at the amino
acid level and has a distinct signature sequence that differentiates it from those of subtypes
A, B, and D (Gordon et al, 2003; Velazquez-Campoy et al, 2001). A subset of these
signature residues, present in the hinge (M361/R411CH69K) and a-helix (L89M) of C (and
A) proteases, has been linked to increased catalytic activity (Velazquez-Campoy et al,
2001). Another signature pattern, identified in >80% of C viruses from South Africa, is
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T12S/ T15V/L191/193L (Gordon et al, 2003). The 12S, 15V, and 191 residues of this motif
are located near the N terminus of the protease in an extended r3-chain. The 93L
polymorphism is located within a hydrogen-bonded turn immediately upstream from the
protease-reverse transcriptase (RT) cleavage site, in close proximity to 12S/15V/191 and
the dimerization domain (Pettit et al, 2003; Shehu-Xhilaga et al, 2001; Swanstrom and
Wills, 1997; Tessmer et al, 1998). All of these polymorphisms lie outside the catalytic site
of the protease, in regions that would be expected to alter the enzyme's activity toward its
natural cleavage sites, leading to adaptive (compensatory) changes in the cleavage site
itself Since protease inhibitors (PIs) are currently the most active antiretroviral drugs used
for the treatment of HIV-1 (Zennou et al, 1998), it is important to collect information, not
only on the C protease but also on its drug responsiveness, substrate-inhibitor specificities,
and cleavage site characteristics. This information is needed to design PIs that are
maximally effective against C viruses and to obtain new insights into the mechanism of
drug resistance. Studies have shown that resistance mutations in the B protease are
associated with impaired proteolytic processing, decreased enzymatic activity, and a
failure to produce mature infectious virions (Croteau et al, 1997; Doyon et al, 1996;
Zennou et al, 1998). Compensatory cleavage site mutations can partially compensate for
these defects (Zybarth and Carter, 1995). In this report, we describe the natural variability
of subtype C cleavage sites in viruses from Africa, India, and Brazil and compare the
results to cleavage site patterns in representative B and group M viruses.
4.2 Methods
4.2.1 Cleavage Site Characteristics
The HIV-1 protease is a small, 99-amino-acid aspartic enzyme that mediates the cleavage
of Gag, Gag-Pol, and Nef precursor polyproteins. These reactions occur late in the viral
life cycle, during virion assembly and maturation at the cell surface. The process is highly
specific, temporally regulated, and essential for the production of infectious viral particles
(Jacks et al, 1998; Kaplan et al, 1994; Krausslich et al, 1989; Swanstrom and Wills, 1997).
As shown in Figure 13, the main structural proteins are formed by cleavage of the Pr55gag
polyprotein into matrix (MA; p17), capsid (CA; p24), nucleocapsid (NC; p7), p6gag, and
two spacer peptides, p2 and pl. The viral enzymes are formed by cleavage of Pr160gag-
pol, a fusion protein derived by ribosomal frame shifting (Jacks et al, 1998). Although
Pr160gag-pol also contains p17, p24, and p2, its C-terminal cleavage products are NC, a
transframe protein (TFP), p6pol, protease (PR), reverse transcriptase (RTp51), RNase H
(RTp66), and integrase (IN) Ikuta et al, 2000, Tessmer et al, 1998). In total, 12 proteolytic
79
reactions are required to generate a mature infectious virion. Each reaction occurs at a
unique cleavage site that differs in amino acid composition (Billich et al, 1988). Some
cleavage sites contain phosphorylated Ser/Thr or Tyr residues that alter the sites'
susceptibilities to cleavage (Tozer et al, 1999). P6gag, the major phosphoprotein of HIV-
1, plays an essential role in the release of virus from the membranes of infected cells
(Muller et al, 2002).
4.2.2 Sequence Data and Construction of Cleavage Site Fragments
A total of 84 full-length nucleotide sequences were selected for analysis. These sequences
included two C isolates from South Africa, TV001 and TV002 (Zur Megede et al, 2002),
in addition to another 25 subtype C, 30 subtype B, and 27 representative group M
reference sequences (including A [n=3], B [n=4], C [n=5], D [n=3], F1 and F2 [n=4], G
[n=2], H [n=2], J [n=2], and K [n=2] subtypes) extracted from the Los Alamos database
(Table 10) (Kuiken et al, 2002). Sequences were selected based on the patient being
treatment naive. Since the prevalence of drug resistance in untreated patients has been
reported to range from 1 to 11 % (Little, 2000), sequences were also screened and excluded
from the study if they were found to contain primary resistance mutations. The majority of
the sequences were obtained by direct DNA PCR amplification and cloning of peripheral
blood mononuclear cells. Nucleotide sequences were aligned by CLUSTAL W
(Thompson et al, 1994) and manually edited with the codon alignment of the Genetic Data
Environment (GDE version 2.2) program (Smith et al, 1994). Calculation of the pairwise
distance matrix, phylogenetic inference, and tree construction were performed on a dual-
processor Linux computer by using the PAUP version 4.0b2a program (Sinauer
Associates, Sunderland, Mass.) and a GDE for Linux HIV-1 interface (De Oliveira et al,
2002). Thirty-base-pair segments, consisting of 15 nucleotides (5 amino acids) on each
side of the 12 cleavage sites, were extracted and concatenated into a 360-bp nucleotide
sequence.
4.2.3 Reconstruction of Ancestral Cleavage Site Sequences
To examine the evolutionary histories of individual cleavage sites, Phylogenetic Analysis
under Maximum Likelihood (PAML) software (Rambaut, 2000) was used to identify
amino acid and nucleotide substitutions along each branch of the tree. Branch lengths were
estimated using a nucleotide substitution model; amino acid sequences were deduced from
the reconstructed nucleotide triplets. The analyses involved the use of maximum-
likelihood methods and a time-reversible model which assume different substitution rates,
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Figure 13. Schematic of the Gag and Gag-Pol processing sites showing the 12 individual protease
cleavage sites: 5 cleavage sites in Gag (p17/p24, p24/p2, p2/NC, p7/pl, and pl/p6gag), 6 cleavage sites
in Gag-Pol (NC/TFP, TFP/p6pol, p6pol/PR, PR/RT, RT/p66, and p66/IN), and a single site in Net ...
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Table 10. Sequences used for the analysis of protease cleavage sites'












































































































































































Identification information for the sequences is in the format: subtype.country.
isolationyear.commonname. The country is represented by the two letter country code using the international
naming convention from ISO 3166
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base frequencies, and transition/transversion rate ratios (kappa) (Yang, 2000; Yang et al,
2000). Using this approach, we were able to reconstruct the ancestral sequences and
internal nodes for each of thel2 protease cleavage sites in the B, C, and M group data sets.
The number of proximal ancestors for each data set was n - 1, which translated into 29
ancestral sequences for subtype B, 26 sequences for subtype C, and 26 sequences for the
group M viruses. The most recent common ancestor (MRCA) nucleotide sequence for
each virus in the three data sets was saved and translated into its corresponding amino
acids.
4.2.4 Diversity and Cleavage Site Polymorphisms
Nucleotide diversity at cleavage sites was measured using a Kimura 2-parameter model
with a distance matrix implemented in the MEGA program version 2.0 (Arizona State
University, Tempe). Amino acid diversity was measured using a Poisson distribution
method implemented in the same MEGA package. P values for diversity measurements
were calculated by applying the t test to the distance matrix of each data set. To determine
whether the sequences had evolved over time, amino acid profiles for individual Gag,
Gag-Pol, and Nef cleavage sites were compared to the inferred MRCA for that site.
4.2.5 Assessment of Positive Selection Pressure
Nucleotide sequences were also analyzed with Codeml, a program from the PAML
software package (Rambaut, 2000). The likelihood ratio test (Anisimova et al, 2001) and
recently developed codon-based models (Yang, 2000, Yang et al, 2000) were used to
assess natural selection and adaptive evolution at the amino acid level. These selection
models use maximum-likelihood scores to account for variation in the dnlds
(nonsynonymous/synonymous) ratio (6)) at individual codons along the length of the
sequence. High rates of synonymous mutation are indicative of conservation and a strict
requirement for biological function, while high rates of nonsynonymous substitution are
indicative of adaptive change in response to host selection pressure. An individual amino




No primary RT- or PI-resistant mutations were detected among the 84 full-length
sequences selected for study. Although attempts were made to include only sequences
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amplified directly from HIV-1 proviral DNA and to match these sequences based on
duration of infection, plasma viral load, and CD4 count, this proved difficult. A
surprisingly small amount of full-length sequence data was available from treatment-naive
patients infected with subtype B, and when available, it was often poorly annotated.
Despite these limitations, the frequency and pattern of naturally occurring polymorphisms
observed in this study were remarkably similar to those reported for a control group of
subtype B infections treated with nucleoside reverse transcriptase inhibitors but not with
PIs or nonnucleoside reverse transcriptase inhibitors (Cote et al, 2001). Most of the non-C
sequences came from regions of the world where treatment is not yet readily available.
4.3.2 Genetic Diversity and Patterns of Amino Acid Variability at Individual
Cleavage Sites
Variation at the 12 cleavage sites of subtypes B and C and group M is shown in Table 11.
Seven (58.3%) sites (p17/p24, p24/p2, NC/pl, NC/TFP, PR/RT, RT/p66, and p66/IN)
were found to be relatively well conserved, both over time and between subtypes, with a
mean intrasubtype distance ranging from 0.40 (0.20%) to 7.49 (5.62%). The remaining
live (41.7%) sites exhibited moderate (pl/p6gag) to extensive (p2/NC, TFP/p6pol,
p6pol/PR, and Nef) variation, with mean intrasubtype diversities reaching levels as high as
42.42 (15.16%). For the purposes of this study, we have referred to these three patterns as
conserved, moderately variable, and variable. Polymorphisms were more common among
C than B viruses (P=0.0001). Overall, six cleavage sites (p17/p24, p2/NC, NC/pl, PR/RT,
RT/p66, and Nef) had significantly higher levels of diversity among C viruses
(P=0.0001); five sites (p24/p2, pl/p6gag, NC/TFP, p6pol/PR, and p66/IN) had similar
levels of diversity in both subtypes, and one site, TFP/p6pol, was highly variable among B
and group M viruses (mean distances, 16.7 and 24.7%, respectively) but relatively
conserved in C viruses (mean distance, 7.6%) (P=0.0001). Compared to the M data set,
the level of polymorphism at C cleavage sites was as wide ranging as that observed for the
entire M group, a data set containing nine different HIV-1 subtypes. One cleavage
site, p17/p24, was significantly more diverse in subtype C (mean divergence, 5.15%) than
in group M (mean divergence, 2.23%) and subtype B (mean divergence, 2.31%) viruses
(0.0001 for both comparisons). Seven sites (p24/p2, p2/NC, NC/pl, p6poi/PR, RT/p66,
p66/IN, and Nef) exhibited similar levels of diversity in both data sets (P=0.004-0.961).
Only four group M cleavage sites (pl/p6gag, NC/TFP, TFP/p6pol, and PR/RT) had mean
diversities that were significantly greater than that observed for subtype C (P=0.0001).
For >50% of the sites, the variability of B viruses was significantly lower than that
84
observed for subtype C or group M (P=0.0001), despite the fact that the B viruses covered
a broader time frame. The observed polymorphisms were not randomly distributed across
the variable cleavage sites but were confined to specific amino acids, most of which were
positively selected in C but not in B viruses (Figure 15). The least variable residues were
the P1 positions of pl/p6gag, TFP/p6pol, and Nef and the P1' positions of p6pol/PR and
Nef. As shown, these positions flank the scissile bond, with P1 located immediately
upstream and P1' located immediately downstream of the cleavage junction. The most
variable positions were the P1, P3, P4, P5, P3', and P5'residues of p2/NC; the P3' residue
of pl/p6gag; the P1' and P4' residues of TFP/p6pol; the P1 to P4 residues of p6pol/PR;
and the P3 to P5 and P2' residues of Nef.
4.3.3 Subtyping and Phylogenetic-tree Analysis
When subjected to phylogenetic analysis (Figure 14), the concatenated 360-bp fragments
of the group M data set fell into eight subtype-specific clusters representing subtypes A, B
and D, C, F, G, H, J, and K, with the cleavage sequences for subtypes B and D segregating
together in the same subcluster. This pattern was supported by high bootstrap values, by
high-score maximum-likelihood trees, and by phylogenetic analysis of the deduced amino
acids. These findings reveal the subtype-specific nature of protease cleavage sites and
suggest that the evolution of cleavage sites parallels that of the full-length genome. With
the exception of C.981NO22, B.AROO.ARMS008, and B.US.P896, all of the cleavage site
fragments in the B and C data sets segregated into two distinct monophyletic groups
representing either subtype B or subtype C viruses (data not shown). The longer branch
lengths in the C subcluster were reflective of the increased diversity of C viruses relative
to subtype B.
4.3.4 Identification and Dating of Common Ancestors
Maximum likelihood methods were next used to reconstruct the internal nodes of the
phylogenetic tree and to estimate the times of divergence of individual sequences from
their MRCA. These estimates were determined by measuring the number of substitutions
along each branch of the tree. MRCAs for the B, C, and group M data sets are shown in
Figure 15. Two different patterns were observed based on the relationship between a given
sequence and its MRCA. Conserved (n=7) and moderately variable (n=1) cleavage sites
shared the same (identical) MRCA among all three data sets. The proximal location of the































Table 11. Inter- and intra-subtype diversity at 12 cleavage sites, expressed as amino acid distances
between sequences
Mean % distance P value
Protease site Subtype B Subtype C Group M B vs C B vs M C vs M
p17 - p24 2.31 5.15 2.23 <0.0001 0.806 <0.0001
p24 - p2 2.41 3.07 2.67 0.077 0.454 0.267
p2 - p7 18.66 42.42 39.22 <0.0001 <0.0001 0.062
p7 - p1 0.40 5.42 5.22 <0.0001 <0.0001 0.7244
pl - p6gag 8.93 9.81 14.47 0.318 <0.0001 <0.0001
NC-TFN 5.30 3.90 6.30 0.0012 0.0215 <0.0001
TFN-P6" 1 16.69 7.60 24.70 <0.0001 <0.0001 <0.0001
p6° ° ' PR 17.66 16.28 15.55 0.15 0.019 0.365
PR - RT 0.70 1.56 2.93 <0.0001 <0.0001 <0.0001
RT - p66 0.81 7.49 6.03 <0.0001 <0.0001 0.004
p66 - IN 2.44 2.22 2.24 0.524 0.61 0.961
Nef 11.89 24.52 25.68 <0.0001 <0.0001 0.33
Gag (501 aa) 6.99 9.75 15.72 <0.001 <0.001 <0.001
Pol (1004 aa) 6.02 5.83 5.89 0.376 0.419 0.875
Nef (207 aa) 14.66 16.50 18.50 0.07 <0.001 <0.001
12 protease sites 4.80 10.10 12.10 <0.001 <0.001 <0.001
(360 by -120 aa)
aamino acids, aa
Figure 14. Phylogenetic relationships of the South African Tygerberg virology (TV) cleavage site
sequences relative to other subtypes in the group M data set. This representative maximum-likelihood
tree is based on concatenation and analysis of the 12 protease site nucleotide sequences as a single
segment of 360 bp. An indication of the degree of sequence dissimilarity is given by the distance from
the central node. The percentage of bootstrap trees out of 1,000 replications supporting a particular
phylogenetic group is shown alongside the node considered.
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Figure 15. Amino acid polymorphisms at Gag, Gag-Pol, and Nef cleavage sites. The letters refer to the amino acid
substitutions; the numbers in parentheses refer to the number of times the substitution was observed. Each
cleavage site sequence consists of the 5 amino acids upstream and the 5 amino acids downstream of the scissile
bond, indicated by a shill. The labeling of amino acids is according to the convention of P1 to P5 going from the
scissile bond toward the amino terminus and P1' to P5' going toward the carboxy terminus. Positively selected
amino acids are marked with asterisks. Dots represent amino acids that are identical to those in the M MRCA.
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diversification occurred after subtype divergence. In contrast, variable cleavage sites
(n=4) showed a high degree of divergence both from their subtypespecific MRCA and
from the group M MRCA. Ancestral nodes for the variable sites were located closer to the
tips of the tree (data available upon request).
4.3.5 Variability of Cleavage Sites Relative to Other Regions of the HIV-1 Genome
For C viruses, the average intersequence divergence among the concatenated cleavage site
fragments was higher (10.1%) than those observed for the Gag (9.8%) and Pol (5.8%)
proteins but lower (16.5%) than that observed for Nef. In contrast, B cleavage sites were
significantly less diverse (4.8%; P=0.0001) than those of the Gag (7.0%), Pol (6.0%), and
Nef (14.7%) proteins of subtype B. Among group M viruses, cleavage site diversity was
significantly higher (12.1%) than that calculated for Pol (5.9%) but lower than that
determined for Gag (15.7%) and Nef (18.5%). These results are presented in more detail in
Table 11.
4.3.6 Physical-chemical Properties of Amino Acids at P1-P1'Cleavage Junctions
Overall, excluding the highly conserved asparagine (N) residue at the P1 position of
NC/p1 and NC/TFP, >97.0% of P1-Pr amino acids in group M were nonpolar. Of these,
77.8% were hydrophobic, 21.5% were small amino acids (78.9% proline, 20.8% alanine,
and 0.3% glycine), 0.3% were polar uncharged (one serine and three glutamine), 0.2%
were polar charged (one arginine and one aspartic acid), and 0.3% were ungrouped
(cysteine) residues. These amino acids were localized at specific positions within the
cleavage sequence. The small amino acids were localized primarily to the P1' position of
p17/p24, p24/p2, TFP/p6po1, p6po1/PR, and PR/RT. Hydrophobic amino acids were
concentrated at the P1-P1' junction. As previously reported for HIV-1 B (23), the P1-P1'
amino acids of subtype C fell into two different patterns defined by the size of the P1'
amino acid: type I, represented by p2/NC and pl/p6gag, and type II, represented by
p17/p24 and p24/p2. Both types carried large nonpolar, hydrophobic amino acids (leucine,
tyrosine, phenylalanine, and methionine) at position P1 and either a large (type I) or small
(type II) hydrophobic amino acid (proline, alanine, or glycine) at P1'.
4.3.7 MRCAs and Subtype-specific Signature Patterns
A summary of amino acid signature patterns relative to the subtype B and C and group M
MRCAs is shown in Tables 12 and 13. Mutations at cleavage sites defining the enzymatic
(PR/RT, RT/p66, and p66/IN) and structural (p17/24, p24/p2, and NC/p1) components of
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HIV-1 were relatively uncommon and, when detected, were found at greater frequencies
among C versus B viruses. In total, only 1.2, 0.8, and 1.1% of the 840 amino acids at each
of the PR/RT, p66/IN, and p24/p2 cleavage sites carried substitutions. As a result, the
majority of sequences at conserved sites (81.5 to 96.7%) were identical to both the
subtype-specific MRCA and the common ancestor of the group M viruses. Several
cleavage sites involved in the regulation of polyprotein processing and protease activation,
p2/NC, TFP/p6po1, and p6pol/PR, were highly variable and differed significantly from
both the subtype-specific and group M MRCAs. With the exception of the TFP/p6pol site,
which was more variable in subtype B, divergence from the MRCA was greatest for C and
M viruses. None of the p2/NC and p6pol/PR sequences in the group M data set was
identical to the M MRCA signatures for p2/NC and p6pol/PR, STAIM/MQKGN and
TSFSF/PQITC, respectively.
4.3.8 Positive Selection of Amino Acids at Protease Cleavage Sites
The concatenated 360-bp cleavage site fragments were next compared internally to assess
the mutational behavior of P1-P5 and P1'-P5' sites in the absence of drug therapy. As
described in Materials and Methods, the analyses were performed using codon-based
maximum-likelihood methods that test for the variation in selection pressure (dn/ds) at
individual amino acids along the length of the sequence. Application of the likelihood
ratio test indicated that the best-fit model for subtype C and group M sequences was the
positive-selection (discrete) model (x 2 = 54.47; P < 0.0001 and 62.34 and P < 0.0001,
respectively), while for B viruses the neutral model performed as well as the positive
model (x2 = 1.2; P > 0.05). Overall, when analyzed as a single concatenated fragment, all
three datasets were found to be under negative (purifying) selection, with dnlds (w) values
ranging from 0.26 to 0.31 for all sites. Only 20 (16.6%) of the 120 amino acids within the
12 cleavage sites of subtype C were found to be under positive selection, with a w3 value
of 1.7. Group M and subtype B cleavage sites had fewer positively selected amino acids:
11.1 and 6.7%, respectively (Figure 15).
4.4 Discussion
The presence of polymorphisms in the protease of subtype C would be expected to result
in adaptive (compensatory) changes in the natural cleavage sites that are recognized and
cleaved by the C enzyme. To test this hypothesis, we examined the prevalences and
patterns of cleavage site mutations in the Gag, Gag-Pol, and Nef proteins of subtype C















































































































methods, we identified two groups of natural cleavage site sequences. The first group
consisted of eight sequences, seven of which were highly conserved in all HIV-1 subtypes,
and an eighth sequence which was moderately variable. Mutations at these sites were
uncommon and, when present, were observed at relatively equivalent frequencies among
different subtypes. These cleavage sites, which defined the main structural (MA, CA, and
NC) and enzymatic (RT, RNase H, and integrase) proteins of HIV-1, were under strong
negative (purifying) selection pressure, had a common ancestor, and showed little genetic
evolution over time. The second group consisted of five cleavage sites that were under
positive (diversifying) selection pressure, exhibited extensive inter- and intrasubtypc
variability, and showed little (or no) resemblance to the common ancestor of group M or
to the subtype-specific MRCA. Our data showing that the majority (58.3%) of cleavage
sites are highly conserved in all subtypes was not unexpected, given the narrow specificity
of the HIV-1 protease relative to cellular proteases, such as pepsin (Ridky et al, 1996). The
strong purifying selection pressure exerted on these sites is presumably a reflection of the
need to maintain the spatial configuration of the enzyme-substrate complex, conserve the
hydrophobic nature of the scissile bond, and retain the biological activity of functionally
important sites, such as the P1' proline of p17/p24 and the P1 and P 1 '-P5' residues of
NC/p 1. Cleavage of the p17/p24 site is known to play an important role in virion
maturation, while processing of NC/pl is required for ribosomal frame shifting and Gag-
Pol expression (Ericson-Viitanen et al, 1989, Jacks et al, 1998; Kaplan et al, 1994;
Krausslich et al, 1989, Pettit et al, 1994). In B viruses, cleavage of p17/24, p24/p2, and
NC/pl has been shown to be suboptimal, with the NC/p 1 site being rate limiting (Pettit et
al, 2002). It has been suggested that the slow, regulated cleavage of these structural
proteins may represent a common strategy to ensure that the assembled virions have the
full complement of proteins needed to bud from the cell surface, bind to a new cell, and
initiate a new round of viral replication (Tessmer et al, 1998). The carboxyl terminus of
NC is particularly interesting. Unlike other cleavage sites, which carry an aromatic amino
acid at P1 and either a leucine or proline residue at P1', the C termini of NC/p1 and
NC/TFP carry an asparagine (N) residue at P1 opposite a phenylalanine (F) residue at P1'
(Cote et al, 2001, Pettit et al, 2003; Pettit et al, 2002; Pettit et al, 1994). In this study of 84
untreated patients, no mutations were detected at the P2 or P1 '-P3' positions of NC/pi or
NC/TFP and only a single N3C mutation was detected at P1. Taken together, these
findings underscore the unique nature and limited mutability of the NC/pl and NC/TFP
cleavage junctions. Although these sites were strongly conserved in natural infection,
recent studies have shown that an A3V substitution at the P2 positions of NC/p 1 and
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NC/TFP is a common adaptive change, occurring in 29% of PI-resistant patients taking
indinavir, saquinavir, and/or ritonavir for the treatment of subtype B (Cote et al, 2001;
Doyon et al, 1996; Zennou et al, 1998; Zhang et al, 1997). This valine substitution is
frequently associated with an M46 I or L mutation (and possibly a V82 mutation) in the
protease and leads to altered polyprocessing and improved growth of protease-mutated
viruses. Whether similar "second locus" mutations will be observed during the treatment
of non-B subtypes remains to be established. The identification of common patterns may
facilitate the development of broad based inhibitors with increased specificity and
i mproved binding to the mutated protease. These secondary inhibitors might preempt (or
delay) the emergence of resistance. Our analyses also revealed important differences
among HIV-1 subtypes. Particularly intriguing was the identification of five cleavage sites
that exhibited extensive variability across all subtypes, with C viruses being significantly
more variable than subtype B. Variation was restricted to a few specific amino acids, most
of which were positively selected in C but not in B viruses. In contrast to conserved sites,
variable cleavage sites tended to be those with regulatory rather than structural or
enzymatic functions. At least four of the variable sites (p2/NC, pl/p6gag, TFP/p6pol, and
p6pol/PR) are known to play major roles in the regulation of polyprotein processing and,
in the case of TFP/p6pol, in the activation of the protease enzyme (Pettit et al, 2003; Pettit
et al, 2002; Pettit et al, 1994; Ridky et al, 1996; Shehu-Xhilaga et al, 2001). Studies of
subtype B have shown that p2/NC is the initial and most rapidly processed cleavage site,
controlling both the rate and the order of Gag and Gag-Pol polyprocessing (Shehu-Xhilaga
et al, 2001). Our results indicate that p2/NC is by far the most variable cleavage site, with
intrasubtype diversity ranging from 18.7% in subtype B to levels of 42.4% in subtype C.
The pl/p6gag cleavage product, p6gag, is a major phosphoprotein that is critical to the
release of mature, infectious virions (Muller et al, 2002). Although not well studied,
phosphorylation of Gag and Gag-Pol sequences has been shown to alter susceptibility to
cleavage, attenuating or even preventing the proteolytic process (Tomasselli and
Heinrickson, 1994). The TFP/p6pol cleavage site, defining the N terminus of p6pol, was
the only site to have a significantly higher level of diversity among B than among C
viruses. TFP/p6pol is a novel cleavage site located 8 amino acids downstream from NC in
the TFP domain of Gag-Pol (Pettit et al, 2003, Tessmer et al, 1998). Although TFP/p6pol
lies outside (and upstream) of the protease, the EDL tripeptide of this cleavage site (ENL
in the case of C viruses) has been postulated to have a major influence on protease
activation and on the timing and specificity of Gag-Pol cleavage, delaying the release of
the protease until after the viral particle has budded from the cell membrane. Such a
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mechanism may protect the cell from the cytotoxic effects of proteolysis (Thomas et al,
1996; Tomasselli and Heinrickson, 1994). The observed subtype variation in the cleavage
sites controlling the initiation and rate of Gag and Gag-Pol processing (p2/NC) and the
activation of protease (TFP/p6gag) suggests that there may be important differences in the
way that B and C viruses regulate polyprocessing and virion assembly. Subtle cleavage
site differences could, over time, have a major differential impact on the pathogenesis of
HIV-1 subtypes and on response to therapy. Early treatment studies suggest that C viruses
give an excellent initial response to highly active antiretroviral therapy but that the
duration of the response may be less than that reported for B viruses.
In summary, our results point to important inter- and intrasubtype differences in protease
cleavage sites, especially in the p2/NC, TFP/p6pol, and p6pol/PR sites. The main
limitations of our study relate to the cross-sectional nature of the data sets and the limited
availability of well-matched pretreatment controls for use in the B data set. Despite these
limitations, the potential impact of our findings on HIV-1 disease progression and
response to therapy wan -ants further investigation, both at the patient level and in vitro
using site-directed mutagenesis. The separate monophyletic clustering of B and C
cleavage sites suggests that cleavage sites have evolved in a subtype-specific manner. The
divergence between ancestral and contemporary sequences in the C data set and the
location of an ancestral node distal to the group M MRCA suggest that variation in C
cleavage sites began early, prior to the diversification of HIV-1 subtypes. A more detailed
investigation of C cleavage sites, both over time and in response to therapy, is in progress.
The present study forms the baseline for these ongoing studies.
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Chapter 5
Molecular Characteristics of Retrospective South African Drug
Naive Samples
5.1 Introduction
The history of Southern African HIV infection dates back to 1982, when the first South
African AIDS cases were reported among the homosexual population (Sher et al, 1989).
Until 1987, HIV-1 diagnosis was almost completely limited to the male portion of the
population. In 1988, Martin et al reported a HIV-1 prevalence of 20% among homosexual
men and 1% among heterosexual men attending a STD clinic in Johannesburg. The same
clinic found al.2% and 0.8% HIV prevalence among black females and males
respectively. In 1989, Sher presented data from a number of surveillance studies on the
prevalence of HIV infection in South Africa that showed an increase in the number of
AIDS cases among the black population, through the heterosexual route of transmission. It
was later shown that two HIV-1 epidemics were present in South Africa, a smaller
epidemic among the homosexual and bisexual men associated with subtype B and a few
subtype D infections, and a subtype C epidemic among the heterosexual population
(Williamson et al, 1995; Van Harmelen et al, 1997). By 1992, the reported cases in women
roughly equalled those in men. Another study in rural KZN found the prevalence in
women to be three times higher in females than in males (Abdool Karim et al, 1992). The
prevalence of HIV-1 continued to increase, with 16% of pregnant women attending
antenatal clinics testing seropositive in 1997 (Van Harmelen et al, 1999). Van Harmelen
noted geographical variation in the extent of the epidemic within South Africa. KZN had
the highest prevalence in the country with 26.92%, while the Western Cape had a
prevalence of only 6.29% (Van Harmelen et al, 1999). This increased to 36.2% in KZN
and 8.7% in the Western Cape by 2002 (Zur Megede et al, 2002). In 2002, Bredell et al
reported that while subtype C was still predominant, there was an increase in the number
of non-C subtypes detected. Other subtypes were probably introduced independently into
different regions of South Africa by immigrants from other African countries (Van
Harmelen et al, 1999; Bredell et al, 2002).
Between 1984 and 1990, serum was routinely collected and virus isolated from patients in
the Western Cape diagnosed with AIDS and AIDS related conditions (Engelbrecht et al,
1995). To our knowledge, these samples represent the only properly stored archival
specimen bank in SA, and thus may serve as an important source of information on
relating to the evolutionary history of HIV-1 in South Africa. Accurate surveillance of
HIV-1 prevalence and incidence, and systematic monitoring of the genetic diversity,
distribution and spread of HIV-1 variants is critical not only to the design of effective
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vaccines and intervention strategies, but also to formulate policy and predict the future
directions of the global AIDS pandemic. An understanding of the extent of genetic
diversity in different geographic regions, and of its changing dynamics over time is also
needed to ensure that diagnostic assays are sensitive and appropriate for the population
being studied, and that they remain sensitive and specific over time.
As discussed in Chapter 3, recent sequencing in our laboratory has indicated the
HIV/AIDS epidemic is still primarily subtype C restricted, while in Cape Town, the
epidemic is still diverse, but becoming more subtype C dominated (Bredell et al, 2002;
Engelbrecht et al, 2001). To search for underlying genetic differences between these two
regional epidemics, we have conducted a collaborative study with colleagues from
Tygerberg Hospital, University of Stellenbosch, Cape Town. The study involved
comparative sequencing of the RT and PR, as well as env in a subset of samples, of
representative archival and contemporary sequences from Cape Town, and representative
currently circulating and archival HIV-1 strains from Durban and the surrounding areas.
The results of this study provide a baseline for examining the impact of specific amino
acid substitutions on the structure, function and biological properties of HIV-1 C viruses
and the relationships between genetic variation, resistance and response to therapy.
5.2 Methods
5.2.1 Samples
Thirty archival samples and nine contemporary samples (2002) were obtained from
colleagues at Tygerberg Hospital, Western Cape. Although these samples were randomly
chosen from the archival specimen bank to span from the earliest samples in 1984 to 1992,
there is a potential sampling bias, as surveillance in the earlier days of the epidemic was
not systematic. The samples from the Western Cape were compared with 8 archival
samples (1996-1998) collected as part of the national seroprevalence survey, and 46
contemporary (2002) samples from KwaZulu-Natal, a subset of the samples described in
Chapter 3.
5.2.2 RNA Extraction and Resistance Genotyping
HIV-1 RNA was extracted and sequenced using the VirosegTM system (Applied
Biosystems) according to the manufacturer's protocol and as described in Chapter 3.2.4.
Sequences were analysed for resistance as described in Chapter 3.2.5. Signature patterns
(VESPA), biologically significant sites (PROS1TE, selection pressure (PAML) and the
Molecular clock were estimated as described in Chapter 2.1.
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5.3 Results
HIV-1 subtypes circulating in CT between 1984 and 1992 included subtypes B, C and D,
with a predominance of subtype B infections (Table 14). This appears to have changed
over time, with subtype C becoming the predominant subtype, although the other subtypes
are still present. This is in sharp contrast to KZN, where subtype C appears to have
dominated from the onset of the local epidemic (Figure 16). Comparative phylogenetic
analysis revealed few genetic changes in biological important sequences, or in signature
patterns. However, a number of signature mutations occurred at polymorphic sites, namely
the absence of the RT 211K polymorphism found in the subtype C recent isolates (Table
15). This amino acid is under strong positive (diversifying) selection pressure and may
offer a fitness advantage to C viruses. When analysed using models that discriminate
positive, neutral, and purifying selection pressure at different positions along the length of
the protein, the protease and RT were found to be under strong purifying selection with
more than 97 % of sites having a co value < 0.5). Positions under positive selection
included 37N and 63P in protease and positions 123D, 174Q, 211K, 245Q and 277R in
reverse transcriptase.
The evolutionary rates of the South African HIV-1 C pol and env genes were 35% and
68% higher than for subtype B, respectively. The mutation rates for pol were
approximately 0.001 and 0.00189 sites per year for subtypes B and C respectively, while
the env mutation rate was 0.002 for subtype B and 0.003 for subtype C (Table 16), values
that are similar to other previously published rates (Korber et al, 2000). The molecular
clock hypothesis was only accepted for the pol gene for subtypes B and C.
The relatively high nucleotide mutation rate of the pol gene was not reflected in the amino
acid sequence. Most mutations were silent (synonymous), a reflection of the non-
homogeneous distribution of nucleotide substitutions in the three different codon
positions. The mutation rate in the third position was four times higher than in the second
position, and 30 times higher than in the first codon position. Substitutions at the third
codon position is responsible for many synonymous mutations (Table 17).
Likelihood and genetic distance trees of HIV-1 C polymerase (RT and PR) sequences
from South Africa revealed the presence of multiple scattered lineages. The lineages
probably arose from different introductions of founder strains. The presence of HIV-1
isolates collected prior to 1992 at internal (basal) branches in three of these lineages
suggests that these sequences may represent founder strains that have existed for at least
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South Africa continues to have at least two distinct HIV-1 epidemics characterized by the
presence of different genetic subtypes, epidemic timing and HIV-1 prevalence values
(Bredell et al, 2002; Zur Megede et al, 2002). The impact of these genetic differences on
the transmission dynamics and biological properties of HIV-1 are unknown. Our studies
suggest that there are no primary resistance mutations in the protease and RT of drug naive
subtype C isolates, as well as no major changes in signature sequences of biologically
important sites. However, variation at polymorphic sites may alter the conformation of
RT, PR and env and lead to indirect changes in replicative capacity, ability to cleave Gag-
Pol polyproteins and changes in tropism.
In this study, differences between retrospective and recent sequences from subtype B and
C viruses from the Western Cape and KZN were examined in an attempt to identify codon
positions that were selected over time and could potentially offer a fitness advantage to C
viruses. A few differences were identified, including the RT R211K mutation, that is
under strong positive (diversifying) selection pressure in contemporary subtype C isolates
but absent in subtype B sequences and Western Cape retrospective subtype C isolates.
This mutation, when present with L214F and/or H208Y, has been shown to cause a 2.4- or
8-fold increase in AZT resistance (Sturmer et al, 2003). Another mutation, V601, was
present only in the KZN signature patterns. Both of these mutations do not occur at
functional sites and their potential role in viral fitness needs to be further investigated in
vitro, with site directed mutagenesis and replication assays.
Correlation of subtype distribution with HIV-1 prevalence, suggests that subtype C is
outgrowing other subtypes in Cape Town, while remaining predominant in KwaZulu-
Natal. This is similar to other regions such as the Congo, Tanzania, Burundi, Kenya, China
and Brazil where subtype C is becoming predominant relative to existing subtypes (Soares
et al, 2003; Koch et al, 2001; Rodenburg et al, 2001; Brindeiro et al, 1999; Gao et al,
1998; Yu et al, 1998; Janessens and Nkengasong, 1997). Although subtype B has been
repeatedly introduced in different parts of the world, it doesn't seem to take off in the
same manner as subtype C. Differences in host genetics, socio-economic factors, presence
of other pathogens, as wells as differences in tropism and replicative capacity could
account for the different outcomes.
Taken together, these findings suggest the diversity and distribution of HIV-1 subtypes in
South Africa has changed since the beginning of the local epidemic 22 years ago. Major
changes relate to the increasing prevalence of multiple subtypes, and the rapid ongoing
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spread of subtype C viruses. Evidence of multiple co-circulating subtypes in the Western
Cape emphasizes the need to carefully monitor for the emergence of recombinants. A
number of studies have suggested that subtypes A and C may be more fit in vitro, and
possibly in vivo, at the population level, but the evidence is far from conclusive
(Velazques-Campoy et al, 2001; Velazques-Campoy et al, 2002; Arts et al, 2001; Ball et
al, 2003). For example, the study by Ball et al (2003) found that while subtypes B and C
displayed equal fitness in Langerhans cells, subtype B was more fit in T-cells and
macrophages. They suggest that subtype C was less fit following initial infection and this
could lead to slower disease progression (Ball et al, 2003). This slower disease progression
could in turn allow for an increased time for transmission (Quinones-Mateu et al, 2000).
Continued, ongoing studies such as those described in this thesis, detailing the genetic
changes in subtype C in different population groups over time may shed some light on this
complex issue. Studies will be most informative if conducted in a geographic region where
multiple subtypes co-exist concurrently. This will allow for better comparisons with the




Emergence and Patterns of Resistance in HIV-1 subtype C
Isolates from Treated Patients in KZN, South Africa
6 Introduction
The introduction of HAART for the treatment of HIV-1 has greatly reduced the morbidity
and mortality associated with this disease (Palella et al, 1998). However, these benefits
have mainly been felt in developed countries such as North America and Europe.
Subtype C is one of the most prevalent subtypes worldwide and is especially common in
sub-Saharan Africa where the prevalence is estimated to be up to 36% (UNAIDS/WHO:
Report, 2000). However, most data on the response of HIV-1 to ARV therapy has been
from studies using subtype B. These studies have shown that in previously untreated
individuals with drug-susceptible HIV-1 strains, combinations of three or more drugs from
two drug classes can lead to prolonged virus suppression and immunological
reconstitution (Richman, 1994). However, the drug-induced emergence of resistance
mutations can impact on the patient's current and future therapeutic options. The risk of
developing resistance is dependent on the level of residual viral replication, the ease of
acquisition of a particular mutation, and how this impacts on drug susceptibility and virus
fitness (Shafer et al, 2000).
There is a paucity of data relating to non-B subtypes and ARV therapy (subtype C in
particular), largely because these viruses are prevalent in resource poor settings, where
there is little or no access to ARV therapy (Shafer et al, 1997). Initial reports have shown
that non-B subtypes are as susceptible as wild-type subtype B isolates to ARVs and that
the drugs are safe and effective when applied to C infections (Pillay et al, 2002b; Frater et
al, 2001; Shafer 1997). Drug susceptibility testing, using a recombinant phenotypic assay,
has suggested that C viruses may be hypersensitive to Lopinavir (Gonzales et al, 2003).
However, the efficacy of ARV therapy for the treatment of subtype C, in an African
context (where opportunistic infections and malnutrition are rife), is unproven. Also, drug
resistance may evolve differently in people infected with subtype C (Pillay et al, 2002b).
There is increasing evidence that some HIV subtypes may follow different distinct
pathways during the development of resistance, although many key resistance mutations
occur in both non-B and B subtypes which are exposed to antiretroviral drugs (Palmer et
al, 2001; Weidle et al, 2001). Studies from Israel and other African countries have shown
that some naturally-occurring polymorphisms in subtype C viruses occur at sites known to
cause drug resistance in subtype B (Grossman et al, 2001). Other studies have described
natural polymorphisms in the pol gene of C viruses that may lead to a more rapid
emergence of resistance to NRTIs and NNRTIs, and a reduced in vitro responsiveness to
PIs (Loveday et al, 2002; Perno et al, 2001). Therefore, there remains the possibility that
subtype-specific resistance patterns may emerge in patients failing therapy and that this
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may have an impact on the rate or level of drug resistance (Loemba 2002; Kantor et al,
2003). Key PI-associated mutations such as D3ON and L9OM are significantly less
common in subtype C versus subtype B virus following treatment, as are some RT-
associated mutations including D67N, K103N and T215Y (Grossman et al, 2001; Cane et
al, 2004).
In Chapter 3, we described the naturally-occurring polymorphisms and resistance
mutations in a representative subset of pre-treatment adult and paediatric patients from
KwaZulu-Natal. In this chapter, we investigate the emergence and pattern of resistance in
vivo in patients infected with subtype C. At the time, ARV drugs were not freely available
in South Africa, except in a few controlled studies and in the private sector. We were
fortunate enough to have access to some of these studies that included cohorts from HIV-1
patients co-infected with TB and Karposi Sarcoma (KS) and mothers and babies that
participated in a pMTCT study in the Hlabisa district of Northern Natal. Although the
numbers are small, these studies provide valuable information on the emergence and
pattern of resistance in C-viruses and the interpretation and clinical significance of ARV
resistance in the context of a rapidly expanding subtype C epidemic.
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6.1 Resistance patterns in patients on concomitant TB/HAART and HAART alone
6.1.1 Introduction
The use of ARV drugs in South Africa has mostly been limited to the prevention of MTCT
(Rollins et al, 2002; Morris et al, 2001) and to patients treated in private-practice. There is
a paucity of published reports on the response of South African patients treated with
HAART. In addition, there is limited data on the concomitant administration of HAART
and TB treatment in subtype C infected patients. TB is also one of the world's major
pandemics, and as is the case with HIV, the brunt of the pandemic falls on sub-Saharan
Africa (Grange and Zumla, 2002). Despite efforts to control the spread of TB in this area,
it continues to be a problem, most likely because of the high HIV prevalence. It has
therefore been suggested that strategies to control both TB and HIV simultaneously need
to be developed. However, the application of HIV-1 treatment during TB treatment is a
controversial issue, as many physicians prefer to delay HAART in patients presenting with
TB because of pill burden, drug/drug interactions and toxicity (Mukadi et al, 2001; Dean
et al, 2002).
Little is known about evolution of subtype C in the presence of antiretroviral drugs and the
impact this will have on response to therapy. Further to that, the implications for second-
line and salvage therapy choices are yet to be established. In this section, we present
results on the emergence of resistance in patients failing therapy from two separate
treatment studies conducted in South Africa. One was conducted in the informal
settlement of Khayalitsha, Cape Town, in collaboration with clinicians called the Mêdecin
San Frontiere (MSF), where 287 treatment naive adults were followed for a median
duration of 13.9 months after starting therapy of two NRTIs and one NNRTI. We
investigated the first 50 treated patients to reach study end. The other was a pilot study
(called the START study) conducted in Durban, KZN on patients dually infected with TB
and HIV-1, where concomitant TB/HAART was prescribed.
6.1.2 Selection of patients and samples
Plasma samples were collected from 26 HIV-1/TB co-infected patients at baseline and at
monthly intervals after commencement of concomitant TB and HIV-1 ARV therapy.
Seven patients defaulted and of the 19 remaining patients, sequences were obtained from
16 patients at baseline and at monthly intervals for the two patients failing therapy
(START 4 and 11). In addition, we obtained plasma samples from three of five patients
failing ARV therapy from the MSF study.
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6.1.3 Patient treatment history
The patients on TB/HAART received single daily doses of Rifampicin (600 mg), 3TC,
ddI and EFV until study end (6 months after starting treatment). The MSF patients were
started on a standard regimen of AZT, 3TC and NVP, but two of the patients (MSFCK and
MSFED) changed treatment due to a combination of virologic failure, adverse events
and/or intolerance. Patient MSFCK stopped therapy at 9 months due to an adverse event,
as well as virologic failure. Treatment was recommenced one month later with ddI, d4T
and NFV. At 13 months, the NFV had to be changed (to EFV) when the patient developed
extra-pulmonary TB. Patient MSFED had two short stops and restarted shortly after
commencing treatment, due to AZT intolerance, and had to switch to d4T (before 3
months). All three MSF patients had a clinical history of prior TB (were on cotrimoxizole
before and during treatment) and were late stage (stage 3 or 4) AIDS patients. Sequences
were obtained from three time points after commencement of therapy for each of the
patients.
6.1.4 Methods
6.1.4.1 Viral load assays
Plasma was isolated from EDTA blood tubes by spinning at 1000 rpm for 10 minutes. After
separation, plasma was stored in 1.0m1 aliquots at —80 °C until RNA isolation. RNA was
extracted using a guanidinium-silica method (Nuclisens Isolation Kit from BioMerieux Inc.,
formerly Organon Teknika) and an automated extractor (BioMerieux) with no modifications
to the protocol. Refer to the 9.0m1 lysis buffer protocol in the Nuclisens Isolation Kit package
insert. After isolations, HIV-1 RNA levels were measured using the Nuclisens HIV-1 QT
Amplification and Detection kit, also with no modifications to the protocol. As 1.0m1 of
plasma was used for all viral load determination, the lower limit of detection was 40-50 copies
per ml; the highest was >5000 000 copies per ml. Reproducibility and accuracy of the viral
load assay was assessed every six months through participation in the VQA quality assurance
panel.
6.1.4.2 Determination of CD4+ and CD8+ T-cell Subsets
T-cell counts and percentages were determined using a murine monoclonal antibody cocktail
of anti-human CD45, CD3, CD4 and CD8 antibodies (TetraOne, Beckman Coulter). Ten
microlitres of the antibody cocktail were added to 100 ul of patients' peripheral blood
collected in an EDTA container. After ten minutes of incubation, the sample was placed in the
TQ-Prep (Beckman Coulter) in order to lyse the red blood cells and fix the leukocytes.
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Absolute counts and percentages were determined using a single platform protocol and 100 ul
of Flow Count Beads (Beckman Coulter) on the Epics XL-MCL flow cytometer (Beckman
Coulter). The CD4+ and CD8+ cell count protocol was designed based on the manufacturer's
specifications for TetraOne (Beckman Coulter) analysis. The initial voltages were set using an
unstained sample and then a sample with known CD45, CD3, CD4 and CD8 counts and
percentages. Colour compensation was conducted to prevent over-estimations in cell counts
and percentages by eliminating fluorescent emission overlap from analysis. The
reproducibility and accuracy of the T-cell counts were also assessed every three months
through participation in the UK NEQUAS quality control panel.
6.1.4.3 Resistance genotyping
Resistance genotyping was performed using the Viroseq kit (Abbott Diagnostics). Briefly,
HIV-1 RNA was extracted from plasma using the Sample Prep module from the Viroseq
kit, according to the manufacturers protocol. The RNA was reverse transcribed with
Moloney murine leukemia virus reverse transcriptase. A 1.8-kb fragment containing the
protease (amino acids 1 to 99) and reverse transcriptase (amino acids 1 to 335) regions
was then amplified in a 40-cycle PCR with Amplitaq Gold DNA polymerase and
AmpErase dUTP/uracil-N-glycosidase to minimize the risk of cross-contamination. PCR
products were visually quantified by agarose gel electrophoresis. Following purification,
the products were sequenced with six of the seven kit primers (primer D was not used) and
Big-Dye terminator reagents and run on a 3100 genetic analyzer (Applied Biosystems).
Sequences were assembled, translated, and analyzed for the presence of amino acid
polymorphisms. A report was generated for each sequence, with mixtures of wild-type and
mutant bases being classified as mutant.
6.1.4.4 Sequence analysis
Sequences were analysed as described in Chapter 2. Briefly, sequences were subtyped by
phylogenetic analysis using PAUP* and an appropriate model of evolution. Sequences
were analysed for positive selection using the codeml program of the PAML software
package (Rambaut, 2000). An individual amino acid was considered to be positively
selected if the dnlds ratio was significantly greater than 1.0. The most recent common
ancestors were reconstructed using the baseml option of the PAML software package and
codon models selected by the LRT method. Reconstructed ancestral sequences were saved
and used to construct a Maximum-likelihood tree with all sequences available for each
patient and other subtype C sequences obtained from GenBank (Rambaut, 2000; Yang,
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2000; Yang et al, 2000). The tree was rooted with a homologous region from the HXB2
reference strain. Sequences were screened for the presence of biologically important sites
using Prosite, a database of protein families and domains.
6.1.4.5 Prediction of tertiary and secondary structure
RT nucleotide sequences were translated and submitted to Swiss-Model, a site for 3D
homology modelling of protein structure (http://www.expasy.org/swissmod/SWISS-
MODEL.html), to determine the impact of novel, positively selected sites on the structure
of the RT enzyme Models were visualised with Deep View Swiss-pdbViewer, an interface
allowing the analysis of several proteins at the same time (Guex and Peitsch, 1997).
Secondary structure was predicted using the PhD software program via the Predict protein
server (http ://www. embl-heidelberg.de/predictprotein/predictprotein.htme
Prediction of secondary structures is a step towards the prediction of the three-dimensional
structure of a protein by providing a rough estimate of structural features, and with at least
one known homologue available, the PhD method has an expected overall accuracy of
71.4% for proteins (Rost et al, 1994).
6.1.5 Results
6.1.5.1 Mutations associated with resistance to RT inhibitors
Patients failing therapy displayed a variety of drug resistance mutations (Figure 17). In
START 4, the V106M, Y181C and K219N mutations were detected from one month after
starting treatment and were the only amino acids detected at those positions. The L74V,
K101E and M184V mutations occurred as quasispecies with the wildtype from two
months after starting treatment, but by the fourth month, they were the only amino acids
detected at those positions. For START 11, we did not detect any resistance mutations
until the second month and these mutations (K65R, V106M and G190A) were the only
amino acids detected at those positions. Patient MSFCK displayed the M184V and G190A
mutations at the first time point, with the addition of T215F in the second. The third time
point showed the addition of the K103N, and the loss of the M184V mutations. This
corresponded with a change to d4T, ddI and EFV. Patient MSFED had the D67N, M184V
and G190S mutations in the first two time points. The third time point showed the
accumulation of the mutations associated with multi nucleoside RT inhibitor (NRTI)
resistance (F116Y and Q151M) in addition to the D67N, M184V and G190S mutations.
Patient MSFSD did not have any resistance mutations in the first time point, but acquired
the K103N and M184V mutations in the second and then losing the M184V again in the
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third. Figure 17 shows the pattern of emerging primary drug resistance in these five
individual patients in relationship to changes in CD4 T-cell counts and plasma viral load.
6.1.5.2 Frequency of polymorphisms before and after treatment
Figure 18a illustrates the frequency of polymorphisms in the RT, before and after
treatment for the five patients. Primary resistance mutations were only found after
treatment, with the M 184V as the highest frequency. Polymorphisms not previously
associated with resistance that were detected only after treatment included: K21I, K32N,
K49R, V90I, I135M, E203K, K281R and K311Q. Other polymorphisms increased (V36A)
or decreased (R123G/S and R277K) in frequency. Although patients were on different
drug regimens, this graph highlights the development of polymorphisms in response to
ARV treatment.
6.1.5.3 Correlation of mutations with alterations in functional properties of RT.
A few differences were observed at sites important for function between drug naïve and
those failing treatment. At least three treatment induced genetic changes would be
expected to have a significant impact on the functional properties. The first of these was
the loss of the cAMP, cGMP dependant PK site at RT 102 to 105, and the gain of a
myristoylation site at RT 99 to 104 and a N-glycosylation site at RT 105 to 106 due to the
K103N mutation. This is consistent with results from our previous study (Gordon et al,
2003). Another difference was the loss of a MSFCK M7 site at RT 215 to 218 caused by a
T215F mutation in the second and third time points from patient MSFCK. A third
difference noted involved the TKP site at position 174-181 in RT, which spans the active
site of the RT enzyme. This region was highly conserved in our retrospective subtype B
and D sequences (data not shown), but variable in C. Loss of the site is caused either by
the loss of a K or Rat RT 173 or 174, the loss of a D or Eat RT 177, or the loss of a Y at
RT 181. There was no consistent pattern seen in those isolates that lost this TKP site.
Lastly, a PKC site at RT 123 to125 was found in 10/16 (62.5%) of the START baselines,
which is a great increase compared to our previous study of around 25% (Gordon et al,
2003). This was not found in the MSF isolates, or our retrospective B and D isolates.
6.1.5.4 Positively selected sites in the RT
We analysed the selection pressure exerted on the treated isolates in different subgroups:






















100000 • Y181C •
K219N
10000 - •














  0  





Sll 3TC, ddl, EFV
10 0 0 0 0 0
10 0 0 0 0










G19OA T 50 0G190A • • • GI90A - 4 0 0
none • - 3 0 0
















n •100 n • 








































































Figure 17. Longitudinal analysis showing the changes in resistance patterns, viral load and CD4+
counts in five patients who developed drug resistance during the first 8 to 15 months of therapy. These
patients were: START 4 (a), START11 (b), and MSFCK (c), MSFED (d) and MSFSD (e)
samples together as well as separately (Table 18). As expected, codons under strong
positive selection pressure were at sites known to cause primary (confers resistance on
their own) or secondary (confers resistance when occurring with other mutations) drug
resistance in subtype B. These were: RT 65, 74, 101, 106, 181, 184, 190, 219 and 334.
Interestingly, other codons under positive selection in the START 4 and 11 subgroup
included codon 123 which codes for a PKC phosphorylation site in 62.5% of the baselines
and in START 11 before and after treatment. Also, codons 173 and 174 were both under
positive selection in the START treated samples and foim part of a TKP site with codon
181. This TKP site is found in 6/16 (37.5%) of the START baselines (including START 4,
but not START 11). This site is lost in START 4 due to the Y181C mutation. The 123,
173 and 174 codons were not under positive selection when START 4 and START 11
were analysed separately.
In START 11, eight mutations caused amino acid change and all were positively selected.
Three of the eight (K65R, V106M and G190A) were at sites associated with resistance in
sub-B, while mutations at codons 274, 275, 278, 281 and 292 were at sites not previously
associated with drug resistance. There were interesting changes observed at these
positions, namely, at codon 274, there is a change from V to I in months 2 to 7, but
changes at codons 275, 278 and 281 occur at months one and two, but revert to the .
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baseline sequence from month 3 to month seven. If one takes the ancestral sequences into
account, it appears that the mutations at codons 275 and 278 (present in the ancestral
sequence) were lost during viral evolution, but regained during therapy (as a result of drug
selection pressure) and was lost again, probably because the original sequence had more of
a fitness advantage. I292V was only present at month four, which could possibly correlate
with a rapid increase in viral load to 240 000 after it had come down to 9200. In START4,
11 mutations resulted in amino acid change. All of those at positions associated with drug
resistance were also positively selected, as well as V21I, V202I, E203K and E207A that
were positively selected sites, but not previously associated with resistance. V211 and
E203K are detected from month two onwards, and could be compensatory mutations in
response to the L74V, K101E and M184V drug resistance mutations. In a similar fashion
to the mutations seen in START 4, V2021 and E207A occur from months one to four and
then revert back to the baseline sequence in month six. When the START 4 and 11
baseline samples were removed from their respective subgroups, there were no longer any
codons under positive selection, suggesting that the resistance mutations had become fixed
very early on.
The MSF samples had fewer codons under positive selection, with eight in the RT. These
included codons 103, 151, 184, 190 and 215, also codons known to cause drug resistance
to RT inhibitors. Novel codons included RT 135, RT 162 and RT 177. In patient MSFED,
seven sites were positively selected, six of these at positions associated with drug
resistance. Codon 123 was the only site not previously associated with drug resistance. In
patient MSFCK, four of the 13 mutations that resulted in amino acid change were at sites
associated with drug resistance (103, 184, 190 and 215) and were positively selected. Of
the remaining nine amino acids, five (102, 113, 123, 135 and 196) were also positively
selected. Finally, for patient MSFSD, three mutations resulted in amino acid change
(K103N, 1135M and M184V).
6.1.5.5 Subtyping and Phylogenetic analysis
All START and MSF isolates were classified as subtype C. All isolates from each patient
clustered together and were supported by bootstrap values above 90%. As can be seen
from the phylogenetic tree (Figure 18b), the branch lengths for the START 4 and 11 time
points were very short, indicating a rapid evolutionary rate. This could be interpreted as a
rapid evolution to their resistant genotype, followed by very little genetic evolution
subsequently. This could also be seen, but to a lesser extent, for the MSF samples.
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Table 18. Positively selected sites in the PR and RT (excluding primary resistance mutations). Samples
were analysed together (START baselines and START 4 and 11) and individually.



































































































Figure 18b. Subtype C specific Maximum-likelihood tree of all available START and MSF sequences
(including the generate Most Recent Common Ancestor lamp and reference subtype C strains from
Botswana (BW), Brazil (BR), Ethiopia (ET), India (IN), South Africa (ZA and TV), Tanzania (TZ)
and Zimbabwe (ZM). The tree was rooted with HXB2.
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6.1.5.7 Changes in predicted tertiary and secondary structure
Primary resistance mutations are either associated with excision of the incorporated
ddNTP (eg T215Y), improved discrimination between the NRTI and the natural dNTPs
(eg K65R) or changes in conformation of the dNTP-binding pocket (eg K103N) (Parkin et
al, 2003; Lennerstrand et al, 2001; Van Laethem et al, 2000). Accessory mutations that
compensate for any loss of fitness caused by the drug-induced resistance mutations are
usually involved in stabilizing the 3D structure (Courcambeck et al, 2000). 3D homology
models generated using Swiss-model (Figure 19) show changes in structure over time at
codons that are under strong positive selection, as well as changes at site associated with
primary resistance for START 11 (Figure 19a), START 4 (Figure 19b), MSFCK (Figure
19c), MSFED (Figure 19d), MSFSD (Figure 19e). Of note was the K65R mutation,
located in the "fingers" domain of RT that caused a marked change in the orientation of
that side chain in START 11 from month 2 onwards (Figure 19a). Some positively
selected sites in START 4 were at external residues (RT 21, 202, 203, 207 and 311) and
probably served to stabilize RT (Figure 19b). Changes at codon 102, which lies in the
palm domain of HIV-1 RT and is very close to the NNRTI binding sites, is noted at the
same time as the acquisition of the K103N mutation in MSFMSFCK_M14 (Figure 19c).
The close proximity of codons 116 and 151 are shown in Figure 19d. Mutations at these
positions occurred in MSFED, causing multi NRTI resistance. The position of codon 67
near the opening of the binding groove suggests a possible interaction with the template
primer complex (Figure 19d). The I to M mutation at codon 135 in MSFSD appeared to be
linked to the appearance, and subsequent disappearance, of the M184V mutation (Figure
19e).
6.1.6 Discussion
Antiretroviral therapy can prolong the lives and improve the health of patients with HIV-1
infection. However, the emergence of mutations that cause resistance to ARV drugs can
li mit the efficacy of ARV treatment regimens. These mutations are often in complex
patterns and the interpretation of these genotypic changes and their clinical implication
presents a challenge (Shafer et al, 2000; VanDamme, 2001). To compound that, there is a
paucity of data available on the efficacy of ARV drugs and the emergence of drug
resistance among non-B subtypes, particularly subtype C. Recent reports suggest that
subtype C will respond equally as well as subtype B to therapy, but that the impact of
signature subtype C sequences on therapy needs to be further investigated (Kantor et al,
2003; Grossman et al, 2001; Loemba et al, 2002).
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Figure 19a. The predicted tertiary structures for STARTII. Sidechains are coloured as follows: RT 65
(blue); 106 (bright green); 181 (red); 190 (orange); 274 (yellow); 275 (pink); 278 (purple); 281
(burgundy); 292 (dark green); 334 (turquoise). The Lysine at RT65 occurs in the "fingers" domain of
RT and usually comes into contact with the template-primer complex during normal RT activity. The
change to an Arginine at month 2 causes a marked change in the orientation of the side chain. The
changes that occur at the positively selected sites are more complex and are located mainly in the
"thumb" domain of the RT. At months 1 and 2, it appears that the side chain at RT281 curls upward,
with a corresponding downward movement of RT275. The normal orientation is resumed from month





Figure 19b.The predicted tertiary structures for START4. Sidechains are coloured as followes: RT
21 (dusky pink); 74 (sky blue); 101 (teal); 106 (bright green); 181 (red); 190 (orange); 184 (dark
blue); 202 (blue); 203 (green); 207 (brown); 232 (turquoise); 219 (black); 311 (burnt orange).
Mutations at RT202, 203 and 207 were positively selected. Although very closely situated to each
other, RT203 is more external than the other two residues. Other positively selected residues, RT
311 and RT21 are also situated on the surface of the RT enzyme. Mutations at these locations
probably serve to stabilize the enzyme.
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Baseline
Figure 19c.The predicted tertiary structures for MSFCK. Sidechains are coloured as followes: RT 102
(dark green); 103 (pink); 113 (light blue); 123 (bright blue); 135 (grey); 184 (dark blue); 190 (orange);
196 (bright pink); 215 (cream). Changes in conformation for condons 196, 135 and 123 all occur from
MSFCK_M6 onwards. Codon 102 lies in the palm domain of HIV-1 RT and is very close to the
NNRTI binding sites, and its change in conformation is noted at the same time as the acquisition of the




Figure 19d. The predicted tertiary structures for MSFED. Sidechains are coloured as followes: RT 67
(dusky pink); 101 (teal); 123 (bright blue); 184 (dark blue); 190 (orange); 116 (grey-green); 151 (pink);
334 (lime). Perhaps most important is the close association between codons 116 and 151 in
MSFED_M12, which causes multi NRTI resistance. Codon 67 is situated near the opening of the
binding groove and is in a good position to interact with template primer complex.
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Month 6
Figure 19e.The predicted tertiary structures for MSFSD. The only change in MSFSD occur at codons
103 (pink), 135 (grey-green) and 184 (dark blue). Codon 135 appears to change from an I to M in
association with the M184V mutation and reverts back to the wild type in conjunction with the
reversion to wildtype at codon 184.
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HPAGL
PHD_Sec ....... EEE ............ HHHHHHHHHHHHHHHH .EE EEEEEE ...... EHHHHHHHHHHHHHHHH ..........
START4_Ml
PHD_Sec ...... EEEE ............ HHHHHHHHHHHHHHHH . SE EEEEEE ..... EEHHHHHHHHIPH.HH.H
START4_M2 I V
PHD_sec ...... EEEE ............ HHHHHHHHHHHHHHHH.. .EE ...... EEEEEE ...... EHHHHHHHHHHHHHHHHH .........
START4_M3 I V
PHD_sec ...... EEEE ............ HHHHHHHHHHHHHHHH. 	E EEEEEE ...... EHHHHHHHHHHHHHHHH ..........
START4_M4 I V
PHD_sec ...... EEEE ............ H.H.H.HHHPH.H.H. E EEEEEE ....... EHHHHHHHHHHHHHHHH ...........
START4_M6 I... V
PHD_sec ...... EEEE ............ HHHHHHHHHHHHHHHH 	E EEEEEE ...... EHHHHHHHHHHHHHHHH ..........
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START1121 .......................
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MSFED_M13 N
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START4_M1 M C
PHD_sec .... EEEEE ... EE ....... EEEEE ......... EEEEEE ..... HHHHHHHHHHHHHHHHH...EEEEEEE....E ......HHHHH
START422 F M C V
PHD_sec .... EEEEE ... EE ....... EEEEE ......... EEEEEE ..... HHHHHHHHHHHHHHHH....EEEEEEE....E ...... HHHHH
START4273 F M C V
PHD_sec .... EEEEE ... EE ....... EEEEE ......... EEEEEE ......... HHHHHHHHHHHHHHHH....EEEEEEE....E ...... HHHHH
START424 E 	M C V
PHD_sec .... EEEEE ... EE ....... EEEEE ........ EEEEEE ..... HPHHHHHHHHHHHHHH....EEEEEEE....E ...... HHHHH
START426 R 	M C V
PHD_sec .... EEEEE .. EE ....... EEEEE ........ EEEEEE ..... HHHHHHHHHHHHHHHH. .EEEEEE 	  	HHHHH
START11_BL KKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRA
PHD_sec .... EEEEE .. EE ....... EEEEE ........ EEEEEE ..... HHHHHHHHHHHHHHHHH. .EEEEEE ........... HHHHH
START11211 V 
PHD_sec .... EEEEE .. EE ....... EEEEE ........ EEEEEE ..... H-HHHHHHHHHHHHHHH. .EEEEEE HHHHH
START1122 M A
PHD_sec ....EEEEEE .. EE ....... EEEEE ........ EEEEEE ..... HHHHHHHHHHH.HHHH .EEEEEE ........... HHHHH
START1123 M A
PHD_sec ....EEEEEE .. EE ....... EEEEE ........ EEEEEE ..... HHHHHHHHHHHHHHHH. ...EEEEEE HHHHH
START11_M4 M A
PHD_sec ....EEEEEE .. EE ....... EEEEE ........ EEEEEE ..... H.HHHHHHHHHHHHHHH. .EEEEEE IFIHHH
START1125 M A
PHD_sec ....EEEEEE .. EE ....... EEEEE ........ EEEEEE ..... H.HHHHHHHHHHHHHv EEEEEE ........... HHHHH
MSECK_BL KKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRAQNPGIVIYQYMDDLYVGSDLEIEQHRA
PHD_sec .... EEEEE .. EE ....... EEEEE ........ EEEEEE ..... HHHHHHHHHHHHHHHH . EEEEEE HHHHHH
MSECK_M6 M V A G
PHD_sec .... EEEEE .. EE ....... EEEEE ........ EEEEEE ..... HHHHHHHHHHHHHHHH. .EEEEEE uHHHHH
MSECK_M7 M V A G
PHD_sec .... EEEEE .. EE ....... EEEEE ........ EEEEEE ..... HHHHHHHHHHHHHHH. EEEEEE HHHHH
MUCK_M14 .QN ......... M G
PHD_sec .... EEEEE .. EE ....... EEEEE ........ EEEEEE ..... HHFHHHHHHHHHHHH EEEEEE HHHHH
MSFED_BL KKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPNIVIYQYMDDLYVGSDLEIGQHRA
PHD_sec .... EEEEE .. EE ....... EEEEE ........ EEEEEE ..... IFHHHHHHHHHHHHHHH. .EEEEEE HHHHH
MSFed_M6 0 ......................... G V S
PHD_sec .... EEEEE .. EE ....... EEEEE ........ EEEEEE ..... HHHHHHHHHHHHH.M. EEEEEE HHHHH
MSFED_M7 Q .................................. G V S
PHD_sec ....EEEEEE .. EE ....... EEEEE ........ EEEEEE ..... H
, HHHHHHHHHHHHHH. .EEEEEE ........... HHHHH
MSFED212 Q ........... Y G M S
PHD_sec .... EEEEE .. EE ....... EEEEE ........ EEEEEE ..... HHHHHHHHHHHHHHHHH. . EEEEEE H4HHH
MSFSD_M6 KKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRA
PHD_sec ....EEEEEE .. ES ....... EEEEE ........ EEEEEE ..... HHHHHHHHHHHHHHHHH. .EEEEEE HHHHH
MSFSD_M10 N M V
PHD_sec .... EEEEE .. EE ....... EEEEE ........ EEEEEE ..... H
—HHHHHHHHHHHHHH. .EEEEEEE HvHHH
MSFSD_M12 N 
PHD_sec .... EEEEE .. EE ....... EEEEE ........ EEEEEE ..... friHHHHHHHHHHRHHHH. .EEEEEE HYHPH
124
START4_HL
210 220 230 240 250 260 270 280 290 300
KVEELREHLLKWGETTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGVKALTDIVPLTE
EAE
PHD_sec HHHHHHHHHH EEEEEEE EEE ......... HHHHHHHHH. HHHHHHHH ............ HHHHHHHF.......................... E..HHHHH
START4_M1 .I 	A N H
PHD_sec HHHHHHHH.H”H EEEEEEE EEE ......... .HHHHHHHH.HHHHHHHH HHHHHHHH ............... HHHHH. HHHHH
START4_M2 .IK 	A N 
PHD_sec HHHHHHHHHHHH ............ EEEEEEE ...... EEE ........ PHHHHH.HH.HHHHHHHH HHHHHHHH .................. HHHH.HHHHH
START4_M3 .I 	A N 
PHD_sec HHHHHHHHHHHH EEEEEEE  .......EEE ........ HHHHHHHHH.HHHH.H.H HHHHH.HH HHHHH
START4244 .I N 
PHD_sec HHHHHHHHHHHH ............ EEEEEEE  .......EEE ........ HHHHHHHHH. HHHHHHHH .. . HHHHHHHH HHHHH
START4_M6 K N 
PHD_sec HHHHHHHH7HH ..................................... EEEE.EE EEE ........ HHHHHHHHH.HHHHHHH HHHHHHHH HHHHH
START11_BL KIEELREHLLKWGFTTPDKKBQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGVQVKNLCKLLRGAKALTDIVPLTEEAE
PHD_sec HHHHHHHHHH”H EEEE.EE E HHHHHHHHH.HHHHHHHH HHHHHHHH	E 	HHHHH
START11_M1 K H R
PHD_sec HHHHHHHHHHHH ............... EEEE.EE E HHHHHHHHHH. HHHHHHHH .... HHHHHHH
—............................. HHHH..HHHHH
START11_M2 IK 	H R 
PHD_sec HHHHHHHHHHHH EEEEEEE E H.HHH4HHH4 HH.HHHHH H.HHH.HHH HHHP H.HRH
START11_M3 I
PHD_sec HHHHHHHHHHHH ........... EEEEEEE E HHHHHHHHHH.HHHHHHHH H.HHHHHHH ............ HHHH. .HHHHH
START11_M4 I V
PHD_sec HHHHHHHHHHHH ............... EEEEEEE E HPHHHHHHHH .H.HHHHH HHH.HHHIMI E HHHHH
START11215 I
PHD_sec HHFH.H.HHH.H EEEEEEE E HHHHHHHHHH.HHHHHHHH ............ HHHHHHHHH ..... HHHH..HHHHH
MSFCK_M7 KIEELREHLLKWGETTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAE
PHD_sec HHHHHHHHHHHH ........... EEEE. EE HH.HHHHHH HHHHHHHH  HHHHHHHH E HHH.H
MSFCK_M6
PHD_sec HHHHHHHH.HHH EEEE EE E H.H.HHHHHH HHHH.H.H ............ HHHHH.HHI 1 HH. HHHH
MSFCK_M7 F 
PHD_sec HHHHHHHHHHHH ........... EEEEEEE E HHHHHHHHHH. HHHHHHHH 1- HHHHHHFH HHHH..HHHHH
MSFCK_M14 F.........
PHD_sec HHHHHHHHHHHH EEEE.EE E H.HHHHHHHH.HHHHHHHH HPHHHHHFH HHHE..HHHHH
MSFED_BL KIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTERAE
PHD_sec HHHHHHHHHiHR EEEEEEE E .H.HHHHHH.HHHHHHHH HHHHHHHH E HHHHH
MSFED_M6
PHD_sec rill.H"H.HHHT EEEE. EH E HH.HHHPHF .HHH.HHH HHH.HHH. 	E 	HHH.H
MSFED_M7
PHD_sec HHHHHH.H
—H.H EEEEEEE E -HHHHHHHH. HHHHHHHH HHHHHHHHH ........ E...HHHH
MSFED_M12
PHD_sec HHHHHHHHHHHH EEEE EE E .HHH.HHHH HHHHFHPH HHHHHHHH .........E.. HHHHH
MSFSD_M6 KIFELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAE
PHD_sec HHHHHHHHHHHH .................................. EEEE.EE E HHHHHHHHH.HHHHHHH................. HHHMHHHH 	E HHHHH
MSFSD_M10
PHD_sec HHHHHHHHHHHH EEEE.EE E HHHHHHHHH.HHHHHHHH . . . ..HHHHHHHH . E..HHHHH
MSFSD_M12
PHD sec HHHHHHHHHHHH .................................. EEEE.EE E FHHHHHHHH.HHHHHHHH . . . ..HHHHHHHH....................  .. E..HHHHH
310 320 330 335
START4M1 LELAENREILKEPVHGVYYDPSKDLIAEIQKQGND
PHD_sec HHHHHHHHHHHHHH ...................... HHHHHHHHHH...
START4_Ml
PHD_sec HHHHHHHHHHHH,,  ... .HhHHHHHHH...
START422
PHD_sec HHHHHHHHHHHHH ......................... HHHHHHHHHH...
START4_M3
PHD_sec HHHHHHHHHHHHH ......................... HHHHHHHHHH...
START4_M4
PHD_sec HHHHHHHHHHHHH.. EE ............ HHHHHHHHHH...
START4_M6
PHD_sec HHHHHHHHHHHHHH ...................... HHHHHHHHHH...
START11_BL LELAENREILKEPVHGVYYDPSKDLIAEIQKQGND
PHD_sec HHHHHHHHHHHHH. . EE —HHHHHHHHH...
START1l_Ml
PHD_sec HHHHHHHHHHHHH.. EE .. HHHHHHHHH...
START11_M2




PHD_sec HHHHHHHHHHHH — 	HHHHHHHHHH...
START11_M5
PHD_sec HHHHHHHHHHHHH ......... HHHHHHHHHH...
MSFCK_M7 LELAENREILKEPVHGVYYDPSKELIAEIQKQGDD




PHD_sec HHHHHHHHHHHHH. EE .. HHHHHHHHH...
MSFCK_M14
PHD_sec HHHHHHHHHHHHH ......... HHHHHHHHHH...
MSFED_HL LELAENRE ILKEPVHGVYYDPSKDLIAE IQKQGLD
PHD_sec HHHHHHHHHHHHH .EE .... PHMHHHHHHH...
MSFed_M6 A 
PHD_sec HHHHHHHHHHHHH.. EE .... HHHHHHHHHH...
MSFED_M7 A 
PHD sec HHHHHHHHHHHHH..EE 'HHHHHHHHH...
MSFED_M12 A 
PHD_sec HHHHHHHHHHHH. . EE PHHHFHHHHH...
MSFSD_M6 LELAENREILKEPVHGVYYDPSKDLIAEIQKQGDD
PHD_sec HHFHHHHHHHHHH..EE ............. HHHHHHHHHH...
MSFSD_M10
PHD_sec HHHHHHHHHHHHH.. EE ............ HHHHHHHHHH...
MSFSD_M12
PHD sec HHHHHHHHHHHHH. . EE ............ HHHHHHHHHH...
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Figure 20. Comparison of the predicted secondary structures for the 5 patients. Beta sheets are
represented by an "E" and helixes are represented by an "H". The time points are given after the
sample name and an underscore (eg START11_M1 represents the structure for the month one sample.
K65R and D67N appear to cause lengthening of the helix in START11 and MSFED respectively. The
V901 mutation in MSFCK_M7 appears to have the same effect. L74V does not appear to change the
secondary structure in that region. The secondary structure at RT101-200 appeared to be conserved,
with only slight variability at RT189, but this could be an artifact of the software. The length of the
helix at RT 290-300 appeared to be very variable, but the pattern was not consistent, nor was it
directly related to a mutation in that region. A predicted sheet was conserved at RT315-316 in
MSFED and MSFSD, but was variable in the other isolates. Resistance mutations generally did not
occur in sheets or helices, except the following mutations: K65R (sheet), L74V (helix), V106M (sheet),
Y181C and M184V (sheet).
This is one of the few reports from South Africa on the response of subtype C to HAART
outside of the prevention of mother to child transmission trials, and these preliminary
results augur well for the use of RT inhibitors in the treatment of subtype C. Overall the
patients responded well to treatment with an accumulative figure of 7/69 patients failing to
achieve suppression of viral replication up to 13 months after starting treatment. These
data not only increase the information on the response of C viruses to treatment, but also
increases the information on the concurrent use of TB and HIV treatment.
Generally, the resistance mutations seen in our isolates were consistent with those seen in
subtype B, with the exception of the V106M mutation seen in the two patients on EFV.
This mutation has recently been accepted as signature mutation in subtype C patients
treated with EFV (Brenner et al, 2003). The V106M (GTG to ATG) mutation is said to
confer high-level multi non-nucleoside RT inhibitors (NNRTI) resistance, while the
V106A (GTA to GCA) mutation, which occurs more commonly in subtype B isolates,
only causes NVP resistance without any cross-resistance to the other NNRTIs. The rapid
development of EFV resistance in these patients is consistent with sub optimal treatment
that most likely occurred as a result of non-adherence and to a lesser extent, drug/drug
interactions of the TB drugs and EFV. Because EFV is one of the drugs of choice in
resource poor settings, (it is inexpensive and easily administered as a single daily dose), its
use in these settings needs to be closely monitored.
With the exception of START 11, which had already acquired its resistance mutations at
the second month and did not alter after that time point, the patients displayed a
progressive accumulation of mutations. Multi NRTI resistance was only found in one of
the patients (MSFED), who developed mutations at Q151M and F116Y. The Q151M
complex confers the ability of RT to discriminate between an analogue and its natural
counterpart (Deval et al, 2002). It has been suggested that multi NRTI resistance via
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Q151M is more common in non-B subtypes (Kantor et al, 2003). All the MSF samples had
developed the M184V mutation, which confers 3TC resistance. This is common, as the
M814V is usually the first mutation to appear due to its low genetic barrier. However, this
mutation was lost again in 2 of the 3 patients by the third time point. It has been observed
that the M184V mutation disappears as rapidly as it appears once the drug selection
pressure exerted by the 3TC is removed (Van Laethem, personal communication). This
correlates with the change in treatment of MSFCK, but not in MSFSD. Also, the M184V
mutation did not appear in START11 at all. Therefore, an alternate explanation could be
proposed, since the M184V mutation occurs in the highly conserved YMDD motive of the
active site of RT and it is possible that the loss of fitness caused by this mutation is not
well tolerated by subtype C viruses. In these 2 patients, it appeared that the K103N
mutation emerged as M184V disappeared. However, as we only performed population
sequencing and did not clone any of our isolates, we cannot rule out the possibility that the
M184V mutation was still present in a minority population. Perhaps it could be said that
subtype C viruses do not use the preferred pathways that are seen in the development of
subtype B resistance, e.g. the use of the alternate D67N pathway for AZT resistance as
seen in patient MSFED.
The drug resistance mutations in the START patients became fixed as early as one month
after starting treatment, with very little evolution in subsequent time points. This correlates
well with our results on selection pressure which show that these mutations were
positively selected for very early on, followed by strong purifying selection at subsequent
time points (i.e. a reluctance to change from the resistant genotype).
The amino acids under positive selection in RT included codons that are known to cause
drug resistance to RT inhibitors in subtype B, as well as other polymorphisms that have
not been associated with drug resistance (e.g. RT 21, 202, 203, 207 and 232 in START 4
and RT 274, 275, 277, 280, and 291 in START 11).
Most of the resistance mutations, such as K65R, K103N, M184V, G190A/S have been
reported to cause decreased replication capacity in subtype B isolates (Bloor et al, 2003;
White et al, 2002; Huang et al, 2003), while compensatory mutations are usually involved
in stabilizing the 3D structure (Wrobel et al, 1998; Courcambeck et al, 2000). It has been
suggested that some combinations of mutations give the virus a selective advantage in the
presence of various drug combinations (Shafer R et al, 2000; Sturmer et al, 2003;
Courcambeck et al, 2000), and therefore screening for positively selected codons could
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potentially be useful for identifying novel drug resistance mutations that are peculiar to
subtype C, or mutations that compensate for any lack of fitness caused by the resistance
mutations. One such mutation is RT 202 which is involved in the stabilization of the 3D
structure of RT (Wrobel et al, 1998) and could also be involved in the compensation of
any loss of fitness, in a similar way that the RT 208, RT 211 and RT 214 mutations
stabilize the 3D structure in response to the 215 resistance mutation (Sturmer et a, 2003).
Interestingly, mutations at 3 external residues (K101, K103 and V106) are involved in
drug resistance (Wrobel et al, 1998). Most of these external residues are hydrophilic, with
the exception of V 106, 1142 and 1195. V106 has a high variability although it is more
buried than the other external residues. In a paper by Kantor et al, (2002), RT 207 was
reported as a subtype C polymorphism that occurred more commonly in treated than in
untreated subtype B isolates and RT 203 was reported to be a treatment related mutation.
In the same paper, RT 174 was present at higher rates in treated persons infected with
subtype C, suggesting an association with drug resistance in this subtype (Kantor et al,
2002). RT 174, which is under positive selection in the START samples, forms part of a
TKP site with codon 181 (a drug resistance site) and is located in the region associated
with the template-primer complex interaction (Gonzales et al, 2001). Many of the
positions associated with NRTI drug resistance interact with the incoming dNTP or
template primer complex during strand synthesis. K65 and Q151 in RT form part of the
loop between the P2 and P3 strands in the fingers of HIV-1 and make contact with the
incoming dNTP, positioning it in the active site (Courcambeck 2002; Sturmer et al, 2003).
Changes in the geometry of the dNTP binding pocket are brought about by the direct
interaction of the altered residue with the incoming dNTP (Drosopoulos et al, 1998). Our
preliminary results on the structural interactions of novel, positively selected mutations
have shown a definite relationship between structural changes at those sites and the
development of resistance. These interactions are complex and requires much deeper
analysis.
Unfortunately, nearly all the patients developed multi NNRTI resistance, with only one
patient (MSFED) still able to use DLV. These patients would have to change to a PI
inclusive regimen, which is limited to RTV or Kaletra in those patients on TB/HAART. It
would be prudent to make TDF available in South Africa in the future, as it has a higher
genetic barrier and would be essential for patients that have limited therapeutic options.
In conclusion, treatment of HIV/AIDS in South Africa is just beginning, and these initial
results suggest that the response to ARVs will be the same as seen in Europe and North
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America. However, these patients should be closely monitored for viral rebound very early
on in treatment (i.e. follow up visits should be scheduled earlier than 6 months). With
therapeutic drug monitoring (TDM), one could monitor the drug levels in each patient, and
in this way ensure that sufficient levels are reached for optimal treatment. Also, until
more is learned about the phenotypic impact of these mutations on subtype C viruses, we
cannot rule out the possibility that C viruses can rapidly compensate for the loss of fitness
caused by resistance mutations, causing them to become fixed very early after starting
treatment.
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6.2 Characterization of Resistance Patterns in Mother-infant Pairs 6 Weeks After
Single Dose NVP
6.2.1. Introduction
It has been shown that administration of NVP to HIV-1-infected pregnant women at the
onset of delivery, and to the infant during the first 72 hours after birth, decreases
transmission of HIV-1 infection from mother-to-infant by nearly 50% (Becker-Pergola et
al, 2000; Eshleman et al, 2001a). This regimen is extremely cost-effective (approximately
$4 per mother-infant pair), making it the drug of choice to prevent MTCT in developing
countries (Saloojee, 2001). However, there are ongoing concerns about the development
of drug resistance and its potential impact on subsequent treatment. Resistance to NVP
after just a single dose is thought to develop because of the long half-life of the drug in the
body. Women receiving a single dose experienced an exposure of 1-2 weeks of active, but
diminishing concentrations of NVP, creating selection pressures similar to those
experienced during NNRTI monotherapy. Early studies have already demonstrated the
rapid emergence of drug-resistant virus during monotherapy with NVP (Havlir et al, 1996;
Richman et al, 1994). Mutations present as minor variants within the viral quasispecies are
selected for during therapy when other drugs are not present to completely and rapidly
suppress replication.
There have been reports stating that viruses carrying the NVP-resistant mutations are less
fit than wild-type viruses (Collins et al, 2004). Therefore, these viruses should be quickly
overgrown with wild-type virus in the absence of drug selection pressure. A recent study
by Kantor et al, (2003b) found that there appeared to be rapid reversion to wild type
occurring by eight and 24 weeks after receiving a single dose of NVP. However, there is
growing evidence that the K103N mutation can persist as a minor population of the viral
quasispecies for many years, which can very quickly re-emerge with the reintroduction of
drug selection pressure (Little et al, 2004; Mellors et al, 2004; Palmer et al, 2004). The
persistence of such mutations, even at undetectable levels, can influence future therapy
options. Current recommendations are that NVP should be made available to women
treated with NVP for the prevention of MTCT as a viable prophylactic agent during future
pregnancies as well as for future therapy (Wainberg, 2000).
There is little information on whether different HIV-1 subtypes develop resistance to NVP
at the same rate and as a result of the same mutations. Recent reports show that while the
pattern of resistance is the same in A and D subtypes, the rate of NVP resistance was
higher in subtype D isolates (Eshleman et al, 2004a). In a study by Kantor et al (2003b) in
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women with subtype C viruses, an alarming 75% of samples had resistance mutations at
two weeks after receiving NVP. This report has renewed the debate over the longer-term
consequences of NVP resistance in women receiving pMTCT prophylaxis, and could have
serious implications for policy in resource-poor settings, where single-dose NVP is
administered at delivery. In this study, the pattern of resistance mutations in both the
mothers and the infants, 6 weeks after receiving single dose NVP, was investigated. We
also used codon-based substitution models and maximum-likelihood methods to better
understand the role of pre-treatment polymorphisms on the emergence of NVP resistance,
and to assess the biological consequences of genotypic resistance, as defined by changes
in the phosphorylation and myristylation domains of the RT enzyme.
6.2.2 Methods
6.2.2.1 Sample Information
NVP resistance patterns were examined in 30 mother-infant pairs (including a set of twins)
infected with HIV-1 subtype C, who had participated in a pMTCT program. In this
program, women received 1 dose of oral NVP intra-partum (200 mg) and the newborn
received 1 dose as well (2 mg/kg) within 72 hours of birth. The baseline samples from 11
of the mothers were also analysed.
6.2.2.2 RNA Extraction, RTPCR and Resistance Genotyping
HIV-1 RNA was extracted from 6 week post-partum dried blood spots using the NASBA
system (Nuclisens Isolation Kit, Organon Teknika, Boxtel, NL), according to the kit
protocol. HIV-1 RNA was amplified and sequenced using the VirosegTM system (Applied
Biosystems) according to the manufacturer's protocol and as described in Chapter 3.2.4.
Sequences were analysed for resistance as described in Chapter 3.2.5.
6.2.2.3 Nucleic Acid Sequence Analysis
The codeml program of the PAML software package (Rambaut, 2000) was used to
identify prositively selected sites in 12 maternal baseline sequences and 30 mother and
infant 6 week samples. All sequences were screened for the presence of biologically
important sites using PROSITE, a database of protein families and domains. Mean inter-
and intra-patient genetic distances were measured using the Kimura 2-u parameter model
with a distance matrix implemented in the MEGA 2.0 package (Kumar et al, 2001).
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6.2.2.4 Subtyping and Phylogenetic Analysis
Subtyping was performed by phylogenetic tree analysis using PAUP* (Swofford, 1999),
as described in Chapter 2.1.3. The relationship between resistant and non-resistant mothers
and infants were investigated in using neighbour joining and maximum likelihood
methods and the GTR I+G evolutionary model that was selected using MODELTEST
3.0A (Posada and Crandall, 1998). The tree was rooted with a homologous region of the
consensus subtype C reference strain obtained from the Los Alamos database
(http://hiv.lanl.gov/content/hivdb/SUBTYPE  REF/align.html). Trees were viewed with
Treetool and Treeview.
6.2.3 Results
6.2.3.1 Resistance Associated Mutations
No primary resistance mutations to NNRTI or protease inhibitors were detected in any of
the pre-treatment (baseline) sequences. A single mother-infant pair was found to carry the
NRTI mutation, G333E, which facilitates dual resistance to AZT and 3TC when present in
association with M184V and standard AZT resistance mutations. Six week after the
administration of single dose NVP, 11 of 30 (37%) mothers had primary mutations
associated with NVP resistance. K103N was the most common mutation found alone
(63.6%), or in combination with Y188C (9.0%), Y181C and Y188C (9.0%), or V106M,
Y181C, Y188C and G 190A (9.0%). Of the 31 children tested (including a set of twins),
11 (35.5%) had primary resistance six weeks post-NVP. Among infants, Y181C was the
most frequent mutation, occurring alone (72.7%) or in combination with K103N (18.2%),
or V106M (9.0%) (Table 19).
Study No. Mutations Study No. Mutations
mZAl29 V106M, Y181C cZAl29 -
mZA133 K103N cZA133 Y181C
mZA134 K103N cZA134 Y181C
mZA135 K103N cZA135 V106M, Y181C
mZA136 K103N, VIO6M, Y181C, Y188C, G190A cZA136 K103N, Y181C
mZA137 - cZA137 YI81C
mZA140 K103N cZA140 K103N, Y181C
mZA145 G333E cZA145 G333E
mZA146 K103N, Y181C, Y188C cZA146 Y181C
mZA151 K103N cZA151 -
mZA152 K103N, Y188C cZA152 Y181C
mZA154 - c i ZA154
c2ZA154 Y181C
mZA155 K103N cZA155 Y181C
mZA157 K103N cZA157 Y181C
Table 19. Resistance mutations seen in the mothers and infants. The study numbers beginning with
"m" denotes the mother and those beginning with "c" denotes the infant. "c 2 " indicates one of the twin
pairs.
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6.2.3.2 Positively Selected Sites and Genetic Diversity
Sites that became positively selected in the mothers after single dose NVP treatment
included RT207 and RT272. Some sites were only positively selected in the non-resistant
samples (mothers and infants) including RT162, RT214 and RT286, while RT277 was
only positively selected in the mothers and not in the infants. RT123 and RT245 were the
only codons under positive selection in RT in the resistant infants (Table 20).
The nucleotide distances from the mother-child transmission pairs are shown in Table 21.
The mean inter-host diversity among maternal samples collected at baseline, and at 6
weeks post NVP, was 5.1% (±0.3) and 5.1% (±0.3), respectively. These distances are
comparable to those previously reported for HIV-1-infected adults in KwaZulu-Natal
(KZN), South Africa (4.9% ±0.27) (Gordon et al, 2003). The mean inter-host diversity
among neonatal samples collected at 6 weeks post-NVP was 5.5% (±0.3). Within host
variation between maternal samples collected at baseline and 6 weeks ranged from 0.1%
(±0.1) to 1.2% (10.3) (mean, 0.35% [±0.17]).
The overall mean genetic diversity between the mothers and infants was 5.1% ± 0.003.
The highest genetic diversity was seen between the resistant and non-resistant mothers
(5.7% ± 0.003) and between the resistant and non-resistant infants (5.6% ± 0.004).
From Figure 21, sequences from matched mother-infant pairs were more closely related to
each other than from sequences obtained from unrelated mothers and infants. There was
no clustering of samples that harboured resistant mutations. This was also the case in the
tree drawn with all 30 mother-infant pairs (Figure 22). A low genetic diversity
(represented by short branch lengths) in some of the mother's baseline and respective 6
week sample suggests that the strains circulating in the mother had undergone very little
genetic evolution between the baseline and 6 week sampling time. This was usually not
the case in the respective infant sample, which generally had longer branch lengths. These
observations were supported by the genetic distances estimated using MEGA (Table 21).
A possible explanation could be that the transmitted variants were either from another
compartment such as the vagina, or minor variants in the mothers. Unfortunately, because
there were only 3 sequences in total from each matched pair, not much more can be said
about the variants that were transmitted. More time points are needed to obtain better
resolution in the tree.
6.2.3.3 Analysis of Functional Changes using Prosite
Functional sites in the RT from baseline sequences of 11 mothers, as well as 6 week
samples from the mothers and infants were compared. Ten of the resistant mothers
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Table 20. Sites under positive selection in mothers and infants before and after single dose NVP.
RT207 and 272 were only positively selected in the mothers after single dose NVP, while RT277 was
only positively selected in the mothers and not in the infants. RT123 and 245 were the only codons
under positive selection in RT in the resistant infants and RT162, 214 and RT286 were only positively
selected in the non-resistant samples (mothers and infants).
Mothers Before NVP
(n=11)
Mothers After NVP (6wk) Infants After NVP (6wk)
Nonresistant (n=18) Resistant (n=12) Nonresistant (n=19) Resistant (n=12)
19
20 20 20 20
35 35 35 35
PR 60 60
61






123 123 123 123 123
162 162
166
173 173 173 173
178
207 207 207
211 211 211 211
RT
214 214 214









334 334 334 334
335 335
Table 21. Pairwise genetic distance between mother-infant pairs + the standard error
(SE), using the Kimura-2 parameter model as implemented in MEGA.
% Diversity ± SE




























n = number of sequences analyzed
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replaced a cAMP, cGMP protein kinase phosphorylation (PK) site with a myristoylation
and glycosylation site at positions 99-104 and 103-106, respectively (Figure 23). In turn,
all resistant infants harboured strains that lacked a tyrosine kinase phosphorylation (TKP)
motif (KNPEIVIY) immediately upstream from the polymerase active site, at codons 174
to 181. Viruses containing a Lysine (K) at codon 174 had a TKP site, while viruses
containing the 174Q substitution lacked this TKP site. Interestingly, this same
phosphorylation motif is also affected by the primary resistance mutation, Y181C, a
mutation which replaces the C-terminal tyrosine with a cytosine residue. Prior to NVP,
174K and 174Q substitutions were present at approximately equal frequencies, 55.6% and
44.4%, respectively. Post-NVP, the frequency of 174Q increased to a level of 83.3%
among mothers and infants who developed K103N and (or) Y181C resistance mutations.
Among women and children who did not develop resistance, the 174Q allele was detected
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Figure 21. Neighbour-joining tree of sequences derived from a subset of 11 matched mother-infant
pairs. Maternal sequences obtained at baselines and 6 weeks post delivery are denoted by the prefixes
"b" and "m" respectively. The infant sequences obtained at 6 weeks, are labelled with the prefix "c".
The time from delivery (in weeks) is noted after the letter "p", with negative values representing
baseline samples taken before delivery. Bootstrap re-sampling values of >90% are represented by an
(*). As expected, sequences from matched mother-infant pairs were more closely related to each other,




























































Figure 22. Maximum-likelihood tree of mother and infant pairs, with a consensus subtype C sequence as the
outgroup. Mothers' sequences are denoted by a square and infants' sequences are denoted by a circle. Resistant
isolates are coloured in red and non-resistant isolates are coloured in blue. No clustering of resistant isolates was
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Figure 23. Comparison of functional sites in selected mothers' baseline samples (a); non-resistant
mothers (b) vs resistant mothers (c); and non-resistant infants (d) vs resistant infants (e). The K103N
mutation resulted in the loss of a cAMP, cGMP dependant protein kinase phosphorylation site at
codons 102 to 105 in RT. This was replaced with a myristoylation site at codons 99 to104 and a
glycosylation site at codons 103 to 106. All resistant infants lacked a tyrosine kinase phosphorylation
site at codons 174 to 181, near the RT active site.
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6.2.4 Discussion
The HIVNET006 and 012 trials account for the majority of the research done on the use of
NVP in the prevention of mother to child transmission in developing countries. In these
studies, NVP resistance was detected at 6-8 weeks post-partum in approximately 20% of
the women who had received NVP as part of their pMTCT program (Musoke et al, 1999;
Eshleman et al, 2001b; Eshleman et al, 2002). These results are mainly from subtype A
and D viruses. More recent reports from Kantor et al (2003b) have shown an even higher
rate of resistance mutations in subtype C infected mothers, with 75% at two weeks and
34% at 6 weeks post partum. This is consistent with the data presented here, where 40% of
the mothers and infants tested harboured resistance mutations at six weeks after receiving
NVP.
Prior to the introduction of NVP, extensive polymorphism was observed at several amino
acid positions associated with maintaining the tertiary structure and facilitating
conformational changes in the RT enzyme. Of particular interest for this study, was the
identification of four highly variable residues that could accommodate from three to seven
different amino acid substitutions at each position. Some of the most common naturally-
occurring polymorphisms at these positions, relative to subtype B, were D123G/S,
K173A/T/I, Q207E/D and V245E/K, changes which altered the charge of the subtype C
RT enzyme. Analysis using codon-based ML substitutions models, indicated that all of
these polymorphic sites were under positive selection pressure. There was a strong
correlation between the development of resistance and the presence of specific amino
acids at positions 173, 207 and 211, in close proximity to the polymerise active site
(YMDD), and at several more distal codons, located at positions 123 and 286. Of
considerable intrigue, was the finding that variation at position 173 was often linked to
changes in the adjacent amino acid at position 174.
In the HIVNET studies, K103N was the most common mutation seen in the mothers and
the Y181C mutation was most commonly seen in the infants, which is also consistent with
the findings in this chapter. These mutations (K103N and Y181C) occur at positions that
introduce or alter putative myristoylation and phosphorylation sites in the RT. Of note, the
K103N mutation results in a change from a cAMP, cGMP dependant PK phosphorylation
site to a myristoylation and N-glycosylation site. Not much is known about the role of this
myristoylation site in RT, although they usually play a role in transportation of Gag and
GagPol virus particles to the cell membrane, as well as the increased expression of IL2, a
T-cell activator. The most common resistant mutation seen in the infants, Y181C, was
linked to the absence of a TKP site in that position. The presence of a Lysine (K) or
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Glutamine (Q) at position 174 influenced the presence or absence of the TKP site,
respectively. While K174Q substitutions were present at approximately equal frequencies
in isolates prior to NVP, the frequency of 174Q increased to a level of 83.3% among
mothers and infants who developed K103N and (or) Y181C resistance mutations. It could
be possible that the dual combination of 174Q and Y181C, may make it more difficult to
re-instate this TKP site following the clearance of NVP. This 174Q/181C combination
occurred in 81.8% of children and 36.4% of mothers with primary resistance to NVP.
Phosphorylation modulates the activity of many proteins that interact with nucleic acids
including DNA and RNA polymerases (Idriss et al, 1999).
In the wildtype RT enzyme, 2 beta sheets form a hydrophobic pocket where NVP binds,
blocking further polymerization (Zhang et al, 1996). The NVP makes contact with the side
chain of the residues of Tyrosine 181 and 188 in the p66 subunit (Spence et al 1995). The
Y181C mutation induces conformational change, and consequently decreases the drug
binding affinity. Surprisingly, the amino acid at 181 is internal in the RT protein, and
therefore would not necessarily play a role in phosphorylation. However, reports of
reduced incorporation and high efficiency of phosphorylytic removal of d4T in isolates
with the Y181C mutation certainly suggests a role in the biochemical polymerization
reaction of RT. Differences in myristoylation and phosphorylation sites have been noted
between subtypes (De Oliveira et al, 2004). However, the impact of these changes remains
to be established.
One of the key questions is whether resistance was transmitted from mother to infant, or
whether the resistance developed independently in the infant. Phylogenetic analysis of 12
mother-infant pairs for which the baseline sequences were available, showed longer
branch lengths and greater genetic diversity in most of the infant sequences. Also,
resistance was only detected in one of the twin infants and in two mother-infant pairs,
resistance was only detected in the infant and not in the mother. This, coupled with the
predominance of the Y181C as opposed to the K103N mutation in the infant, supports the
independent evolution of resistance in the infant. The studies by Eshleman et al (2004b)
and Kantor et al (2003b) report a change in the prevalence of mutations over time, with the
Y181C mutations appearing earlier (7 days to 2 weeks) and the K103N mutation later (6-8
weeks). They attribute this difference to a difference in NVP susceptibility and fitness of
HIV-1 with these mutations. Therefore, there is a possibility that the burst of viral
replication after primary infection in the baby preferentially selects for the Y181C
mutation (Krivine et al, 1997). Of course one cannot rule out the possibility that a resistant
minor maternal variant could have been transmitted to the infant via the breastmilk.
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Transmission by breastfeeding is estimated at 0.5-2% per month (Lee et al, 2003). There
have been recent reports of breastmilk shedding of HIV-1 virus in Zimbabwean patients,
with up to 65% of samples tested harbouring resistant virus. In these cases, however, the
K103N mutation was the most frequent mutation in the breastmilk and one would assume
that this mutation would then be more frequent in the infants as well (Lee et al, 2003).
In the studies by Eshleman et al (2001b and 2004b), as well as Kantor et al (2003b), the
K103N and Y181C mutations went to undetectable levels in the plasma over time.
However, these resistance mutations may still be archived as proviral DNA. Therefore, the
critical issue would be whether there are longer-term consequences of briefly selecting out
these resistant viruses, such as compromising future treatment efficacy. Some theorise that
i f NVP was reintroduction at delivery during a second pregnancy, mutants were only
likely to reappear after delivery. This coupled with a low rate of resistance, such as that
seen in North America (11% to 20%) would be a negligible risk when compared to the
benefit of the use of NVP. Unfortunately, it appears that the situation is not the same for
subtype C infected mothers, where the rate of resistance mutations is higher. As subtype C
is found predominantly in resource-poor settings where NNRTIs would be included in a
first-line treatment regimen, the consequences of the development of resistance after a
single dose of NVP needs to be carefully considered. These findings, together with data
from other studies, reinforce the view that although NVP is effective, affordable and
simple to administer, the search for safer regimens to prevent MTCT should be intensified.
At the very least, use of NVP for prevention of MTCT needs to be optimised.
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6.3 Development of ARV Drug Resistance in Plasma and Peripheral Blood
Mononuclear Cells (PBMCs) in KS Patients
6.3.1 Introduction
Potent combination ARV therapy can reduce plasma HIV levels to below the limit of
detection for up to two years or more (Gulick et al, 2000). However, it has been shown
that HIV-1 persists in cells and tissues long after HAART has suppressed plasma HIV-1
RNA levels below 50 copies per ml (Wong et al, 1997; Chun et al, 1998). The problem is
that ongoing viral replication is often accompanied by the acquisition of resistance
mutations (Gunthard et al, 1999; Zhang et al, 1999). Several studies have shown that
mutations can develop separately in the different cellular reservoirs (Blankson et al, 2002;
Gunthard et al, 2001; Eron et al, 1998). Resistant viruses with mutations different to those
seen in the blood have been isolated from the brain, vagina and male genital tract (Solas et
al, 2003; Eron et al, 1998). Strain et al (2003) have reported that the emergence of drug
resistant variants was delayed in the PBMC DNA, indicating that only a small minority of
PBMC are productively infected, despite high levels of viral replication in lymphoid
tissue. However, once viral variants that are able to replicate for a certain period enter the
latent reservoir, they remain archived for a very long period (Verhofstede et al, 2004).
This has serious implications for long-term treatment efficacy.
Kaposi's sarcoma (KS) is usually found in HIV-1 positive patients with late stage disease.
KS is a cancer-like disease that usually shows up as spots on the skin (lesions) that look
red or purple on white skin, and bluish, brownish or black on dark skin. It is also seen in
the linings of the mouth, nose, or eye, but can also spread to the lungs, liver, stomach and
intestines, and lymph nodes. Between 1988 and 1996, the incidence of KS in South Africa
rose at least threefold and continues to increase as the HIV epidemic grows (Sitas et al,
2001). In many people, HAART can stop the growth or even clear up skin lesions. In
addition to HAART, KS treatments include freezing with liquid nitrogen, radiation,
surgery and chemotherapy. In this study, the resistance patterns in HIV-1 positive patients
presenting with KS and treated with HAART and chemotherapy or HAART alone are
investigated, with particular attention to the difference in viral populations present in the
plasma and the PBMCs.
6.3.2 Methods
6.3.2.1 Sample information
Venous samples were obtained at enrolment (baseline), day 1, 3, 7, 14, 28, month 3 and
month 6, from HIV-1 positive patients with Karposi Sarcoma attending the dermatology
141
clinic at King Edward VIII Hospital, Durban, South Africa. In total, 20 patients were
enrolled in an ARV program to treat KS patients and were given AZT, 3TC and EFV,
either in combination with chemotherapy or HAART alone. Buffy coat and cell free
plasma were separated by centrifugation. PBMCs were isolated from the buffy coat by
Ficoll-Histopaque separation according to the manufacturers protocol. PBMCs were
counted and stored as dry pellets at approximately 1X10 6 cells per aliquot. Plasma and
PBMCs were stored at —80°C until used. Resistance genotyping was performed
prospectively on samples showing viral rebound. Earlier time-points from those patients
were sequenced retrospectively.
6.3.2.2 RNA Extraction, RTPCR and Resistance Genotyping
Samples were tested for viral load and CD4+ counts as described in Chapter 3.2.2. HIV-1
RNA was extracted, amplified by RTPCR and sequenced using the VirosegTM system
(Applied Biosystems) according to the manufacturer's protocol and as described in
Chapter 3.2.4. Sequences were analysed for resistance as described in Chapter 3.2.8.
6.3.2.3 Subtyping and Phylogenetic Analysis
Subtyping was performed by phylogenetic tree analysis using PAUP* Swofford, 1999), as
described in Chapter 2.1.3. Briefly, sequences were compared to subtype reference strains
in the Los Alamos subtype database (http://hiv-web.lanl.gov/content/hiv-
db/SUBTYPE REF/align.html). Following degapping with the degapped option in
PAUP*, phylogenetic trees were generated on a Linux computer with the F84 model of
substitution and the neighbor-joining method (version 4.0b2a) of PAUP* (Swofford,
1999). Trees were rooted with a homologous region of HIV-1 group 0 (OCM_MP5180).
The subtype C and B sequences were examined separately in trees rooted with a subtype C
and B reference strain, respectively. Trees were viewed with Treetool and Treeview.
6.3.3 Results
6.3.3.1 Comparison of Resistance Mutations in Plasma and PBMCs
Four patients showed signs of increase in plasma viral load and were genotyped, two were
from the HAART/Chemotherapy arm (KAR05 and KARI 1), and two were on HAART
alone (KAR01 and KAR09). The plasma and PBMC viral load for the four patients were
compared and these results are shown in Figure 24. KAR01 and KAR05 were tested for
resistance at month 6. KAR01 developed the V108I, Y181C and M184V mutations and
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month 3, with KAR09 showing the V1061 and Y181C mutations. No drug resistance
mutations were detected in KAR11. Sequences from the plasma and PBMC samples
obtained at 6 months were compared for both KAR01 and KAR05. No resistance
mutations were found in the PBMC sample for KAR01. For KAR05, the PBMC sequence
developed the V106M mutation in addition to the mutations found in the plasma.
6.3.3.2 Evolution of Resistance
Analysis of the baseline plasma samples from these patients showed that KAR09 had
already harboured the resistance mutations before starting the treatment. The other patients
did not display any resistance mutations at baseline.
Although no resistance mutations were detected in the PBMCs of KAR01, there were
differences identified between plasma and PBMC sequences at codons 32, 53, and 169 in
the RT (Figure 25). The V32I mutation was seen in the month 6 plasma sample and a
V32K mutation in the PBMC sample from the same time point. An E53D mutation was
only seen in the month 6 plasma sample and a D169E mutation was only found in the
PBMC sample. The E219D and K300E mutations were in both the plasma and PBMC
month-6 samples.
For KAR05, an additional plasma sample was sequenced from Day28. No resistance
mutations were detected at this time point. Polymorphisms at RT 36, 72, 128, 158 and 277
were only fount in the Day28 sample. Differences at sites not related to resistance were
also seen between the plasma and PBMC samples, namely at codons 207, 281 and 292.
The Q207V and K281R mutations were seen only in the month 6 plasma sample and the
I292L mutation was only seen in the PBMC sample. Overall, there did not appear to be a
pattern of an accumulation of mutations in either of the resistant isolates.
We also examined additional plasma and PBMCs sequences at baseline and Day3 for
KAR11, the patient that did not appear to develop resistance. In this patient, 16
polymorphisms were seen in the RT region, all of which were in the month 3 plasma
sample. The amino acid sequence was very conserved in the other time points.
Finally, additional sequences were obtained at Day3 and Day28 for KAR09.
Polymorphisms were seen at 5 sites in the RT region, 58, 215, 245, 326 and 334. The
T215A mutation was seen in the Day3 plasma sample, but was not seen again at later time
points. Also, the E334D mutation was seen in the Day3 PBMC sample and was not seen at
later time points. V245E was seen in the Day28 plasma sample, but was also not seen at
month 3. T58P and I326L were only seen in the month 3 sample. Again, there did not
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Figure 25. Comparison of RT sequences in the plasma and PBMCs for all patients. Resistance

















































Figure 26. Neighbour-joining tree of the resistant isolates and subtype reference strains. Bootstrap
values >90% are represented by a "*". KAR09 isolates clearly clustered with the subtype B reference
strains, while KAR01, KAR05 and KAR11 fell within the subtype C cluster. As expected, sequences
from each isolate clustered together.
*
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6.3.3.3 Subtyping and Phylogenetic Analysis
Three of the four patients were infected with subtype C strains (KAROL KAR05 and
KAR11) and one with subtype B (KAR09) (Figure 26). Figure 27 shows the relationship
between the patient isolates (plasma and PBMC) obtained from different time points.
KAR09 showed very little genetic evolution between the different time points,
characterised by very short branch lengths. The PBMC sequence was dispersed within the
sequences obtained from the different plasma time points. KAR01 and KAR05 also did
not show any clustering of plasma or PBMC sequences. Interestingly, there did appear to
be some separation of plasma and PBMC sequences of the earlier isolates from KAR11.
6.3.4 Discussion
During HIV infection, virus may persist as latent reservoirs, where virus replication is
restricted, but there is also the potential to rekindle productive viral infection when
treatment is interrupted (Neuman et al, 1999; Davey et al, 1999). It may also persist at
sites with low drug penetration, where there is ongoing viral replication. This replication
may then lead to drug resistance in those cells or tissues (Gunthard et al, 2001). In this
study, the development of resistance in plasma and PBMCs was investigated in patients
failing therapy, using sequential samples with detectable viral load. Resistant virus was
detected in three patients, two were classified as subtype C and the third as subtype B.
Resistance was not related to the presence or absence of chemotherapy in the treatment
regimen. In the two patients infected with subtype C, resistance was detected in the
PBMCs of only one of the two, with the pattern of resistance different in the plasma and
the PBMCs. Interestingly, the PBMCs had a greater number of resistance-associated
mutations. However, the isolates were not cloned, and some mutations may have been
missed by population sequencing. Future work will include cloning all isolates (plasma
and PBMC), as well as tissue biopsies, so that the evolution of resistance in these patients
can be more fully elucidated.
Although PBMCs have the potential to harbour a small latent reservoir of infectious virus
under HAART, the baseline plasma sample from KAR05 did not appear to have
resistance, so it is unlikely that the PBMCs were initially infected with resistant virus
(Zhang et al, 1999). It has been shown that the PBMCs can be dynamically replenished
during ongoing viral replication (Gunthard et al, 2001). Therefore, it is more likely that the
PBMCs were seeded with resistant virus from another reservoir or compartment,
potentially the macrophages or KS lesion. KS is known to stimulate the HIV-1 trans-


























Figure 27(a) An HXB2 rooted neighbour-joining tree using sequences from all the KAR09 (subtype B)
available time points (represented by purple squares and circles). There was no clustering of PBMCs
or plasma sequences, with very little genetic diversity between the sequences obtained for this patient.
(b) Neighbour-joining tree using sequences from all the time points available for KAR01 (blue),
KAR05 (red) and KARI 1 (green) (subtype C isolates). The tree was rooted with a subtype C consensus
sequence. Coloured squares represent plasma sequences and coloured circles represent PBMC
sequences.
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(Vogel et al, 1998). The PBMCs do not usually contribute to the majority of rebounding
virus in the plasma and an alternate reservoir could possibly be contributing to the
resistance seen in the plasma, particularly since one of the resistant patients did not have
detectable resistance mutations in the PBMCs. Unfortunately there were no other
sequences available from earlier time points for the PBMCs or from the KS lesions for
comparison. The difference in the evolution of resistance in the two subtype C infected
patients could also suggest that host-specific factors are also contributing to the evolution
of the virus in vivo, as has been shown by Anastassopoulou et al (2003).
Interestingly, no resistance was found in the plasma or PBMCs of KARL 1. This increase
in viremia could have been related to a burst of residual viral replication in that patient
(Gunthard et al, 1999; Havlir et al, 2000). Of course, it is possible that a minor resistant
population exists in this patient, which was missed by population-based sequencing. The
patient infected with subtype B had detectable NNRTI resistance mutations at baseline.
This highlights the importance of performing routine resistance testing at baseline. Also,
this also highlights the problem that resistance mutations can develop in the PBMCs and
once they are archived, they remain a concern for the efficacy of future therapy in those
patients.
149
6.4 Surveillance of ARV Drug Resistance in a HIV Clinic in KZN, South Africa
6.4.1 Introduction
Antiretroviral therapy can prolong the lives and improve the health of patients with HIV-1
infection. However, resource-poor countries have been slow to provide access to ARV
drugs. This is in the process of changing as the availability of generic ARV drugs
increases. The planned treatment of large numbers of HIV-1-infected persons in South
Africa has underscored the urgent need to develop simple, standardized once-daily drug
dosing regimens that are inexpensive, specific, and appropriate for use in Africa.
Unfortunately, the emergence of mutations that cause resistance to ARV drugs can limit
the efficacy of treatment regimens. Therefore it is of paramount importance that effective
and affordable tools are developed for monitoring treatment responses, not only in
individual patients, but also at the population level. Although South Africa has only
recently implemented its national ARV program, there are patients who have already been
treated in the private sector, prior to the establishment of the official National Guidelines
for ARV therapy. As a result, some patients may have received sub-optimal regimens.
Equally as important, these patients may have received little or no formal adherence
training. In light of this, the screening for drug resistance is important to ensure that each
patient receives optimal therapy and avoids the use of ineffective drugs. This section
focuses on the surveillance of drug resistance in a single HIV clinic. It provides
information on the prevalence and pattern of resistance mutations in a treatment
experienced subtype C population.
6.4.2 Study Population
Samples were obtained from HIV-1 positive adults and children attending the
Sinikithemba clinic at McCords Hospital. McCords is a state subsidised, independent, not
for profit, hospital in Durban, KZN. The first 100 patients on treatment presenting at the
clinic were included in the analysis. These consisted of 96 adults (46% females and 54%
males) and 4 children (75% males and 25% females); see Table 22. Some patients had
already been treated at other centres, including the private sector, before coming to the
Sinikithemba HIV Clinic. Most of these patients had been on treatment for a longer
period and this was reflected in their treatment histories that included mono and dual
therapy. Patients started on treatment at the Sinikithemba Clinic were all given HAART.
In some cases, patients were changed from ddl, d4T and EFV to CBV and EFV because
CBV was cheaper and more easily administered. A list of the various treatment regimens
for the entire cohort are shown in Table 23.
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Average age (years) 33.5 35.3 7
Average Viral Load 26396 26423 N/A
Average CD4 count 194 183 515
Average stage of Disease (WHO) Stage 1 2/85* (2%) 2/83 (2%) 0/2 (0%)
Stage2 7/85* (8%) 7/83 (8%) 0/2 (0%)
Stage3 59/85* (69%) 58/83 (70%) 1/2 (50%)
Stage4 17/85* (20%) 16/83 (19%) 1/2 (50%)
Patients currently on treatment 86/100 (86%) 82/100 (82%) 4/100 (4%)
Patient not currently on treatment 14/100 (14%) 14/100 (14%) 0/100 (0%)
Average time on treatment (months) 7.31 6.92 17
* Total number of patients for which the information was available
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6.4.3 RNA Extraction and RTPCR and Resistance Genotyping
Samples were tested for viral load and CD4+ counts as described in Chapter 3.2.2. HIV-1
RNA was extracted, amplified by RTPCR and sequenced using the VirosegTM system
(Applied Biosystems) according to the manufacturer's protocol and as described in
Chapter 3.2.4. Sequences were analysed for resistance as described in Chapter 3.2.8.
6.4.4 Subtyping and Phylogenetic Analysis
Subtyping was performed by phylogenetic tree analysis using PAUP* Swofford, 1999), as
described in Chapter 2.1.3 and Chapter 3.2.5. Sequences were analysed for recombination
using SimPlot as described in Chapter 2.1.4.
6.4.4 Results
A total of 23 isolates with detectable viral load were sequenced. Of these, 21 isolates
(91%) were classified as subtype C. The remaining two isolates were classified as an A/G
recombinant (Figure 28) and subtype A (Figure 29). The breakpoint in the A/G
recombinant was midpoint in the PR, with all of RT being classified as subtype A (Figure
28). Eighteen (18%) of the patients that were enrolled displayed drug resistance mutations.
Their resistance profiles and treatment histories are shown in Table 24. Of particular
importance was the finding that all but one of the resistant patients that had been on a
NNRTI inclusive regimen had lost the NNRTI class of drugs, with >90% of the resistant
isolates harbouring viruses resistant to NNRTIs (Figure 30a) and >70% of those
harbouring multi-NNRTI resistant viruses (Figure 30b). The most common NNRTI drug
resistance mutations that were seen were the K103N/S (33%) and V106M (27.7%)
mutations. The V106M mutation occurred in 4 of 6 patients currently receiving EFV,
(MCO27, MCO35, MC089 and MC177). This mutation also occurred in an isolate from a
patient receiving a NVP-containing regimen. Of the 5 patients currently receiving NVP
mutations at codon 103 were most common (K103N=2 and K103S=1). Other common
NVP related drug resistance mutations seen were the Y188L/C (27.7%), G190A (22.2%),
A98G (11.1%), V179D (11.1%), K101E/Q (11.1%), V106A (5.5%), Y181C (5.5%),
P225H (5.5%) and F227L (5.5%) mutations. The F227L mutation occurred in conjunction
with the V106A mutation, which is said to augment NVP resistance (Shafer, 2003). The
most common NRTI mutation was the M184V mutation (38.8%), which occurred in 88%
of the resistant isolates that were currently on 3TC. Other NRTI mutations were the
Thymidine analogue mutations (TAMS) [D67N/G (27.75%), K7OR/E (16.6%), L215F/Y,
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Table 23. Treatment data of patients in the study.
Patients currently receiving dual-NRTI regimens Months 
No of Patients 5
Average duration of treatment 15
Different dual-NRTI regimens Average duration of regimen
ddl, d4T (2) 9
3TC, AZT (2) 23
CBV (1) 12
Patients currently receiving HAART, first line 
No of patients 47
Different HAART regimens: Average duration of regimen
CBV, EFV (19) 4
ddl, d4T, EFV (17) 4
d4T, 3TC, EFV (3) 3
ddl, d4T, NVP (5) 8
CBV, NVP (2) 9
RTV, CBV (1) 2
Patients currently receiving HAART, not first line
No of patients 33
No of patients with previous mono-NRTI regimens 2
Different mono-NRTI regimens: Average duration of treatments
RTV (1) 1
d4T (1) 1
No of patients with previous dual-NRTI regimens 11
Different dual-NRTI regimens: Average duration of treatments
ddI, d4T (6) 8
d4T, 3TC (1) 1
3TC ,AZT (2) 10
SQV, RTV (1) 1
CBV (3) 2
No of patients with previous HAART regimens 22
Different HAART regimens Average duration of treatments
ddl, d4T, EFV (12) 6
ddl, d4T, NVP (8) 5
ddl, AZT, NVP (1) 18
ABC, ddl, d4T (1) 8
Current HAART regimens: Average duration of treatments
CBV, EFV (19) 3
ddl, d4T, EFV (3) 6
d4T, 3TC, EFV (3) 3
ddl, d4T, NVP (1) 6
CBV, NVP (3) 4
ddl, AZT, EFV (1) 2
LPV/r, ddl, d4T (1) 7
IDV, RTV, d4T, 3TC (1) 3
No of patients changed treatment > once 5
Patients not currently on treatment 15
No of patients with previous mono-NRTI regimens 3
No of patients with previous dual-NRTI regimens 1
No of patients with previous HAART regimens 11
Number of different HAART regimens Average duration of treatments
3TC, AZT, NVP (1) -
d4T, 3TC, NVP (1) 13
ddl, d4T, EFV (6) 9
ddl, d4T, NVP (2) 4
CBV, EFV (1) 1
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Figure 28. Bootscan result for MC77. The analysis was performed with a sliding window of 250 by and
a step of 50 bp. The breakpoints were estimated to be just before the end of PR and aproximately150
by in RT.
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Figure 29. Bootscan result for MC179. The analysis was performed with a sliding window of 400bp
and a step of 50 bp.
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T69N/A (11.1%), L210W/S (11.1%), K219Q/E (11.1%), G333E (5.5%) and V75I/L
(5.5%)]. While these mutations develop as a result of the selection pressure exerted by the
drugs in the patient's regimen, like the NNRTIs, they may also cause cross-resistance to
other drugs in that class (Figure 31), and thereby limiting the patient's future treatment
options.
Some mutations that were seen have rarely been reported in the literature. These include
the T691 and K7OE mutations, which have rarely been found in treated subtype B isolates
and have not previously been reported for subtype C. The K103S has only recently been
characterized as conferring resistance to all the NNRTIs and at the time of writing this
manuscript, there were no reported subtype C isolates with this mutation. Five patients
were currently receiving dual therapy. Sequences were obtained for four of the patients,
however only 2 of the isolates showed drug resistance mutations (MC109 and MC242).
These patients were both receiving AZT and 3TC, both of whom were children. Common
to both isolates was the M184V mutation, which causes resistance to 3TC. The other
mutations were a variety of TAMs, which are associated with resistance to AZT. In
addition, patient MC242 developed the A98G mutation, which is associated with reduced
susceptibility to the NNRTIs. Seventy-five of the patients were WHO stage 3 or 4, with 60
of the patients having experienced recent co-infections. Almost half of these infections
were mycobacterial. Comparison of the frequency of polymorphisms in the RT between
treated patients with and without resistance mutations are shown in Figure32. While
polymorphisms at RT positions 35, 173, 200, 207, 245, 293 occurred at equal frequencies
in resistant and non-resistant isolates, the R211K mutation was found more frequently in
resistant isolates. Polymorphisms at codons 135, 138 and 324 occurred only in resistant
isolates (>40%).
6.4.5 Discussion
HAART is just becoming available in South Africa, with just a few ARV clinics
operational. The high cost and complexity of treatment and monitoring has been a major
hurdle in the quest to make treatment available for all HIV-1 infected South Africans. The
availability of affordable generic drugs is now making the access to ARVs more
attainable. However, coupled with this increased access to ARVs is the increased
possibility for the emergence and/or transmission of ARV resistant viruses. Resistance is
the result of sub-optimal or inconsistent regimens often due to poor counselling or
interrupted drug supply (Richman, 1994). Inadequate infrastructure to ensure high quality
patient monitoring may further exacerbate the problem. Avoiding resistance is even more
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Table 24. Genotypic profiles of viral isolates for each patient
Sample Stage Subtype Drugs used in therapy
ID
MC017 3 C CBV, ddl, d4T, NVP
MCO27 3 C ddl, d4T, EFV
MCO28 - C ddl, d4T, NVP
MCO35 3 C ddl, d4T, EFV
MCO37 B C ddl, 3TC, NVP
MC043 3 C DdI
MC077 4 A/G CBV, ddl, d4T, EFV
MC181 C d4T, 3TC, EFV
MC106 2 C ddl, d4T, NVP
MC109 - C 3TC, AZT
MC89 3-4 C ddl, d4T, EFV, NVP
MC177 3 C ddl, d4T, EFV
MC179 4 A RTV, CBV
MC197 4 C d4T, 3TC, EFV,
CBV, NVP
MC217 3 C CBV, NVP
MC210 - C 3TC, AZT, NVP
MC242 4 C 3TC, AZT
MC244 3 C 3TC, AZT, NVP
MC010 3 C ddl, d4T, EFV
MCO56 3 C ddl, d4T
MC071 4 C ddl, d4T, NVP
MC087 3 C ddl, d4T
MC092 3 C ddl, d4T, CBV, EFV
* Not currently on treatment





1 400 26 peripheral
neuropathy
M36I, V82I, I93L D67N, KIOIQ, M184V, G190A
4 400 12 chronic diarrhea;
vomiting
M361, I93L VI 06M
910 5 peripheral
neuropathy
M36I, L63V, I93L K70E, V I 06A, V1181, G190A,
F227L
11 000 17 - K2OR, M36I,
L63P, I93L
K65R, T69I, K103N, V106M





12 000 0.5 TB M361, D60E, I93L A98G, K103N, V179D, Y188L
1 500 22 * Osophageal candida L101, M36I, L63T V179D
440 000 L101, M36I M184V, Y188L, P225H
4 300 10 M36I, L63V, I93L Y181C
24 000 9 pneumonia; oral
candida, occ diahroea
M361, 193L D67N, K7OR, M184V, K219E
5 300 6 Taxoplasmosis M36I, D60E,
L63P, I93L
V75I, K103N, V106M, Y188C
3 000 7 M36I, L63Q, 193L D67G, T69A, V106M, Y188L
12 000 2 K2OR, M36I,
L63V, I93L
GI90A
84 000 1 PTB M361, L63A, I93L T69N, K103N
4 800 16 M36I, D60E,
L63P, 193L
D67N, K7OR, M184V, Y188L,
T215F, K219E
310000 3 L101, M36V,
L63V, I93L
K103N, M 184V
4500 36 M361, L63P, 193L M41L, E44D, A98G, M184V,
L210W, T215Y
15000 36 M36I, 193L M41L, F.44A, D67N, K103S,
VIO6M, M184V, L210S,
T215Y, G333E
890 3 herpes simplex, oral
candida; otitis media
M361, L63P, 193L none
8 200 8 on TB Rx K2OR, M36I, I93L none
90 000 6 neuropathy;
myelopathy; bacterial
K2OR, M36I, I93L none
Infection





















            




















Figure 30. a) Frequency of resistance to the NRTIs, NNRTIs and PIs in the resistant isolates. b)
Frequency of multi- NRTI and NNRTI resistance in the isolates. From both figures, a high rate of




3TC AZT dd I d4T DDC ABC TDF EFV NVP DLV
antiretroviral drugs
0 high resistance n intermediate resistance
Figure 31. Levels of cross-resistance to the RT inhibitors. Most resistant isolates showed a high level of
resistance to all the NNRTI with intermediate to high-level resistance also seen in the NRTIs, albeit to
a lesser extent.
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i mportant in countries where first line and second line treatment options are limited. Thus,
surveillance coupled with intense program monitoring is needed to maintain program
effectiveness. This study was conducted to monitor the prevalence of resistance in a local
HIV clinic as well as to increases the data on the response of subtype C viruses to therapy.
Interestingly, one of the resistant isolates were classified an A/G recombinant by
phylogenetic analysis. This is the first report of an A/G recombinant isolated from
KwaZulu Natal. Other non-C isolates have previously been reported in Cape Town with
one C/D recombinant reported for KwaZulu-Natal (Gordon et al, 2003).
From those included in the study, resistance mutations were detected in 18 (18%). This
figure is better than the estimated prevalence of 36% resistant virus among Ugandan
patients and 40-57% resistance among patients from Cote d'Ivoire on HAART (Vergne et
al, 2003). The high prevalence of resistance in these countries is thought to be a
consequence of the inappropriate use of mono and dual therapy with NRTIs. This could
also explain some of the resistance seen in the patients in this study. Although treatment
in this setting was under controlled conditions, some of the patients had come from the
private sector prior to the establishment of the National Guidelines for ARV treatment and
where there was not the same level of control. Consequently, some of the patients were
treated with sub-optimal regimens.
Most of the resistance mutations that were seen are known to cause resistance to the
NNRTIs. This is probably due to the low genetic barrier to resistance in this class of drugs.
Of particular interest is the V106M mutation seen in two patients, which is a putative
subtype C signature mutation in EFV experienced patients (Brenner et al, 2003). From the
previous study (Chapter 6.1), I have found that the V106M mutation emerges as early as
one month after starting treatment. The resistance profile of MCO28 was very interesting
because, although the patient had stopped treatment, there were a host of mutations
present, some causing primary resistance to the NNRTIs, while others such as K7OE and
F227L are not known to cause resistance to any current RT inhibitors. It is possible that
the K7OE mutation is an intermediate mutation before the development of the K7OR
variant (a known TAM). Most of the polymorphisms found in the RT that are not
associated with resistance in the context of subtype B, were equally prevalent in isolates
with and without resistance. Two polymorphisms were peculiar to isolates without
resistance: mutations at codon 122 occurred in 80% of patients while mutations at codon
334 occurred in 60% without resistance. There were also a few polymorphisms that only
occurred in resistant isolates: mutations at codons 135 occurred in 56% of resistant
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mutations at codons K275 and P294 occurred in 33% of resistant isolates. Similarly,
polymorphisms in the PR were common to resistant and wild-type isolates, with no
particular mutations occurring more frequently in either group.
Most of the patients included in the study were in the late stages of the disease (stage 3
and 4), and with an average CD4 count of 194. This is not surprising, as most people in
South Africa do not know their HIV status until very late in the infection, when they
begin to show symptoms of AIDS. As a result, most of these patients (60%) had
experienced recent co-infections which further complicated patient management,
particularly TB, which limits the drugs that can be administered to these patients as well
as co-infections such as oesophageal candidiasis which have been associated with a more
rapid progression to death (Morgan et al, 2002) There have also been reports of a more
rapid progression to AIDS if HAART is initiated after CD4 counts fall below 200
cells/ml, than if initiated at counts between 200 to 350 (Chan et al, 2002). However, there
is still some benefit in treating late stage AIDS patients, as adults and children with
advanced AIDS who rarely survive more than two years, are increasing their survival
time as well as quality of life. (Morgan et al, 2002).
A major problem for most HIV-1 positive patients contemplating starting ARV treatment
is cost of the ARVs and monitoring (CD4s and viral loads). Those that can afford the
drugs, may not be able to afford the monitoring. Sometimes the patients start treatment,
but later find that they can no longer afford the ARVs due to a change in financial
circumstances, and stop treatment until they can purchase them at a later date. Twenty
five (25%) of the patients in the study had stopped taking their drugs at some point in
their treatment. Eight of these developed resistance.
Some researchers feel that, particularly in resource poor setting where the choice of drugs
for salvage therapy would be even more limited, the choice of first ARV regimen is of
greatest importance, and therefore should be well tolerated, have a relatively low pill
burden and ease of administration, and have a high genetic barrier to resistance in the
event of less than perfect adherence (Palella et al, 2002; Bartlett et al, 2001). Based on
ease of administration and relative tolerability, the preferred "backbone" NRTI
combination is AZT and 3TC (now available as CBV), with d4T and 3TC or AZT and
ddi as alternatives (Staszewsk et al, 2001). Many researchers have found that EFV with 2
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NRTIs is as effective as 2 NRTIs with a PI such as NFV and INV (Bartlett et al, 2001;
Albrechts et al, 2001).
Finally, although a high level of multi-NNRTI resistance was seen in the patients, all the
resistant patients were still susceptible to the PI class of drugs. As South Africa is limited
in the drug options that are available for salvage therapy, first line regimens need to be
chosen wisely, and it is equally important to have effective second line regimens in place,
given that some level of resistance is inevitable. Resistance genotyping will aid clinicians
who are currently working blindly, ignorant of the resistance status of patients who are
clinically failing treatment. This is particularly true where the patient cannot produce a
complete clinical history. It is hoped that these data will assist in patient treatment
management, and facilitate public health policy and planning.
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Chapter 7
In Vitro Antiretroviral Drug Susceptibility of Subtype C Strains
7.1 Phenotyping of HIV-1 isolates from South Africa
7.1.1 Introduction
HIV replication is markedly inhibited by highly active antiretroviral therapy (HAART).
However, the development of drug resistance is an important factor limiting the
effectiveness of ARV treatment. Mutations associated with resistance to RTIs and PIs
have been extensively characterized (Hirsch et al, 2000; Schinazi et al, 2000). Guidelines
by expert panels have recommended the routine use of drug resistance testing in the
treatment of HIV-1 infected patients (US Dept Health; Hirsh et al, 2000). Current methods
of HIV resistance testing include in vitro phenotyping (drug-susceptibility assays) and
genotypic assays that detect mutations known to confer drug resistance. Genotypic tests
are more commonly used in clinical settings because of their wider availability, lower cost
and quicker turnaround, although phenotypic tests are a more direct measurement of HIV-
1 susceptibility. However, there are limitations to both of these tests. They are both unable
to detect minor drug resistant populations and there is limited knowledge about the clinical
significance of certain combinations of mutations and of certain levels of phenotypic drug
resistance. Most HIV drug susceptibility studies have involved subtype B strains, although
non-B subtypes cause most of the infections worldwide. In a study conducted by Vergne et
al, (2000) on naturally occurring polymorphisms in non-B subtypes, they found the
prevalence of major mutations associated with resistance to NRTIs, NNRTIs and PIs very
low. However they found many accessory mutations related to resistance to NRTIs and
PIs. A significant number of amino acid polymorphisms exist among subtype A, B and C
sequences (Brennan et al, 1997; Becker-Pergola et al, 2000). The high prevalence of the
L1 0I, K2OR, M36I, and L89M mutations in non-subtype B strains is largely known
(Pieniazek et al, 2000; Tanuri et al, 1999). Velazquez-Campoy (2001) have shown that
subtypes A and C proteases have a higher biochemical fitness than subtype B proteases
against the currently available PIs. However, this does not necessarily reflect a lower in
vivo efficacy, because other factors may also be important in antiviral potency (Klabe et
al, 1998).
The recombinant virus assay (RVA). is an innovative method for generating viruses for
drug susceptibility testing (Boucher et al, 1996; Maschera et al, 1995; Kellam et al, 1994).
RVA involves the production of viable virus in vitro by homologous recombination of RT-
PCR products from plasma virus with an infectious PR or RT deleted subtype B cloned
HIV-1 provirus. The resulting recombinant viruses derive all their biological properties
from the molecular clone, except for RT and PR, which are encoded by the genes from the
patient isolates. The drug susceptibility of the viruses is measured using a MTT cell-
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killing assay (Pauwels et al, 1988). Living cells convert MTT (3-(4,5-dimethylthiazol-2-
y1)-2,5-diphenyltetrazolium bromide) into a blue product (formazan), and therefore the
amount of formazan reflects the number of cells protected by the drug against killing by
the virus. The production of formazan can be quantified spectrophotometrically, and this
coupled with the possibility of performing the test with microtiter plates, facilitates testing
of large numbers of viral isolates. The biochemical and phenotypic roles of the natural
polymorphisms found in the PRs of C viruses are poorly understood. In this chapter, we
characterize the drug susceptibility of subtype C isolates from South Africa to the




10 patient samples were phenotyped (Table25). The majority (8/10) were drug naive,
while two were known to have had prior treatment with d4T, 3TC and NVP. Seven of the
isolates were classified as subtype C. For comparison, the D/C recombinant described in
chapter 3 was included, as well as a retrospective subtype B isolate from Cape Town. One
of the treated isolates was also classified as subtype B.
7.2.2 Preparation of PCR products for transfection
Viroseq RT PCR products were lyophilized and transported to the Molecular Virology
Laboratory in the Genetics Department at the University of Rio de Janeiro, Brazil. The
products were reconstituted with 40u1 sterile filtered water and the protease and RT
regions were amplified separately using the primers described by Maschera et al, 1995
(protease) and Boucher et al, 1996 (RT). Briefly, primers 5'GGG AAG ATC TGG CCT
TCC TAC AAG GG 3' (forward) and 5' GGC AAA TAC TGG AGT ATT GTA TGG 3'
(reverse), 200uM dNTPs, 1.5mM Mg2+ , 250 nM primer and 0.75U AmpliTaq Gold
(Applied Biosystems) were used to amplify the protease regions under the following
conditions: 35 cycles of 94 °C for 30 seconds, 55 °C for 55 seconds and 72 °C for 1 minute,
after an initial denaturation of 94 °C for 12 minutes. The following primers were used to
amplify the RT region with the same conditions: RT 5' GGA CAT AAA GCT ATA GGT
ACA G 3' (forward) 5'CTG CCA GTT CTA GCT CTG CTT C3' (reverse). The vectors
used were: pGEMT3APR, which carries defective HIV HXB2 genomic cDNA that lacks
the gene for PR (APR) (Maschera et al, 1995) and ART which lacks the first 290 by of RT.
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The vectors were prepared by overnight digestion with either Bstell (APR) or Smal
(ART). Each PCR product was co-precipitated with the respective vector (i.e. PR
products with the protease vector). Briefly, 1 ug of the PCR product and 1 ug of the
vector was precipitated with 3 times the volume of ethanol and 10% of a 3M sodium
acetate solution and centrifuged at 12000 rpm for 20 minutes. The supernatant was
aspirated and the pellet washed with 70% ethanol. The supernatant was aspirated
again and the pellet was dried on a heating block for 5 minutes.
7.2.3 Cell Electroporation
Two days before performing the transfection, cell cultures were prepared with 2.5 X
105 MT2 cells/ml. At DayO, cells were counted and spun at 2000 rpm for 8 minutes
and resupended at 2 X 10
7 
cells/ml in RPMI with 20% FBS. Cells were left on ice for
10 minutes. Each PCR product/vector precipitate was resuspended with 25 ul sterile
water. 250 ul of cells and each resuspended PCR product/vector were added to
separate cuvettes and electroporated with a BioRad Gene Pulser (900 I.LF capacitance;
high ohms; 250 V). 125 ul RPMI was added to the cuvette to gently wash the cells
away from the sides of the cuvette and clumps were gently resuspended. The
electroporated cells were transferred to a flask with 5 ml RPMI and 25 ul fresh cells
(2 X 10 7cells/m1) were added to the flasks. Cell cultures were incubated at 37°C and
monitored daily for syncytium formation. Fresh medium was added to maintain an
optimal cell concentration of approximately 0.2 X 10 6 cells/ml. Viral supernatants
were harvested by centrifugation (1000 x g for 10 minutes) when the culture
contained 100% full blown syncytia, which indicated that nearly all the cells in the
culture were involved in giant cell formation. Viral stocks were stored at —70°C for
subsequent titration and sensitivity testing. Homologous recombination led to the
generation of a chimeric virus containing PR or RT sequences derived from patient
viruses. A chimeric virus containing the NL4-3 PR (HXB2/NL4-3-PR) was also
generated as a subtype B control virus to obtain the reference IC50 during the
phenotypic assay.
7.2.4 Determining the virus TCID50
The virus culture to be tested was thawed and serially diluted (1 in 10) up to e.
A 0.2 X 10 6 concentration of cells was prepared and infected with the different virus
dilutions by spinning at 1200 x g for 2 hrs in a process called "spinoculation".
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Figure 33. Template of the plate layout for determining the virus TCID 50 •




3 Number of Uninfected Number Total Number % Total
4 Dilutions Infected Wells Wells Infected Uninfected Infected
5 1.00E-05 12 =B10-B5 =SUM( B5. B8) =SUM(C5: C5) -D5/(D5+E5)
6 1.00E-06 8 =B10-B6 =SUM( 86: B8) =SUM(C5: C6) =D6/(D6+E6)
7 1.00E-07 1 =B10-B7 =SUM(B7: B8) =SUM(C5:C7) =D7/(D7+E7)
8 1.00E-08 0 =B10-B8 =SUM(B8_ B8) =SUM(C5:C8) =D8/(D8+E8)
9
10 Num Wells 12
1 1 mls/well 0 01
12
13 Prop.Dist =(H10-.05)/(H10-110)






G H I J
1
2
3 Log Dilution Above
4 Above 50% % Above 50% % Below 50% 50%
5 =IF(F5>0.5,"TRUE","FALSE") -1F(AND(G5="TRUE",66-"FALSE"),F5,0) AF(AND(G4="TRUE",G5-"FALSE"),F5,0) =IF( H5>O,LOG(A5),0)
6 -IF(F6, 0.5,"TRUE","FALSE") =IF(AND(G6="TRUE",G7-"FALSE"),F6,0) -1F(AND(G5-"TRUE",G6="FALSE"),F6,0) -11
, (116>O,LOG(A6),0)
7 -IF(F7, 0.5,-TRUE","FALSE") -IF(AND(G7="TRUE",G8="FALSE"),F7,0) =IF(AND(G6-
-TRUE",G7="FALSE"),F7,0) =IF(117>0,LOG(A7),0)
8 -IF(F8>0.5, -TRUE","FALSE") =IF(AND(G8-"TRUE",G9-"FALSE"),F8.0) -IF(AND(G7
-"TRUE".G8-"FALSE"),F8,0) =1F(1-18>O,LOG(A8),0)
9








Figure 34. Template of the Excel spreadsheet for the calculation of the virus TCID 50 •
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After the spinoculation, the cells were resuspended in 3 ml of RPM! and added to the
plate in duplicate as shown in Figure 33. Plates were incubated in a CO2 incubator at
37°C and developed on the 6
th
 or 7 th  day by adding 40 ul MTT (7mg/m1) to each well
and incubating at 37 °C for 30 min to 2 hrs. One hundred microlitres of lysis solution
was added to each well (0.4% HC1 + 2% Trition X 100 up to 100 ml with
isopropanol) and mixed by pipetting until all crystals had dissolved. Plates were read
at 490 and 640 nm. The TCID50 was determined as shown in Figure 34. All statistical
treatments for calculation of the IC50s for the isolates were performed by using the
Analyze-it program (version 1.62) for Microsoft Excel statistics package and
Sigmaplot software.
7.2.5 Performing the Phenotyping
Cells were infected with the virus to be phenotyped (using the virus' TC 11)50), in
conjunction with a wildtype reference strain (pNL4-3) and a "mock infection" of cells
without virus (Figure 35). The reference strain was included on each plate. The
required volumes of filtered drugs were added and serially diluted (in duplicate),
leaving the last row without the drug (just virus and cells) and an equal volume of
cells was added to each of the wells. Plates were incubated in a CO 2 incubator at 37
°C
and developed on the 6 th or 7
th
 day in the same way as described above.
7.2.6 Calculation of drug susceptibility
Susceptibilities of chimeric virus to Amprenavir, Indinavir, Lopinavir, Ritonavir,
Saquinavir, and Nelfinavir were determined by 3-(4,5-dimethylthiazol-2y1)-2,5-
diphenyltetrazolium bromide (MTT)-based cell viability assays, each of which was
performed in duplicate, as described previously (Hertogs et al, 1998). The percentage
of viable cells obtained by the MTT assay after seven days of infection was plotted
semi-logarithmically against the concentrations of the drugs tested. A Hill's three-
parameter nonlinear regression was performed to obtain the sigmoid curve of viable
cells and the IC50 for each virus tested. The fold-change of resistance was calculated
by comparing the isolate's IC50 with the IC50 for the drug susceptibility wild-type
reference strain (Figure 36).
7.3 Results
Attempts to obtain a recombinant clone for the PR region of ZA012 and ZA024, as
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Figure 35. Template of the plate layout for determining the virus drug susceptibility. The drugs
were serially diluted in duplicate, with 2 drugs per plate. Each plate contained the reference
strain pNL4-3.
100 Wild type (pNL43)
50
Patient s train   
D. Drug concentration  
Figure 36. Calculation of fold change. The fold change was calculated by dividing the patient
strain IC50 by the reference strain ICso.
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well as the RT region for ZA010, were unsuccessful. As a result, the response of these
isolates to the drugs targeting these regions could not be determined. Phenotypic
resistance to one or more drugs was detected in samples ZA024, R555, PT01 and
PT02 (Table 26). ZA024, a drug naive isolate harbouring the K103N mutation,
showed a greater than 100 fold resistance to EFV, and a 16-fold resistance to NVP.
The two treatment experienced isolates, PT01 and PT02, both showed resistance to
the NNRTI drugs tested. In addition, PT02 had a >100-fold resistance to 3TC, while
PT01 only showed a 20-fold resistance to 3TC when compared to pNL4.3, even
though both patients had a similar clinical history. ZA023 did not show phenotypic
resistance, possibly because the K103N mutation was present as a minority strain and
was not detected by the phenotyping assay. Most of the isolates showed
hypersusceptibility to Lopinavir, with the IC5os for those isolates being up to 16.2
times lower than that for the reference strain HXB2/NL4-3-PR. There were no other
observable differences in drug susceptibility to the commercially available PIs tested.
7.4 Discussion
HIV-1 sequences vary widely around the world, but mutations that potentially
contribute to resistance to drug targeting the PR and RT of HIV-1 occur in both B and
non-B subtypes. In spite of this, very little information is available on the drug
susceptibility of non-B subtypes, particularly subtype C. Although HIV-1 subtype C
does not appear to have any primary mutations in its signature PR and RT sequence, it
does has several accessory mutations that are associated with resistance in the context
of subtype B (Grossman et al, 2000; Vergne et al, 2000). Since
accessory/compensatory mutations are often associated with the restoration of viral
fitness in the presence of crippling primary mutations (Hirsch et al, 2000; Schinazi et
al, 2000) the impact of the mutations seen in subtype C on the long-term efficacy of
ARVs is not known.
In this chapter, samples from drug naive subtype C, B and D/C isolates and 2 drug
experienced isolates (one subtype C and one subtype B), were phenotyped using the
recombinant virus assay described by Hertogs et al, (1998). The drug naive subtype C
isolates showed a similar response to the RT inhibitors as the wild type strain.



































































































































































































































































































































































































































































mutation, showed a greater fold-resistance when compared to the wild-type strain than
the subtype B isolate with the same resistance mutation. However the significance of
this is unknown, as the M184V mutation usually confers high-level (>100 fold)
resistance to 3TC (Havlir et al, 2000; Descamps et al, 2000). As resistance mutations
often occur in complex patterns, it is likely that the effect of the other mutations
present in each isolate is influencing the response to 3TC.
The impact of the accessory mutations in PR on drug susceptibility was minimal, even
with up to 3 accessory mutations in a single isolate. Unfortunately, the vector used in
this assay did not incorporate the 3' end of gag, which included sites that have been
linked to PI resistance, which could influence the susceptibility of the virus.
The assay is also limited in that a subtype B backbone was used as the vector for the
recombination, and whether the responses will be the same with a subtype C
backbone is yet to be determined. The assay did not detect resistance to the K103N
mutation in ZA023, probably because the mutation was present as a minor population
in that sample, which is another of the limitations of the assay.
The retrospective subtype B isolate was resistant to both AZT and 3TC in vitro.
Although this patient was said to be drug naive, it is very possible that the patient had
received treatment. At that time (around 1991), the most likely treatment would have
been dual therapy with AZT and 3TC. The public health importance of this finding is
that drug resistant HIV-1 was present in South Africa more than a decade ago.
Although our studies have shown minimal resistance in the general drug naive
population in KwaZulu-Natal, this result suggests that the population in the Cape had
greater access to treatment in the past than patients in KwaZulu-Natal and could
consequently result in the transmission of resistant strains. This emphasises the urgent
need for screening for resistance in drug naive patients in this region.
Interestingly, the subtype C isolates showed a hyper-susceptibility (a lower IC 50) to
Lopinavir which was not seen in the wild-type strain. Further analysis by Gonzales et
al (2003) using site-directed mutagenesis showed that this hyper-susceptibility was
linked to the presence of the I93L mutation found in most subtype C isolates.
Although other studies have also reported no difference in the IC5Os for subtype B
and subtype C strains when the other PIs were tested, they did not included Lopinavir
among the antiretroviral compounds tested in their phenotyping assays (Harrigan et al,
2001; Velazquez-Campoy et al, 2001). It has been reported that hyper-susceptibility
can influence the clinical outcome in patients on Amprenavir treatment, whose
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isolates carry the N88S mutation (Velazquez-Campoy et al, 2001). Gonzales et al
(2003) suggest that the in vitro phenotypic hyper-susceptibility of subtype C isolates
with the 193L mutation could result in different clinical outcomes, but caution that
these findings need to be further tested in controlled clinical trials comparing the
virological responses of patients infected with subtype B HIV isolates and those




Since subtype C began its spread across southern Africa in the late 1980s, major outbreaks
have now occurred in every country in this region. Zimbabwe, Botswana and South Africa
have been most severely hit by the outbreak of HIV-1 subtype C infections. Despite this,
few studies have examined the genetic diversity and molecular phylogeny of subtype C
viruses in South Africa, and particularly in Kwazulu-Natal where the HIV-1 prevalence is
highest (Rollins et al, 2002). One of the main objectives of this thesis was therefore to
define the spectrum of naturally occurring resistance-associated polymorphisms and
mutations in RT and protease of subtype C viruses in KwaZulu-Natal, as South Africa
begins its national ARV roll-out.
With the exception of two primary resistance mutations, K103N and G190A, which
occurred in a single husband-wife pair, no other major resistance-associated mutations to
the available PIs and RTIs were found in a cohort of 72 drug naive isolates from
KwaZulu-Natal. However, similar to other studies from Zimbabwe and Botswana,
signature subtype C polymorphisms were found in these isolates, particularly in the PR
region, that have been linked to increased catalytic activity in subtypes A and C (Kantor et
al, 2002; Velazquez-Campoy et al, 2001). A few of these isolates were phenotyped and
were found to be as susceptible as wild-type subtype B to the available PIs and RTIs
(similar to a study by Harrigan et al, 2001). Interestingly, the isolates were also found to
be hypersusceptible to LPV, possibly linked to the 193L signature subtype C mutation in
the PR (Gonzalez et al, 2003). To better understand the mechanisms of resistance and viral
pathogenesis, sites under positive selection were identified using the methods proposed by
Yang (2000). Most of the codons in the PR and RT genes (>95%) were under strong
purifying (negative) selection pressure, particularly at sites related to viral structure and
function. The remaining 5% of amino acids were under strong diversifying (positive)
selection pressure. Seven of these amino acids (PR 12S and 191; RT 36A, 39E, 123G,
211K, and 245Q) were present in both the KwaZulu-Natal and subtype C consensus
sequence but not in the consensus sequences of subtypes A, B, and D, suggesting that
these signature residues may offer a subtype-specific fitness advantage to C viruses.
Soares et al (2003a) have shown an association between ARV treatment and the D/G123S
mutation in subtype C isolates from Brazil. The R211K signature mutation in the RT was
absent from retrospective subtype C isolates from the Western Cape and KwaZulu-Natal.
R211K has been associated with resistance in the RT in subtype B isolates suggesting that
the evolution from an Arginine to a Lysine at that position could confer over time a fitness
advantage in the presence of drug selection pressure. The V601 mutation, which occurs as
a signature in our isolates (although also prevalent in other subtype C viruses), was not
under positive selection, and did not occur at a site related to function. Whether this
176
mutation plays a role in viral fitness has yet to be determined. Naturally occurring
polymorphisms also resulted in significant variation in the number and type of
phosphorylation sites in both the pol and env genes. Of note was the loss of a
glycosylation site at the beginning of the V3 loop in env which was associated with the
presence of a serine PKC phosphorylation site at position 11-13 in the V3. This suggests a
potential linkage between deglycosylation and phosphorylation in the V3 loop of C viruses
related to tropism in C viruses.
Some of these isolates were phenotyped using the RVA, in collaboration with our
colleagues in Brazil, and showed similar responses to the RT inhibitors as the wild type
subtype B strain. Interestingly, the subtype C isolates showed a hyper-susceptibility (a
lower IC50) to Lopinavir which was not seen in the wild-type strain. Further analysis by
Gonzales et al (2003) using site-directed mutagenesis showed that this hyper-susceptibility
was linked to the presence of the I93L mutation found in most subtype C isolates. This
could influence the clinical outcome of patients infected with subtype C and treated with
Lopinavir, but requires further investigation. Also, a subtype B backbone was used as the
vector for the recombination, and whether the responses will be the same with a subtype C
backbone is yet to be determined.
Phylogenetic analysis of the drug naive isolates showed that the epidemic in KwaZulu
Natal is characterized by multiple circulating HIV-1 subtype C sublineages in both the
Indian and Black communities, characteristic of multiple introductions of subtype C into
South Africa from across its many borders. The presence of HIV-1 isolates collected prior
to 1992 at internal branches of the phylogenetic tree suggests that these sequences may
represent founder strains that have existed in Kwazulu-Natal for at least 10 years. The
increased prevalence of multiple subtypes, including subtype C, in the Western Cape
highlights the change in diversity and distribution of HIV-1 subtypes in South Africa since
the beginning of the epidemic. Archival material available from the Western Cape may
serve as an important source of information on the evolutionary history of HIV-1 in South
Africa and is being investigated further by colleagues from the Western Cape.
The effect of signature subtype C polymorphisms in protease on the 12 protease cleavage
sites showed that seven sites (those with structural or enzymatic functions) are highly
conserved in all subtypes and that they are under strong purifying selection pressure (De
Oliveira et al, 2003; Ericson-Viitanen et al, 1989; Kaplan et al, 1994; Krausslich et al,
1989; Pettit et al, 1994). The remaining five cleavage sites exhibited extensive variability
across all subtypes, with C viruses being significantly more variable than subtype B at all
sites except TFP/p6pol, which is responsible for protease activation. p2/NC was the most
variable cleavage site in subtype C (42.4%). This site controls the rate of Gag and Gag-Pol
processing. The variation in cleavage sites between subtypes suggests that there may be
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important differences in the way that B and C viruses regulate polyprocessing and virion
assembly (De Oliveira et al., 2004; Petit et al, 2003; Petit et al, 2002). These differences
could have a major impact on the pathogenesis of HIV-1 subtypes and on response to
therapy.
A second objective was to determine the impact of naturally-occurring polymorphisms in
subtype C viruses on response to ARV therapy in an African setting (i.e. using PI-
exclusive regimens). Overall the patients responded well to treatment with only 10-18% of
patients on HAART-based regimens developing drug resistance. Generally, the resistance
mutations seen in our isolates were consistent with those seen in treatment experienced
subtype B isolates. Of note was the high level of resistance to the entire class of NNRTIs
seen in all the cohorts. This could be reflective of the predominant use of NNRTI-based
regimens, as well as the low genetic barrier in this class of drugs. Other possible
explanations for the high rate of NNRTI resistance were non-adherence in patients due to
stigma or lack of funds, as well as the use of sub-optimal regimens in patients treated in
the private sector prior to release of the national guidelines for ARV therapy. Comparison
of resistance mutations in the PBMCs and plasma of patients presenting with KS showed
that resistance could evolve separately at both sites, but this was not consistent, and was
probably influenced by host genetic and immunologic factors. Resistance was high (40%)
in matched subtype C infected mother and infant pairs, 6 weeks after receiving a single
dose of NVP to prevent mother-to-child-transmission. The pattern of resistance differed,
with K103N most common in the mothers and Y181C most common in the infants,
consistent with reports from Eshleman et al (2003b) and Kantor et al (2003a). Of note
were the changes in functional properties caused by these mutations, by the introduction or
alteration of putative myristoylation and phosphorylation sites in the RT. The exact role of
these alterations need to be further investigated.
Screening for positively selected sites could be useful for identifying novel drug
resistance-associated or compensatory mutations. Novel mutations that occurred in one or
more patients after therapy and were positively selected included: RT 21, 102, 123, 135,
162, 196, 202, 203, 207, 232, 245, 272, 274, 275, 278, 281, 292, 311 and 334. Some of
these have recently been reported as treatment associated mutations, namely RT 135, 202
and 207, and could be acting as compensatory mutations (Kantor et al, 2002).
Resistance mutations are often accompanied by structural changes that either change the
conformation of the RT binding pocket or stabilize the 3D structure of the enzyme
(Sturmer et al, 2003; Gonzales et al, 2001; Wrobel et al, 1998). Our results on the
structural interactions of novel, positively selected mutations have shown a definite
relationship between structural changes at those sites and the development of resistance.
However, these interactions are complex and require more in-depth analysis.
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These data not only increase the information on the response of C viruses to treatment, but
also increases the information on HIV treatment in the context of co-infections with other
pathogens. TB and other opportunistic infections are a problem in resource-poor settings
and the concomitant use of HAART and TB treatment could have great public health
benefits. However, the rapid development of resistance to EFV with the V106M mutation
in TB patients who fail therapy suggests that the use of this drug needs to be closely
monitored. Therapeutic drug monitoring is one of the methods that can be used to ensure
that sufficient drug levels are achieved in each patient. The high percentage of multi-
NNRTI resistance in the surveillance study has serious implications for the treatment
management of patients in resource poor settings, particularly because of the use of
NNRTI-base drug regimens in these regions.
Recent reports on the prevalence of resistance mutations in mothers and infants after just a
single dose of NVP have increased reluctance on the part of the government to use it in its
pMTCT program. Although the K103N and Y181C mutations associated with NVP
resistance have been reported to disappear from the plasma over time (Eshleman et al,
2001; Eshleman et al, 2003; Kantor et al, 2003), there is the possibility, however, that they
are archived as proviral DNA and could conceivably compromise future treatment
efficacy. Given the high prevalence of HIV-1 infection in South African pregnant women,
the potential risk of developing multi-NNRTI resistance in these patients cannot be taken
lightly (Rollins et al, 2002). Therefore, while NVP is cheap and effective in preventing
MTCT, efforts should increase to find a safer alternative. Mothers going onto ARV
therapy after receiving NVP in the past should be closely monitored for resistance.
Perhaps these patients should go straight on to a PI inclusive regimen, which is also
inherently more potent. Kaletra (LPV/r) is currently being used as part of the second-line
drug regimen in patients failing therapy, and although subtype C isolates have shown
hypersensitivity to LPV in vitro, its efficacy in salvage therapy with a compromised
regimen has yet to be determined (Gonzalez et al, 2003). The rapid development of high
level NNRTI resistance could compromise the effectiveness of the national drug program
unless potent salvage therapies are prescribed, including more potent NRTIs such as TDF.
In South Africa, resistance testing is not provided as "standard-of-care" for patient
treatment management as it is in North America and Europe. Although expensive,
resistance testing provides extensive insight into the presence of drug resistant variants in
the population of viruses within an individual and prevents the use of ineffective drugs in a
drug regimen (Van Laethem et al 1999; Shafer et al 2000). Prospective controlled studies
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have shown that patients and physicians who have access to genotypic resistance data
respond better than those who do not have access to these assays (Durant et al, 1999;
Baxter et al, 2000; Cohen et al, 2000). As a result, expert panels have recommended the
use of resistance testing in the treatment of HIV-1 infected patients (US Dept Health;
Hirsch et al, 2003). Phenotypic resistance tests are a more direct measurement of HIV-1
susceptibility, as the effect of multiple mutations can be taken into account, although it is
much more expensive and time-consuming. Also, RVA phenotypic tests use a subtype B
backbone as the vector for the recombination, which may not give a true reflection of
susceptibility of non-B subtypes to the currently available ARVs. Genotypic tests are more
commonly used in clinical settings because of their wider availability, lower cost and
quicker turnaround. The Viroseq resistance genotyping kit has been successfully used in
both research and diagnostic settings. It has proven to be reliable for use with non-B
subtypes and is a rapid convenient method for determining resistance genotypes
(Eshleman et al, 2004). Unfortunately, the presence complex patterns of resistance
mutations in an isolate may make the genotype difficult to interpret. A limitation of both
the genotypic and phenotypic tests is that they are unable to detect minor drug resistant
populations. This is why it is not recommended to perform resistance testing on patients
who are not currently taking their ARVs.
In the future, the impact on of positively selected phosphorylation sites on viral replicative
capacity and the role of variable subtype C cleavage sites on response to treatment with
Pis needs to be investigated, both at the patient level, and in vitro using site-directed
mutagenesis. The role of novel, positively selected resistance mutations in the
development of resistance, whether conferring resistance on their own, or in combination
with mutations at other sites, needs further investigation.
Conclusion
In conclusion, these initial results suggest that local circulating subtype C strains will be as
susceptible to ARV therapy as subtype B isolates from Europe and North America.
However, the long-term efficacy of HAART on subtype C has yet to be determined.
Changes in phosphorylation sites and the development of novel, positively selected
mutations under drug selection pressure, suggests that subtype C can rapidly compensate
for any loss of fitness caused by drug resistance mutations.
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Appendix A
The control files are described below.
• Seqfile, outfile and treefile specifies the names of the sequence data file, main result file, and
the tre structure file respectively.
• Noisy controls how much output you want on the screen
• Verbose controls how much output is in the result file
• Runmode = 0 means evaluation of the tree topologies specified in the trees structure file.
Runmode = 1 or 2 means heirustic tree search by the star-decomposition algorithm etc.
• Model specifies the model of nucleotide substitution
• Mgene is used for combined analysis of data from multiple genes or the three codon positions.
• Fix kappa specifies whether k in K80, F84 or HKY85 is given at a fixed value or is to be
estimated by iteration from the data.
• Fix_alpha and alpha work in a similar way, where alpha refers to the shape parameter a of the
gamma distribution for variable substitution rates across sites (Yang, 1994)
• Fix rho and rho work in a similar way and concern independence or correlation of rates at
adjacent sites, where rho is the correlation parameter of the auto-discrete gamma model (Yang,
1995).
• NparK specifies nonparametric models for variable and Markov-dependent rates across sites:
npark=1 or 2 means several categories of independent rates for sites, while npark=3 or 4 means
the rates are Markov-dependent at adjacent sites.
• Clock specifies models concerning rate constancy among lineages.
• Nhomo is for baseml only and concerns the frequency parameters in the F81, F84, HKY85,
TN93 or REV models.
• GetSE indicates whether we wnat estimates of the standard errors of estimated parameters.
• RateAncestor=l works with runmode=0. Rates are calculated for sites along the sequence
(output in rates file) and performs marginal ancestral reconstruction (output in rst file)
• Small_Diff is a small value used in the difference approxiamtion of derivatives.
• Cleandata = 1 means sites involving ambiguity characters or alignment gaps are removed from
all sequences. This leads to faster calculation.
• Method: this variable controls the iteration algorithm for estimating branch lengths under a
model of no clock. method = 0 implements the old algorithm in PAML, which updates all
parameters including branch lengths simultanwously.Method = 1 specifies an algorithm which
updates branch lengths one by one. Method=1 does not work under the clock models.
• Ndata: specifies the number of separate data sets in the file.
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